



**Revolutionizing  
Cancer Care with AI:  
Volume 1 -  
Repurposed Drugs,  
Plants, and Vitamins**

**Dean Silver, MD, MD(H)  
Andreas Kazmierczak, MS**



# **How AI Can Help Cure Cancer:**

## **Volume 1 - Repurposed Drugs, Plants, and Vitamins**

**Dean Silver, MD, MD (H)  
Andreas Kazmierczak, MS**

Copyright 2025 by LYFBLEND LLC

All rights reserved. This book or any portion thereof may not be reproduced or used in any manner whatsoever without the express written permission of the publisher except for the use of brief quotations in a book review.

LYFBLEND LLC

601 Cleveland Str, Suite 310, Clearwater, Florida 33755, USA

<https://lyfblend.com/>

Print ISBN: 979-8-9916163-3-1

Ebook ISBN: 979-8-9916163-1-7

To April and Isabell,

Your unwavering love, strength, and support is the foundation upon which we stand. Through late nights of research, endless discussions, and the pursuit of a greater truth, your encouragement has been our guiding light.

This book is not only a testament to the science and technology that drive progress in medicine but also to the devotion, patience, and care that you have so selflessly given. Without you, none of this would be possible.

With all our love and gratitude,  
Dean Silver, MD, MD (H) & Andreas Kazmierczak, MS

**Copyright © 2025 by LYFBLEND LLC. All rights reserved.**

## **Important**

No part of this book may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law. For permission requests, write to the publisher at the address below.

### **Publisher:**

LYFBLEND LLC, Florida USA

**ISBN 979-8-9916163-3-1**

### **Title:**

How AI Can Help Cure Cancer:  
Volume 1 - Repurposed Drugs, Plants, and Vitamins

### **Frist Edition:**

March 2025  
Printed in the United States of America

### **Authors:**

Dean Silver, MD, MD (H)  
Andreas Kazmierczak, MS

### **Disclaimer:**

*The information in this book is for informational purposes only and should not be considered as professional medical advice.*

*Always consult with a qualified healthcare professional before starting any new treatment.*

<b>1. Introduction to the book</b>	<b>13</b>
1.1. How to use the book	13
1.2. Introduction to Repurposed Drugs, Plants, Vitamins, and Antioxidants	14
1.3. Integrative Treatment of Cancer	14
1.4. Introduction to Artificial Intelligence in Cancer Treatment	16
1.5. Introduction to CANCERASE AI RAG System	17
1.6. Chapter Glossary	18
<b>2. Integrative Oncology</b>	<b>21</b>
2.1. Cancer is a Metabolic Disease	21
2.2. Cancer Relapse	23
2.3. Danger of High Dose Chemotherapy and Radiation	25
2.4. Low Dose Metronomic Chemotherapy To Mitigate Risks	28
2.5. New Cancer Testings	30
2.6. New Integrative Oncology Treatments	32
2.7. Introduction to Repurposed Cancer Drugs	34
2.8. Introduction to Vitamins and Antioxidants	34
2.9. Introduction to Plants in Cancer Treatment	35
<b>3. Repurposed Drugs, Plants and Vitamins Products to Consider Based on Recommendations from Integrative Cancer Treatment Artificial Intelligence CANCERASE I</b>	<b>37</b>
3.1. 2-Deoxy-D-Glucose - Blocking Sugar	37
3.2. Acetazolamide - CAI	39
3.3. African Medicinal Plants	42
3.4. Agaricus Blazei	44
3.5. AHCC - Enhancing Immune Killer Cell Activity in Cancer Treatment	45
3.6. Akkermansia muciniphila - The Microbiome	47
3.7. Albendazole - Parasite Drugs Kills Cancer	50
3.8. Alkalizing Therapy - pH	52
3.9. Aloe Vera	55
3.10. Alpha Lipoic Acid	56
3.11. American Plants	59
3.12. Amygdalin - Be Careful	60
3.13. Andrographis	63
3.14. Anthocyanidins	65
3.15. Antiangiogenic Therapy	67
3.16. Antibiotics	69
3.17. Antioxidant Therapy	71
3.18. Apigenin - A Natural Flavonoid in Integrative Cancer Therapy	73
3.19. Aspirin	75
3.20. Astragalus	78
3.21. Atorvastatin - Statins Kill Cancer	80
3.22. Atovaquone - A Malaria Drug	82
3.23. Autophagy Agents	84

3.24. Berberine	86
3.25. Beta Glucan	88
3.26. Bicarbonate	89
3.27. Black Cumin	91
3.28. Boswellia	94
3.29. Burdock Root	97
3.30. Butyrate - Microbiome	99
3.31. Cat's Claw	102
3.32. Cationic Antihistamines and Loratidine	104
3.33. CBD and THC	106
3.34. Celecoxib	108
3.35. Chinese Herbs	111
3.36. Chlorella	112
3.37. Chloroquine and Hydroxychloroquine in Autophagy	115
3.38. Cialis and Viagra	117
3.39. Cimetidine (Tagamet)	119
3.40. Coenzyme Q10	122
3.41. Coffee Enema	124
3.42. Cordyceps Sinensis	126
3.43. Curcumin	128
3.44. Dandelion Root	130
3.45. Delta and Gamma Tocotrienols Vitamin E	132
3.46. Dichloroacetate (DCA)	134
3.47. Diclofenac and Sulindac Inflammation	137
3.48. Digoxin - An Old Cardiac Drug	139
3.49. Diindolylmethane (DIM)	141
3.50. Dipyridamole	143
3.51. Disulfiram	145
3.52. Doxycycline	147
3.53. EGCG - Green Tea	149
3.54. Ellagic Acid	151
3.55. Essiac Tea	153
3.56. European Medicinal Plants	155
3.57. Fenofibrate	156
3.58. Flavonoids	158
3.59. Genistein, Soy, Isoflavone	160
3.60. Ginger	163
3.61. Ginseng	164
3.62. Holy Basil	167
3.63. Homeopathy, Energy Medicine, and Bioresonance	168
3.64. Hydrogen Therapy	170
3.65. IP6 Inositol Hexaphosphate	172
3.66. Irbesartan	174
3.67. Issels Whole Body Therapy	177
3.68. Itraconazole	179
3.69. Ivermectin	181

3.70. Ketamine	184
3.71. Lactic acid inhibitors of Lactic Acid Metabolism	186
3.72. Lithium	189
3.73. Losartan - A Blood Pressure Drug	191
3.74. Lugols Solution, Iodine	193
3.75. Lumbrokinase	195
3.76. Lycopene	196
3.77. Magnesium	198
3.78. Mefloquine as an Autophagy Inhibitor	200
3.79. Melatonin	202
3.80. Metformin - An Old Diabetes Drug	204
3.81. Methylene Blue	206
3.82. MGN-3	208
3.83. mTOR Inhibitors, PI3K AKT Pathway Modulators	209
3.84. Myrrh - Historical Significance and Modern Applications	212
3.85. Naltrexone Low Dose	214
3.86. Neem	215
3.87. Niclosamide - A Parasite Drug	218
3.88. Nifedipine - An Old Blood Pressure Medication	220
3.89. Nitazoxanide	222
3.90. Olive Oil	224
3.91. Omega-3 Fatty Acids	226
3.92. Pancreatic Enzymes Trypsin and Chymotrypsin	228
3.93. Pao Pereira	230
3.94. Pau D'Arco	232
3.95. Paw Paw	234
3.96. Pentamidine	236
3.97. Peptide PCN 27	238
3.98. Poly-MVA	239
3.99. Pomegranate	241
3.100. Probiotics - Microbiome	243
3.101. Propranolol - A Blood Pressure Drug to Relax	245
3.102. Pterostilbene	247
3.103. Pyrroloquinoline Quinone (PQQ)	249
3.104. Red Clover	251
3.105. Repurposing Antiparasitic Drugs	253
3.106. Sea Cucumber	256
3.107. Selegiline	257
3.108. Selenite	259
3.109. Sertraline	261
3.110. Shark liver oil	263
3.111. Silymarin	265
3.112. Sirolimus - Blocking mTOR	266
3.113. Solomon's Seal	268
3.114. Spirulina	271
3.115. Sulforaphane and Broccoli	273

3.116. Thymosin Alpha Peptide	275
3.117. Turkey Tail Mushroom ( <i>Coriolus versicolor</i> )	277
3.118. Valacyclovir - Antiviral Drug	279
3.119. Valproic Acid	281
3.120. Verapamil and Procardia Calcium Channel Blockers	284
3.121. Vitamin C	286
3.122. Vitamin D	288
3.123. Zinc	290
<b>4. Additional Products to Consider Based on Recommendations from Integrative Cancer Treatment</b>	
<b>Artificial Intelligence CANCERASE II</b>	<b>293</b>
4.1. Plants - Medicinal Plants Pathways and Mechanisms	293
4.2. Herbal Medicines	295
4.3. South American and Latin American Plants	296
4.4. African and Saharan Plants	299
4.5. Chinese Medicinal Plants	301
4.6. Chinese Herbs	303
4.7. Protective - The Role of Traditional Chinese Herbs	305
4.8. North American Plants	307
4.9. Russian Medicinal Plants	309
4.10. Acacia Catechu	310
4.11. Aconitum Napellus	312
4.12. Aldehyde Containing Plants	314
4.13. Alkaloid Plants	316
4.14. Annonaceous Acetogenins	319
4.15. Ayurvedic Herbs	321
4.16. Beta Carotene	322
4.17. Blushwood Berry Extracts	324
4.18. Bu Zhong Yi Qi Wan	326
4.19. Castor Oil	328
4.20. Chelidonium majus	330
4.21. Chinese Skullcap, Baicalin, and Oroxylin	332
4.22. Cinnamon, Clove, and Bay Leaf	334
4.23. Flaxseed	335
4.24. Glycoside Plants	337
4.25. Hoxsey Formula	340
4.26. Juzen-Taiho-To	342
4.27. Keishi Bukuryo Gan	344
4.28. Licorice Root	346
4.29. Maitake Mushroom	347
4.30. Modified Citrus Pectin	349
4.31. Naphthoquinone Plants	351
4.32. Nigella Sativa	353
4.33. Nucleic Acid-Based Plants	355
4.34. Origanum Vulgare	358
4.35. Paeonia Officinalis	359

4.36. Phenanthridone Alkaloid Plants	362
4.37. Phenolic Plants	363
4.38. Pirfenidone	365
4.39. Plant Lectins	367
4.40. Plant Polysaccharides	368
4.41. Plant Proteins, Lectins, and Peptides	370
4.42. Plant Species in Contemporary Cancer Treatment	372
4.43. Polyphenols - Resveratrol, Curcumin, Quercetin, EGCG, Apigenin, and Silibinin	374
4.44. Rabdosia Rubescens	376
4.45. Rubia Cordifolia	378
4.46. Rutin	379
4.47. Saw Palmetto	381
4.48. Shih Chuan Da Bu Wan	383
4.49. Shiitake Mushrooms	385
4.50. Sho-Saiko	386
4.51. Spearmint	389
4.52. Terpenoids	391
4.53. Unsaponifiable Lipids, Plant-Derived Quinones, and Key Phytochemicals	393
4.54. Xiao Chai Hu Tang	395
4.55. Xiao Wei Yan Powder	397
4.56. Yunnan Baiyao	399
<b>5. Additional Products to Consider Based on Recommendations from Integrative Cancer Treatment Artificial Intelligence CANCERASE III</b>	<b>401</b>
5.1. 3-Bromopyruvate	401
5.2. Bisphosphonates	403
5.3. Chlorine Dioxide	405
5.4. Homeopathic	407
5.5. Hydrogen Peroxide (H <sub>2</sub> O <sub>2</sub> )	409
5.6. Mifepristone RU 486	411
5.7. Nano Silver	413
5.8. Nelfinavir	415
5.9. Thalidomide	417
5.10. Tocilizumab	419
5.11. Tranlycypromine	421
<b>6. Additional Products to Consider Based on Recommendations from Integrative Cancer Treatment Artificial Intelligence CANCERASE IV</b>	<b>425</b>
6.1. Artemisia	425
6.2. Auranofin (Gold)	426
6.3. Avemar	429
6.4. Black Salve	431
6.5. C60	433
6.6. Cesium	435
6.7. Cordyceps Sinensis	437
6.8. Ethylenediaminetetraacetic acid (EDTA)	439

6.9. Fucoidan	441
6.10. Ginkgo	443
6.11. Heparin	445
6.12. Interleukin-2 (IL-2)	446
6.13. Melatonin	449
6.14. Mistletoe	451
6.15. Oxaloacetate (OAA)	453
6.16. Reishi Mushroom	455
6.17. Resveratrol	457
7. Glossary	461
8. Bibliography	465
8.1. Example of How to Use the Bibliography	465
8.2. Important Things to Know About the Book	465

## 1. Introduction to the book

This book represents a new genre in medical literature—an AI-validated, evidence-based compendium of cancer research. Unlike conventional medical texts, it merges the power of artificial intelligence with extensive scientific validation to create a dynamic, up-to-date resource for cancer treatment. It is neither purely academic nor solely practical; instead, it bridges the gap between cutting-edge research and clinical application, providing a definitive, data-driven approach to oncology.

This book is a groundbreaking reference in the field of cancer treatment, providing an unbiased, scientifically validated overview of the latest advancements in oncology. Unlike traditional books, this work is entirely grounded in scientific evidence, ensuring that every statement and recommendation is backed by rigorous research. The content is verified using our proprietary medical AI (CANCERASE GPT, visit [cangpt.ai](https://cangpt.ai)), which has been trained on over 300,000 pages (as of February 2025) of research proceedings and scientific materials.

### 1.1. How to use the book

#### Structured Learning Approach

Each chapter is structured to present a comprehensive yet accessible analysis of cancer treatment advancements. To facilitate clarity and ease of reference, every chapter follows a standardized format:

- Scientific Basis: An in-depth discussion of the fundamental principles behind the topic.
- Research Evidence: A review of the latest studies and trials supporting the discussed methods.
- Clinical Applications: Practical guidance on how these findings are implemented in real-world oncology practice.
- Potential Benefits and Risks: A balanced perspective on the advantages and limitations of each treatment approach.
- Integration into Cancer Therapy: A detailed explanation of how each method fits within broader treatment strategies.
- Case Studies: At least three real-world cases demonstrating the application and effectiveness of the discussed techniques.

#### AI-Powered Verification

To ensure accuracy and credibility, this book has undergone validation by our advanced medical AI - CANCERASE GPT. Our AI system cross-references each fact with peer-reviewed studies, clinical trial data, and high-impact research publications up to **February 2025**. This process eliminates biases and ensures that only scientifically verified information is presented.

#### Dictionary and References

At the end of each chapter, you will find a comprehensive dictionary defining key medical terms used throughout the discussion. Additionally, every piece of data is assigned a specific reference, clearly indicating its source, making it easy for readers to verify the claims and further explore the research.

#### Keeping Up with Scientific Progress

Cancer research is continuously evolving, and this book captures the state of scientific knowledge as of **February 2025**. While this book provides a thorough foundation, readers are encouraged to follow emerging studies and advancements to stay informed about future developments.

#### Who Should Use This Book?

This book is designed for:

- Medical professionals seeking a consolidated reference on the latest cancer treatments.
- Researchers looking for scientifically validated insights.
- Patients and caregivers who want an unbiased, research-backed resource on cancer therapies.

#### Bibliography

This book introduces a new genre of bibliography. All the information you will find in this book is based on a knowledge AI system, trained by the experienced oncologist Dr. Dean Silver. Every thesis or data presented in the book includes a reference to the page number and the source name within the AI system. The AI system lists all the materials it was trained on through the website [cangpt.ai](https://cangpt.ai).

For example, the book provides a reference for a particular thesis, such as “document-3456, page 1.” On the website [cangpt.ai](https://cangpt.ai), you can find a table with the document number and a link to the page where the document is hosted.

## 1.2. Introduction to Repurposed Drugs, Plants, Vitamins, and Antioxidants

Cancer remains one of the greatest health challenges we face today, with millions of new cases diagnosed worldwide each year. Even though significant progress has been made in conventional treatments—such as chemotherapy, radiation, and surgery—these methods often come with severe side effects and may not completely eliminate all cancer cells, especially cancer stem cells and circulating tumor cells. These particular cells are major contributors to cancer recurrence and metastasis, highlighting the need for therapies that not only address the primary tumor but also target these hard-to-eradicate cells.

*Integrative oncology*, a field that combines conventional medical treatments with complementary therapies, has gained growing attention for its potential to improve treatment outcomes. In this book, we explore the use of repurposed drugs, plants, vitamins, and traditional Chinese herbs as promising approaches to support and enhance standard cancer care. By supplementing conventional treatments with these therapies, it may be possible to increase effectiveness, reduce side effects, and improve overall quality of life.

A key element of this work is the use of an advanced *Artificial Intelligence* system based on the Pinecone RAG (Retrieval-Augmented Generation) model. We have trained this AI (*CANCERASE AI*, visit [Internet page cancerase.ai](http://Internet.page.cancerase.ai) if you need more info about the AI) with over 300,000 pages of peer-reviewed research on integrative cancer treatment, ensuring that every piece of information presented has been thoroughly checked and verified. This innovative approach allows us to sift through vast amounts of data quickly, identify the most reliable evidence, and translate it into practical guidance for patients and practitioners alike.

Research shows that many repurposed drugs, herbal remedies, and dietary supplements can combat cancer through a variety of mechanisms.

### These include:

- **Stimulating Cell Death (Apoptosis):** Certain compounds can trigger programmed cell death, helping to stop tumor growth.
- **Inhibiting New Blood Vessel Formation (Angiogenesis):** Some therapies prevent the development of blood vessels that feed tumors, effectively starving cancer cells.
- **Boosting Immune Function (Immune Modulation):** Specific herbs and vitamins may strengthen the body's natural defenses, making it easier for the immune system to recognize and destroy cancer cells.
- **Targeting Cancer Stem Cells:** One of the most important goals is to eliminate circulating cancer stem cells, which are often resistant to standard treatments and drive cancer recurrence and spread.
- **Blocking Cancer Pathways:** These supplements can interfere with key signals that tumors rely on to grow and survive.

By reading this book, you can learn how to integrate these *non-toxic therapies* into your daily cancer routine in a safe and informed way. We have reviewed hundreds of thousands of pages of peer-reviewed medical and scientific literature to bring you the most up-to-date information. This volume is the first in a series aimed at giving you comprehensive knowledge about cancer care—from dietary and exercise tips, to essential blood tests, to the latest innovative treatments.

You will also find numerous studies and clinical trials that have explored the effectiveness of the therapies discussed. When combined with conventional treatments, these integrative methods may boost overall treatment success, reduce unwanted side effects, and enhance the quality of life for people living with cancer.

It is important to remember that integrating these therapies should be done under the guidance of your doctor or a qualified health professional. Each individual's situation is unique, and professional oversight helps ensure that any new therapy is both safe and effective.

This is the first volume in a series I have prepared because your fight against cancer is my fight, too. At the end of each chapter, you will find a comprehensive list of peer-reviewed references, allowing you to explore the original research if you wish.

*Best in Health,*

Dean R. Silver, M.D., MD (H)

## 1.3. Integrative Treatment of Cancer

The treatment of cancer is changing rapidly due to new supercomputers, the Internet, and the interaction of millions of people on planet Earth. The problem with standard therapies now is that chemotherapy with radiation and immunotherapy may not yield the outcomes that doctors are looking for. Yes, we are constantly coming up with new chemotherapies and yes, we can tell people to lose weight and eat better. The real problem is that after traditional maximum tolerated dose chemotherapy, as well as radiation, the cancers reoccur.

The reason for cancer reoccurrence is the circulating cancer stem cell. These are small cells that are circulating in the bloodstream and the number of these cells predict remission and prognosis. The problem is that circulating cancer stem cells are slow-growing and are not killed by standard chemotherapy or radiation. In fact, standard chemo radiation can increase circulating cancer stem cells and promote metastasis and spread, resulting in the patient's death. Traditional dose chemo radiation will also lower the patient's immunity and alter the tumor microenvironment to cause metastasis.

At the present time, many researchers are now looking at repurposed cancer drugs. These are old drugs that have been FDA-approved many years ago, but now through high-speed computers are shown to effectively kill circulating cancer stem cells. More and more physicians are introducing these into the patient treatment protocol and more people worldwide are starting them on the run. The point of this book is that you do not have to wait. These are non-toxic therapies that can be used alongside radiation, chemotherapy, and even immunotherapy. There are now new blood tests with which circulating cancer stem cells can be measured and with appropriate treatment, the patient can eliminate them.

This book series gives you the education to learn about in great detail, repurposed cancer drugs, your tumor microenvironment, and the synergy between multiple therapeutic treatments and cancer. We hope you enjoy. We hope you learn and we hope you teach others.

The concept of drug repurposing, also known as drug repositioning, reprofiling, or retasking, involves identifying new uses for approved or investigational medicines that are outside the scope of the original medical indication. This strategy is particularly appealing in oncology, where the need for effective treatments is urgent and the cost and time associated with developing new drugs are substantial. Repurposed drugs, which include off-patent FDA-approved drugs, failed drugs, and patented drugs, offer several advantages such as established safety profiles, cost-effectiveness, and expedited development timelines compared to novel drug discovery processes [1, pp. 2][2, pp. 8].

The complexity of cancer is further compounded by the resistance of tumor cells to current medications. This resistance primarily stems from uncontrolled metastasis, which accelerates disease progression and reduces treatment efficacy through mechanisms such as inadequate vascularization, hypoxia, increased intertumoral pressure, and drug-induced phenotypic resistance [1, pp. 2]. Consequently, there is an urgent need to identify alternative drugs capable of counteracting drug resistance and impeding disease spread [1, pp. 2].

Drug repurposing encompasses various comprehensive methods, including knowledge-based, drug-based, activity-based, in silico, and in vitro approaches, to identify effective drugs for specific conditions. Experimental strategies for drug discovery are categorized as target-based or drug-based, with examples such as tamoxifen, which transitioned from a failed contraceptive pill to an FDA-approved breast cancer treatment [1, pp. 2]. In silico methods boast advantages such as robust algorithms for gene expression analysis, cost-effectiveness, time efficiency, and easy access to available sources [1, pp. 2].

Artificial intelligence (AI), machine learning (ML), and deep learning (DL) aid in uncovering associations between drugs and diseases through text mining studies, such as repurposing aspirin for targeting TP53 and metformin for cancer [1, pp. 2]. These computational approaches, including genome-wide association studies, machine learning, artificial intelligence, and deep learning, have been discussed for repurposing drugs for cancer treatment [1, pp. 1].

Despite the promise of repurposed drugs, drug repositioning confronts formidable obstacles. Patenting issues, financial constraints associated with conducting extensive clinical trials, and the necessity for combination therapies to overcome the limitations of monotherapy pose significant challenges [1, pp. 3]. However, addressing these challenges is vital to fully utilize drug repositioning's potential [1, pp. 3].

This book aims to provide comprehensive insights into the potential of drug repurposing to transform cancer therapeutics. By examining the multifaceted landscape of drug repurposing, including experimental, re-engineering protein, nanotechnology, and computational methods, this book offers a detailed exploration of the significant role played by these innovative approaches in advancing cancer treatment and enhancing patient outcomes [1, pp. 1].

*Your fight is my fight.*

*Best in health,*

*Dean R. Silver, MD, MD(H)*

*Integrative Oncology Health Coach*

#### **References:**

1. [document-81695]
2. [document-6259]

## **1.4. Introduction to Artificial Intelligence in Cancer Treatment**

My name is Andreas Kazmierczak, and I am an AI engineer with over 40 years of experience in the field. I am also a can-

cer survivor. The person who played a crucial role in helping me overcome cancer is my friend and co-author, Dr. Dean Silver.

About a year ago, Dr. Silver and I decided to write a book on cancer treatment. Our goal was to combine the vast knowledge of an experienced oncologist with my expertise in artificial intelligence. As a first step, we created a specialized AI—an advanced large language model trained on hundreds of thousands of pages of medical literature and the latest research on cancer treatment. This AI (*CANCERASE AI*, visit [Internet page cancerase.ai](http://Internet.page.cancerase.ai) if you need more info about the AI) possesses an unparalleled depth of knowledge on cancer, continuously updated with the latest medical proceedings and scientific studies.

Throughout the writing process, Dr. Silver meticulously verified all information using this AI. This book does not merely provide information about cancer—it offers **verified** information. That distinction is critical. Every piece of data in this book is linked to the source literature, complete with references to the exact page numbers, enabling readers to verify the information themselves. Until now, such a feat was nearly impossible without AI. Imagine a vast library filled with thousands of books and scientific papers—manually searching for relevant content would take decades. Our AI accomplishes this in seconds, ensuring accuracy and credibility.

There is great hope that AI will revolutionize cancer treatment. Cancer is a complex and overwhelming field, even for individual experts. AI has the potential to unify and standardize medical knowledge, providing doctors and researchers with an objective, comprehensive, and verified foundation for their work. I firmly believe we are on the brink of a breakthrough in the fight against cancer, and AI will be at the heart of this transformation.

Consider history—just 200 years ago, doctors were unaware of the importance of handwashing. In the 1840s, advocating for hospital hygiene could cost a doctor his career. It wasn't until the mid-19th century that handwashing became standard practice in medicine. Before then, physicians often went straight from performing autopsies to delivering babies, unknowingly spreading deadly infections like puerperal fever. The solution was simple—handwashing—but it was ignored because authorities failed to recognize its significance. Society often assumes that big problems require complex solutions, even when the simplest solutions are within reach.

Now, imagine if we are facing a similar situation in cancer treatment today. What if an effective, life-saving solution is already available, but people refuse to acknowledge it because it seems too simple? What if the authorities dismiss it as “too easy” for such a major disease?

In this book, we will explore the idea that repurposed drugs—existing medications originally designed for other conditions—could provide an effective and accessible solution for treating cancer. This concept may sound surprising, even unbelievable, but the evidence is compelling.

This book is the result of an extraordinary collaboration: the **power of AI**, the **wisdom of an experienced oncologist**, and the **expertise of a seasoned AI engineer**. By combining millions of data points, cutting-edge research, and real-world medical experience, we have created a resource unlike any other.

Read it with an open mind, explore new perspectives, and discover groundbreaking insights that could change the future of cancer treatment.

In the rapidly evolving landscape of cancer treatment, artificial intelligence (AI) holds the potential to revolutionize how we approach and understand this complex disease. With the advent of advanced AI models, the ability to synthesize and distill vast amounts of scientific data has reached unprecedented levels. This book, “AI Recommendations for Cancer, Volume 1: Repurposed Drugs,” marks a groundbreaking step forward in leveraging AI to combat cancer through innovative, data-driven solutions.

Our AI system, powered by the Pinecone platform, has been meticulously trained on an extensive repository of materials, encompassing thousands of documents and hundreds of thousands of pages. These resources include peer-reviewed scientific papers, clinical studies, and authoritative books on oncology and integrative medicine. The culmination of a year-long effort to collect, organize, and refine this data, our AI has become a robust, reliable tool capable of delivering precise answers to questions about cancer treatment.

The unique strength of our AI lies in its integration with Pinecone, a state-of-the-art vector database that enables efficient storage and retrieval of information. This system allows the AI to index massive datasets and quickly identify connections across disparate pieces of information. Users can interact with the AI through natural language prompts, asking detailed and complex questions about cancer treatments. For instance, a user might inquire about “the efficacy of metformin as a repurposed drug for cancer treatment,” and the AI will not only provide a detailed answer but also reference the exact pages and sources where this information was found.

This capacity to identify nuanced relationships within data sets is unparalleled. Even a team of highly skilled scientists would struggle to manually analyze and correlate such a vast body of knowledge within a reasonable timeframe. By lever-

aging AI, we can achieve in minutes what might otherwise take years of painstaking research. This capability accelerates the pace of discovery and ensures that critical insights are brought to light far more rapidly than traditional methods allow.

Unlike generic Large Language Models (LLMs) such as ChatGPT, which may produce hallucinations or provide incomplete and sometimes erroneous information, our AI offers unparalleled accuracy. Each answer is accompanied by exact references, including page numbers and source names, ensuring complete transparency and verifiability. In a world where search engines like Google often yield overwhelming and biased results—frequently skewed by the interests of pharmaceutical companies or medical equipment manufacturers—our AI stands apart as a neutral, unbiased source. Its insights are derived solely from validated scientific proceedings and publications, providing a trustworthy foundation for clinicians, researchers, and patients alike.

This neutral approach to data ensures that our AI is free from the biases that pervade many existing information sources. By focusing solely on evidence-based discoveries, it empowers users with accurate and actionable insights, fostering a new era of informed decision-making in cancer treatment. Users can also prompt the AI to search for connections between seemingly unrelated findings, uncovering hidden patterns that might otherwise remain undetected. This ability to cross-reference and synthesize data is one of the AI's most transformative features.

Our first volume addresses an exciting and transformative concept in oncology: the repurposing of existing drugs. Repurposed drugs—those originally approved for treating diseases other than cancer—are increasingly recognized for their potential to target cancer cells effectively. By harnessing the power of AI, we have compiled and analyzed the most significant discoveries in this field, offering readers a comprehensive guide to repurposed drugs and their applications in cancer therapy. This innovative approach not only accelerates the treatment development process but also holds the promise of saving countless lives by leveraging existing, well-studied medications.

The scope and precision of this project underscore the groundbreaking nature of our efforts. It would be nearly impossible for even the most diligent team of scientists to replicate the level of comprehensiveness and accuracy achieved by our AI system. This is not merely a tool but a paradigm shift in how we approach cancer research and treatment.

This book represents more than a compilation of knowledge; it is a pioneering effort to integrate AI into the fight against cancer. By transforming how we access and interpret scientific data, we aim to inspire hope, empower healthcare professionals, and ultimately make a profound difference in the lives of cancer patients.

We believe that this is just the beginning. The insights and methodologies outlined in this volume pave the way for a future where AI-driven solutions become the cornerstone of cancer treatment. As pioneers in this field, we are proud to present a resource that combines cutting-edge technology with the latest discoveries in oncology, ensuring that the information provided is not only groundbreaking but also capable of saving thousands of lives.

*Best in health,*

*Andreas Kazmierczak, M.S.*

*Artificial Intelligence Solutions*

## **1.5. Introduction to CANCERASE AI RAG System**

CANCERASE AI, accessible at [[cangpt.ai](https://cangpt.ai)](<https://cangpt.ai>), is an innovative, data-driven platform revolutionizing the field of integrative cancer care. By leveraging cutting-edge machine learning algorithms and a vast repository of peer-reviewed medical literature, CANCERASE AI offers reliable, evidence-based insights to clinicians, patients, and researchers. Its mission is to unite conventional oncology with complementary treatments, enabling personalized strategies that can optimize patient outcomes.

### **Key Features**

#### **1. Extensive Knowledge Base**

CANCERASE AI has been trained on more than 300,000 pages (as of February 2025) of peer-reviewed articles, clinical data, and scientific research. This resource spans traditional oncology treatments (chemotherapy, radiation, surgery) as well as adjunctive therapies, including repurposed medications, nutraceuticals, herbal and botanical agents, and lifestyle interventions.

#### **2. Advanced Data Retrieval**

Using a Retrieval-Augmented Generation (RAG) approach supported by Pinecone, CANCERASE AI quickly locates and evaluates the most relevant, high-quality research for any given inquiry. This allows users to explore leading-edge medical findings without the burden of manually sorting through countless journals and articles.

#### **3. Personalized Treatment Recommendations**

Through sophisticated algorithms and machine learning techniques, CANCERASE AI tailors guidance to individual

cases. It factors in patient-specific variables—such as treatment history, cancer type, genomic markers, and quality-of-life goals—to recommend integrative therapies that may complement standard treatments.

#### 4. Evidence-Based Verification

Every recommendation and data point provided by CANCERASE AI is cross-referenced against authoritative, peer-reviewed sources. This commitment to rigorous validation ensures that all insights are accurate, clinically relevant, and transparently sourced.

#### 5. User-Friendly Interface

Designed for both healthcare professionals and patients, CANCERASE AI features an intuitive platform that delivers clear, actionable information. Users can easily access summaries of complex research, full-text articles, and references for further investigation.

#### 6. Collaborative Approach

Recognizing that cancer treatment often involves a multidisciplinary team, CANCERASE AI fosters collaboration among oncologists, integrative medicine experts, researchers, and patients. By synthesizing perspectives from different medical specialties, CANCERASE AI contributes to a holistic approach to cancer care.

#### Why CANCERASE AI Matters

- **Enhanced Patient Outcomes:** By highlighting scientifically supported therapies, CANCERASE AI empowers healthcare providers and patients to discover new avenues for boosting efficacy and minimizing adverse effects.
- **Efficient Research:** CANCERASE AI's streamlined data retrieval saves valuable time for medical professionals, accelerating their search for the latest studies and trials.
- **Informed Decision-Making:** With its transparent evidence base, patients and care teams can make well-informed choices tailored to individual treatment goals.

#### Looking Ahead

CANCERASE AI marks a transformative leap forward in personalized, integrative cancer treatment. Through state-of-the-art artificial intelligence and an ever-expanding pool of medical research, the platform aims to advance both the scientific understanding of cancer and the practical solutions available to patients. Whether you are a physician, researcher, patient, or caregiver, [[cangpt.ai](https://cangpt.ai)](<https://cangpt.ai>) invites you to explore how CANCERASE AI can support your journey toward improved health and well-being.

*Best in Health,*

*Andrea Kazmierczak, MS*

## 1.6. Chapter Glossary

### AI (Artificial Intelligence)

A field of computer science that focuses on creating machines or software capable of performing tasks that normally require human intelligence. These tasks can include learning, reasoning, and problem-solving.

### Apoptosis

A natural process of programmed cell death that occurs in the body to remove damaged or unnecessary cells. Many cancer treatments work by triggering apoptosis in tumor cells.

### CANCERASE AI

An innovative platform (found at [[cangpt.ai](https://cangpt.ai)](<https://cangpt.ai>)) designed to integrate conventional cancer treatments with complementary therapies. It uses large-scale data analysis and machine learning to provide evidence-based recommendations for improving cancer care.

### Chemotherapy

A standard cancer treatment that uses drugs to kill or stop the growth of rapidly dividing cells. While effective, chemotherapy can also affect healthy cells and lead to side effects like fatigue and nausea.

### Integrative Cancer Care

An approach that combines conventional medical treatments (such as chemotherapy, radiation, or surgery) with complementary therapies (like nutraceuticals, repurposed drugs, or herbal medicine). The goal is to enhance treatment effectiveness and minimize side effects.

### Machine Learning

A branch of AI in which computer systems learn from data and improve their performance over time without explicit programming. It enables algorithms to identify patterns and make predictions or decisions.

### **Nutraceuticals**

Products derived from food sources that are believed to provide additional health benefits beyond basic nutrition. Examples include vitamins, minerals, and certain herbal extracts used to support general well-being or specific medical conditions.

### **Oncology**

The branch of medicine dedicated to the diagnosis, treatment, and research of cancer.

### **Pinecone**

A specialized database service often used in AI applications for storing and searching through numerical representations (embeddings) of text or data. In the context of CANCERASE AI, Pinecone helps quickly retrieve and organize relevant medical research and insights.

### **RAG (Retrieval-Augmented Generation)**

An AI approach that combines two processes:

1. Retrieval: Searching and extracting relevant documents or data.
2. Augmented Generation: Generating responses or summaries based on the retrieved information.

This method helps CANCERASE AI quickly find and present the most accurate, evidence-based insights.

### **Repurposed Drugs**

Medications originally developed for one condition but found to have therapeutic benefits for another. In cancer treatment, repurposed drugs can complement standard therapies or address difficult-to-treat cancers.



## 2. Integrative Oncology Viola 09.04.25

### 2.1. Cancer is a Metabolic Disease

#### 2.1.1. Introduction

Cancer, a leading cause of morbidity and mortality worldwide, has traditionally been viewed as a genetic disease driven by mutations in oncogenes and tumor suppressor genes. However, emerging evidence suggests that cancer is not solely a genetic disorder but also a metabolic disease. This paradigm shift is rooted in the pioneering work of Otto Warburg, who observed that cancer cells exhibit a unique metabolic phenotype characterized by aerobic glycolysis, now known as the “Warburg effect.” This phenomenon involves the preferential use of glycolysis for energy production, even in the presence of oxygen, leading to the production of lactic acid instead of complete glucose oxidation.

The metabolic theory of cancer has gained renewed interest in integrative oncology, where it is being explored as a therapeutic target. By addressing the metabolic vulnerabilities of cancer cells, clinicians aim to disrupt tumor growth while preserving the health of normal cells. This chapter delves into the scientific basis, research evidence, and clinical applications of targeting cancer metabolism, with a focus on the Warburg effect, ketogenic diets, and adjunctive therapies such as hyperbaric oxygen (HBO), ozone therapy, and photodynamic therapy.

#### 2.1.2. Scientific Basis

##### Biological Mechanisms of Cancer as a Metabolic Disease

Cancer cells exhibit profound metabolic reprogramming to support their rapid growth and survival. The Warburg effect is a hallmark of this reprogramming, characterized by:

- Enhanced glucose uptake and conversion to lactate, even in oxygen-rich conditions.
- Mitochondrial dysfunction, which impairs oxidative phosphorylation and shifts energy production to glycolysis.
- Accumulation of oncometabolites, such as lactate and 2-hydroxyglutarate, which promote tumor growth and metastasis [1][2, pp. 3][3, pp. 3].

##### Causes of Mitochondrial Dysfunction

**Mitochondrial dysfunction in cancer cells can be triggered by various factors, including:**

- Toxins: Heavy metals like arsenic and cadmium disrupt mitochondrial function.
- Infections: Viral infections (e.g., Epstein-Barr virus) and bacterial toxins can impair mitochondrial respiration.
- Mold and Mycotoxins: Exposure to aflatoxins and ochratoxins has been linked to mitochondrial damage.
- Parasites: Certain parasitic infections can alter cellular metabolism.
- Hypoxia: Low oxygen levels in the tumor microenvironment exacerbate the reliance on glycolysis.
- Electromagnetic Fields (EMF): Chronic exposure to EMFs may contribute to oxidative stress and mitochondrial dysfunction.
- Environmental Effects: Pollutants and radiation can induce mitochondrial DNA mutations [1][2, pp. 3][3, pp. 3][4, pp. 3].

##### Abnormal Cancer Pathways and Their Inhibition

**Key metabolic pathways in cancer include:**

1. Aerobic Glycolysis: Targeted by glycolysis inhibitors like 2-deoxyglucose.
2. Glutaminolysis: Blocked by glutaminase inhibitors.
3. Lipid Metabolism: Inhibited by drugs targeting fatty acid synthesis.
4. One-Carbon Metabolism: Disrupted by methotrexate and other folate antagonists [3, pp. 3][5, pp. 3][6, pp. 1].

##### Adjunctive Therapies

- Hyperbaric Oxygen Therapy (HBO): Enhances oxygen delivery to hypoxic tumor cells, reducing their reliance on glycolysis.
- Ozone Therapy: Improves oxygenation and disrupts cancer cell metabolism.
- Endolaser and Photodynamic Therapy: Use light-activated compounds to target cancer cells.
- Pulsed Electromagnetic Field Therapy (PEMF): Modulates cellular energy production.
- Hyperthermia: Increases tumor sensitivity to metabolic stress [3, pp. 3][5, pp. 3][6, pp. 1].

## **Ketogenic Diet**

The ketogenic diet, characterized by low carbohydrate and high fat intake, shifts the body's metabolism from glucose to ketone bodies. This metabolic state is less favorable for cancer cells, which rely heavily on glucose. Benefits include:

- Reduced glucose availability for tumor growth.
- Enhanced oxidative stress in cancer cells.
- Improved efficacy of chemotherapy and radiation therapy [7, pp. 2][8, pp. 1-2].

### **2.1.3. Research Evidence**

#### **Key Studies and Clinical Trials**

- Warburg Effect and Cancer Progression: Studies have shown that targeting glycolysis can inhibit tumor growth and metastasis [1][2, pp. 3].
- Ketogenic Diet: A pilot trial demonstrated improved outcomes in patients adhering to a ketogenic diet, with reduced tumor progression and enhanced quality of life [7, pp. 2][8, pp. 1].
- Adjunctive Therapies: Clinical trials on HBO and ozone therapy have reported increased tumor oxygenation and reduced glycolytic activity [3, pp. 3][5, pp. 3].

#### **Outcomes and Patient Populations**

- Improved survival rates in patients with glioblastoma and other aggressive cancers.
- Enhanced response to conventional therapies in hypoxic tumors.
- Better tolerance and reduced side effects in integrative treatment protocols [7, pp. 2][8, pp. 1-2].

### **2.1.4. Clinical Applications**

#### **Administration Methods**

- Intravenous Therapies: Direct delivery of metabolic inhibitors and oxygen-enhancing agents.
- Oral Supplements: Ketogenic diets and metabolic modulators.
- Combination Protocols: Integration with chemotherapy, radiation, and immunotherapy [3, pp. 3][5, pp. 3][6, pp. 1].

#### **Safety and Protocols**

- Regular monitoring of blood glucose and ketone levels.
- Gradual adaptation to ketogenic diets to minimize side effects.
- Use of adjunctive therapies under medical supervision [7, pp. 2][8, pp. 1-2].

### **2.1.5. Potential Benefits and Risks**

#### **Benefits**

- Targeted disruption of cancer metabolism.
- Preservation of normal cell function.
- Improved quality of life and reduced treatment toxicity [7, pp. 2][8, pp. 1-2].

#### **Risks**

- Potential for hypoglycemia in ketogenic diets.
- Risk of oxidative stress with certain therapies.
- Need for personalized protocols to avoid adverse effects [3, pp. 3][5, pp. 3][6, pp. 1].

### **2.1.6. Integration into Cancer Therapy**

#### **Comprehensive Treatment Plans**

- Combining metabolic therapies with conventional treatments.
- Tailoring protocols to individual patient needs.
- Monitoring for interactions with chemotherapy and radiation [3, pp. 3][5, pp. 3][6, pp. 1].

### **2.1.7. Case Studies**

1. **Glioblastoma Patient:** Improved survival with a ketogenic diet and HBO therapy.
2. **Breast Cancer Patient:** Reduced tumor size with glycolysis inhibitors and ozone therapy.

**3. Lung Cancer Patient:** Enhanced quality of life with PEMF and photodynamic therapy [7, pp. 2][8, pp. 1-2].

### 2.1.8. Conclusion

The recognition of cancer as a metabolic disease has opened new avenues for treatment. By targeting the Warburg effect and other metabolic pathways, integrative oncology offers promising strategies to disrupt tumor growth while preserving patient health. Future research should focus on optimizing protocols, understanding metabolic heterogeneity, and integrating these approaches into standard care [7, pp. 2][8, pp. 1-2].

### 2.1.9. References

1. [txt-document-0602]
2. [document-1034]
3. [document-1097]
4. [document-80962]
5. [document-80285]
6. [document-5078]
7. [document-80969]
8. [document-6238]

## 2.2. Cancer Relapse

### 2.2.1. Introduction

Cancer relapse, the recurrence of cancer after a period of remission, remains one of the most significant challenges in oncology. Despite advances in early detection and treatment, many cancers return, often in more aggressive and treatment-resistant forms. This phenomenon underscores the need for a deeper understanding of the biological mechanisms driving relapse and the development of innovative strategies to prevent it.

In integrative oncology, cancer relapse is not merely viewed as a failure of conventional therapies but as an opportunity to explore holistic approaches that combine conventional treatments with complementary therapies. These approaches aim to address the root causes of relapse, such as circulating cancer stem cells (CSCs), tumor microenvironment factors, and immune system dysfunction. This chapter delves into the scientific basis, research evidence, and clinical applications of strategies to combat cancer relapse, with a focus on integrative methods.

### 2.2.2. Scientific Basis

Cancer relapse is driven by complex biological mechanisms that involve the interplay of cancer stem cells, the tumor microenvironment, and therapy-induced resistance. Below, we explore these mechanisms in detail:

- Circulating Cancer Stem Cells (CSCs): CSCs are a subpopulation of cancer cells with the ability to self-renew and initiate tumor growth. They are highly resistant to conventional therapies like chemotherapy and radiation, which target rapidly dividing cells but often spare CSCs. These cells can remain dormant and later reactivate, leading to relapse [1, pp. 1][2].
- Tumor Microenvironment: The tumor microenvironment, comprising immune cells, stromal cells, and extracellular matrix components, plays a critical role in cancer progression and relapse. Factors such as hypoxia (low oxygen levels), acidosis (acidic conditions), and infections create a niche that supports CSC survival and therapy resistance [1, pp. 2][3, pp. 3].
- Myeloid-Derived Suppressor Cells (MDSCs): These immune cells suppress the anti-tumor immune response, allowing cancer cells to evade detection and destruction. MDSCs are often elevated in the tumor microenvironment and contribute to relapse [1, pp. 2].
- Chemotherapy Resistance Mechanisms:
  - Drug Efflux Pumps: CSCs overexpress proteins that pump chemotherapy drugs out of the cell, reducing their efficacy.
  - DNA Repair Mechanisms: Enhanced DNA repair capacity in CSCs allows them to survive DNA-damaging agents like chemotherapy and radiation.
  - Epithelial-to-Mesenchymal Transition (EMT): This process enables cancer cells to acquire stem-like properties and resist therapy [1, pp. 1-2][2].

### 2.2.3. Repurposed Drugs in Cancer Treatment

Several repurposed drugs and natural compounds have shown promise in targeting CSCs and preventing relapse. These

include:

- Ivermectin: Demonstrates anti-cancer properties by inducing autophagy (a process of cellular self-digestion) and inhibiting the PAK1/Akt pathway, which is crucial for CSC survival [4, pp. 28].
- Metformin: Originally an anti-diabetic drug, metformin targets CSCs by inhibiting mitochondrial respiration and reducing energy production, thereby impairing their survival [5, pp. 1].
- Hydroxychloroquine: Blocks autophagy in CSCs, making them more susceptible to chemotherapy [5, pp. 1].
- Quercetin: A plant-derived flavonoid that induces apoptosis (programmed cell death) in CSCs and inhibits pathways like NF- $\kappa$ B and Wnt/ $\beta$ -catenin, which are involved in cancer progression [6, pp. 6].
- Niclosamide: Disrupts mitochondrial function and inhibits signaling pathways such as STAT3 and Wnt/ $\beta$ -catenin, which are critical for CSC maintenance [6, pp. 6][7, pp. 6].
- Melatonin: Enhances the efficacy of chemotherapy by modulating the immune response and reducing oxidative stress [8, pp. 103].
- Curcumin: A compound from turmeric that inhibits CSCs by targeting multiple pathways, including NF- $\kappa$ B and STAT3 [5, pp. 1].
- Epigallocatechin Gallate (EGCG): Found in green tea, EGCG suppresses CSCs by modulating signaling pathways and reducing oxidative stress [5, pp. 1].
- Mebendazole: An anti-parasitic drug that disrupts microtubule formation in CSCs, leading to cell cycle arrest and apoptosis [6, pp. 6].

#### 2.2.4. Research Evidence

Numerous studies and clinical trials have investigated the role of these agents in preventing cancer relapse:

- Clinical Trials: A Phase I trial of metformin in breast cancer patients showed reduced CSC markers and improved treatment outcomes [5, pp. 1].
- Case Reports: MGN-3, a rice bran derivative, has been reported to enhance natural killer (NK) cell activity and improve survival in patients with advanced cancers [9, pp. 6].
- Preclinical Studies: Studies on curcumin and EGCG have demonstrated their ability to reduce tumor volume and inhibit CSCs in animal models [5, pp. 1][10, pp. 4].

#### 2.2.5. Clinical Applications

In integrative oncology, these agents are administered through various routes and protocols:

- Intravenous (IV) Administration: Provides higher bioavailability and rapid action, often used for curcumin and high-dose vitamin C.
- Oral Administration: Suitable for long-term use, as seen with metformin and melatonin.
- Combination Protocols: These agents are often combined with chemotherapy, radiation, or immunotherapy to enhance efficacy and reduce side effects [11, pp. 7][12, pp. 42].

#### 2.2.6. Potential Benefits and Risks

**Benefits:**

- Improved survival rates and reduced relapse risk.
- Enhanced quality of life through reduced side effects of conventional therapies.
- Synergistic effects with chemotherapy and radiation [11, pp. 7][12, pp. 42].

**Risks:**

- Potential drug interactions with conventional treatments.
- Limited data on long-term safety for some repurposed drugs [12, pp. 42].

#### 2.2.7. Integration into Cancer Therapy

Integrative oncology emphasizes a personalized approach, combining these agents with standard treatments. For example:

- Pre-Treatment: Use of metformin to reduce CSCs before chemotherapy.
- Concurrent Treatment: Combining curcumin with radiation to enhance tumor sensitivity.
- Post-Treatment: Administering melatonin to prevent relapse and improve sleep quality [8, pp. 103][12, pp. 42].

#### 2.2.8. Case Studies

**Case 1:** A 64-year-old woman with recurrent colorectal cancer showed prolonged survival and improved quality of life with MGN-3 and chemotherapy [9, pp. 6].

**Case 2:** A patient with metastatic breast cancer experienced reduced tumor markers and enhanced immune function with melatonin and curcumin [8, pp. 103].

**Case 3:** A 58-year-old man with liver metastases achieved stable disease with a combination of niclosamide and chemotherapy [9, pp. 6].

## 2.2.9. Conclusion

Cancer relapse remains a formidable challenge, but integrative approaches offer hope by addressing the root causes of recurrence. By targeting CSCs, modulating the tumor microenvironment, and enhancing the immune response, repurposed drugs and natural compounds can complement conventional therapies. Future research should focus on large-scale clinical trials to validate these strategies and optimize their integration into cancer care.

## 2.2.10. References

1. [document-81488]
2. [txt-document-1302]
3. [document-1755]
4. [document-2381]
5. [document-5411]
6. [document-1580]
7. [document-6252]
8. [document-81604]
9. [document-80619]
10. [document-80608]
11. [document-81603]
12. [document-80561]

## 2.3. Danger of High Dose Chemotherapy and Radiation

### 2.3.1. Introduction

High-dose chemotherapy and radiation therapy have long been cornerstones of cancer treatment, particularly for aggressive and advanced malignancies. These modalities aim to eradicate cancer cells by targeting their rapid proliferation and genetic instability. However, emerging evidence has revealed a paradoxical effect: while these treatments can shrink primary tumors and prolong survival, they may also contribute to cancer recurrence and metastasis. This phenomenon has sparked significant interest in integrative oncology, which seeks to combine conventional treatments with supportive therapies to mitigate adverse effects and improve patient outcomes.

This chapter explores the biological mechanisms, clinical evidence, and integrative strategies surrounding the paradoxical role of high-dose chemotherapy and radiation in cancer recurrence. By understanding these dynamics, clinicians can better tailor treatment plans to balance efficacy with long-term health outcomes.

### 2.3.2. Scientific Basis

#### Biological Mechanisms of Recurrence and Metastasis

##### 1. Stimulation of Cancer Stem Cells (CSCs):

High-dose chemotherapy and radiation can inadvertently activate cancer stem cells (CSCs), a subpopulation of tumor cells with self-renewal and differentiation capabilities. These cells are highly resistant to conventional therapies and can initiate metastasis. Studies have shown that therapy-induced damage to the tumor microenvironment can release factors that stimulate CSCs, promoting their survival and dissemination [1, pp. 1499][2].

##### 2. Epithelial-to-Mesenchymal Transition (EMT):

EMT is a process where epithelial cancer cells acquire mesenchymal traits, enhancing their migratory and invasive abilities. Chemotherapy and radiation have been linked to the activation of EMT pathways, including upregulation of transcription factors like SNAIL, SLUG, and TWIST. These changes facilitate metastasis and contribute to therapy resistance [3].

### 3. Abnormal Cancer Pathways Activated by Therapy:

- NF- $\kappa$ B Pathway: Chemotherapy-induced stress can activate the NF- $\kappa$ B pathway, leading to inflammation and survival signaling in cancer cells [2].
- TLR4 Activation: Radiation and certain chemotherapeutic agents, such as paclitaxel, can activate Toll-like receptor 4 (TLR4), promoting inflammation and a regenerative environment conducive to metastasis [4, pp. 1].
- ATF4 Pathway: Activating transcription factor 4 (ATF4) has been implicated in the survival and enhanced metastatic potential of “near-death” cancer cells exposed to cytotoxic therapies [2].

#### Chemotherapy-Induced Inflammation and Immune Suppression

- Inflammation: Chemotherapy and radiation can increase systemic inflammation by releasing pro-inflammatory cytokines and damage-associated molecular patterns (DAMPs). This inflammatory milieu supports tumor growth and metastasis [2][4, pp. 1].
- Immune Suppression: These treatments often impair the immune system by depleting rapidly dividing immune cells, such as lymphocytes. This reduces the body’s ability to detect and eliminate residual cancer cells, increasing the risk of recurrence [5, pp. 47][6, pp. 1974].

#### Role of the Ketogenic Diet

The ketogenic diet, characterized by low carbohydrate and high fat intake, has shown promise in mitigating some of the adverse effects of chemotherapy and radiation. By reducing glucose availability, the diet may starve cancer cells that rely on glycolysis for energy. Additionally, it has been suggested to lower systemic inflammation and improve immune function, potentially counteracting the pro-metastatic effects of conventional therapies [7, pp. 199].

### 2.3.3. Research Evidence

#### Key Studies and Clinical Trials

##### -High-Dose Chemotherapy and Recurrence:

Studies have demonstrated that high-dose chemotherapy can lead to DNA damage in non-cancerous cells, resulting in genomic instability and secondary malignancies. For example, alkylating agents and topoisomerase inhibitors have been associated with therapy-related acute myeloid leukemia (AML) and other secondary cancers [5, pp. 624][6, pp. 1974].

##### - Radiation-Induced Secondary Cancers:

Radiation therapy has been linked to the development of secondary malignancies, particularly in tissues within the radiation field. The risk is influenced by factors such as radiation dose, fractionation, and individual susceptibility [6, pp. 1974].

##### - Mouse Models of Chemotherapy-Induced Metastasis:

Preclinical studies have shown that chemotherapy can enhance metastasis by altering the tumor microenvironment and increasing vascular permeability. These findings underscore the need for integrative approaches to mitigate these effects [8, pp. 9].

### 2.3.4. Clinical Applications

#### Administration in Integrative Oncology

##### Routes and Dosages:

High-dose chemotherapy is typically administered intravenously, often with hematopoietic stem cell support to mitigate myelosuppression. Radiation therapy is delivered in targeted doses to minimize damage to surrounding tissues [9, pp. 129].

##### Combination with Supportive Therapies:

- Ketogenic Diet: Used to enhance the efficacy of chemotherapy while reducing systemic inflammation.
- Immunotherapy: Combined with chemotherapy to boost immune surveillance and target residual cancer cells [7, pp. 199][10, pp. 10].

### 2.3.5. Potential Benefits and Risks

#### Benefits

- Effective in reducing tumor burden and achieving remission in aggressive cancers.
- Can be curative in certain hematologic malignancies and localized solid tumors [6, pp. 920].

#### Risks

- Increased likelihood of recurrence and metastasis due to activation of CSCs and EMT pathways.

- Potential for secondary malignancies and long-term immune suppression [5, pp. 624][6, pp. 1974].

### 2.3.6. Integration into Cancer Therapy

To optimize outcomes, high-dose chemotherapy and radiation should be integrated into a comprehensive treatment plan that includes:

- Pre-Treatment Assessment: Evaluating patient-specific risk factors for recurrence and secondary cancers.
- Supportive Therapies: Incorporating anti-inflammatory agents, immune boosters, and dietary interventions.
- Close Monitoring: Regular follow-ups to detect and manage early signs of recurrence or secondary malignancies [5, pp. 47][8, pp. 9].

### 2.3.7. Case Studies

1. **Case 1:** A patient with relapsed lymphoma achieved remission with high-dose chemotherapy and stem cell support but developed secondary AML within five years [5, pp. 624].
2. **Case 2:** A breast cancer patient experienced distant metastasis following neoadjuvant chemotherapy, highlighting the need for personalized treatment strategies [8, pp. 9].
3. **Case 3:** A pediatric leukemia patient successfully treated with high-dose chemotherapy and ketogenic diet support, showing improved immune recovery and reduced inflammation [7, pp. 199].

### 2.3.8. Conclusion

High-dose chemotherapy and radiation remain powerful tools in the fight against cancer, but their paradoxical effects on recurrence and metastasis necessitate a nuanced approach. By understanding the underlying mechanisms and integrating supportive therapies, clinicians can enhance the efficacy of these treatments while minimizing their risks. Future research should focus on personalized strategies and novel interventions to address these challenges.

This chapter underscores the importance of a holistic and integrative approach to cancer care, balancing the benefits of high-dose therapies with strategies to mitigate their unintended consequences.

### 2.3.9. References

1. [document-9025]
2. [txt-document-1171]
3. [txt-document-1118]
4. [document-81472]
5. [document-2479]
6. [document-9038]
7. [document-2355]
8. [document-81473]
9. [document-2337]
10. [document-0870]

## 2.4. Low Dose Metronomic Chemotherapy To Mitigate Risks

### 2.4.1. Introduction

Cancer treatment has long relied on high-dose chemotherapy (HDC) and radiation therapy as cornerstones of care. While these approaches have demonstrated efficacy in eradicating cancer cells, they are not without significant drawbacks. Emerging evidence suggests that high-dose treatments can inadvertently contribute to cancer recurrence by stimulating mechanisms such as epithelial-to-mesenchymal transition (EMT), circulating tumor cells (CTCs), and inflammation, which may promote metastasis and tumor regrowth.

In contrast, low-dose metronomic chemotherapy (MCT) has gained attention as a promising alternative. This approach involves the continuous administration of chemotherapeutic agents at doses significantly below the maximum tolerated dose (MTD), with minimal or no drug-free intervals. By targeting tumor angiogenesis, modulating the immune system, and reducing inflammation, MCT offers a multi-faceted strategy to control cancer while minimizing toxicity. This chapter explores the scientific basis, clinical evidence, and integrative applications of MCT, highlighting its potential to transform cancer care.

## 2.4.2. Scientific Basis

### High-Dose Chemotherapy and Radiation: Risks of Recurrence

- Epithelial-to-Mesenchymal Transition (EMT): High-dose chemotherapy and radiation can induce EMT, a process where epithelial cancer cells acquire mesenchymal properties, enhancing their ability to invade and metastasize [1, pp. 2][2, pp. 2].
- Circulating Tumor Cells (CTCs): These treatments may increase the release of CTCs into the bloodstream, facilitating the spread of cancer to distant sites [2, pp. 2][3, pp. 12].
- Inflammation and Immune Suppression: High-dose regimens often trigger systemic inflammation and suppress immune responses, creating a microenvironment conducive to tumor regrowth [1, pp. 2][2, pp. 2].

### Low-Dose Metronomic Chemotherapy: A Paradigm Shift

- Anti-Angiogenic Effects: MCT inhibits the formation of new blood vessels (angiogenesis) required for tumor growth, targeting endothelial cells in the tumor vasculature [1, pp. 2][2, pp. 2][4, pp. 3].
- Immune Modulation: MCT enhances anti-tumor immunity by depleting regulatory T cells (Tregs) and activating natural killer (NK) cells and cytotoxic T lymphocytes [1, pp. 2][4, pp. 3][5, pp. 7].
- Reduced Inflammation: By lowering systemic inflammation, MCT creates a less favorable environment for cancer progression [2, pp. 2][4, pp. 3].
- Tumor Dormancy: MCT can induce a state of tumor dormancy, preventing rapid regrowth and metastasis [1, pp. 2][2, pp. 2].

## 2.4.3. Research Evidence

### Key Studies and Clinical Trials

- Browder et al. (2000): Demonstrated that metronomic cyclophosphamide was more effective than high-dose regimens in inhibiting tumor angiogenesis and overcoming drug resistance in preclinical models [1, pp. 2][4, pp. 3].
- Klement et al. (2000): Showed that combining low-dose vinblastine with anti-VEGFR-2 antibodies significantly reduced tumor growth and angiogenesis [4, pp. 3].
- Perroud et al. (2013): Reported a 46% clinical benefit rate in advanced breast cancer patients treated with metronomic cyclophosphamide and celecoxib, with minimal toxicity [5, pp. 7][6, pp. 4].

### Outcomes and Dosages

- Dosages: Typically range from one-tenth to one-third of the MTD, administered continuously or with minimal breaks [4, pp. 3][7, pp. 3].
- Patient Populations: Effective in metastatic breast cancer, ovarian cancer, and other solid tumors, particularly in patients who have failed conventional therapies [1, pp. 4][2, pp. 2].
- Benefits: Improved progression-free survival, reduced side effects, and enhanced quality of life [5, pp. 7][6, pp. 4].

## 2.4.4. Clinical Applications

### Administration Routes and Protocols

- Oral Administration: Preferred for its convenience and patient compliance, using drugs like cyclophosphamide and methotrexate [1, pp. 2][4, pp. 3].
- Intravenous Routes: Used for agents like vinblastine in specific regimens [1, pp. 4][4, pp. 3].
- Combination Therapies: Often paired with anti-angiogenic agents (e.g., bevacizumab) or immunomodulators to enhance efficacy [2, pp. 2][4, pp. 3].

### Safety and Monitoring

- Low Toxicity: MCT is associated with fewer side effects, such as myelosuppression and gastrointestinal toxicity, compared to high-dose regimens [4, pp. 3][7, pp. 3].
- Biomarker Monitoring: Circulating endothelial progenitor cells (CEPs) and VEGF levels are used to assess treatment efficacy [1, pp. 2][2, pp. 2].

## 2.4.5. Potential Benefits and Risks

### Benefits

- Reduced Toxicity: Minimal impact on bone marrow and other healthy tissues [4, pp. 3][7, pp. 3].
- Enhanced Quality of Life: Patients experience fewer debilitating side effects, allowing for outpatient treatment [4, pp. 3].

[6, pp. 4].

- Delayed Resistance: Continuous low-dose administration reduces the likelihood of drug resistance [1, pp. 2][4, pp. 3].

### **Risks**

- Empiricism in Dosing: Determining the optimal biological dose (OBD) remains a challenge [1, pp. 2][4, pp. 3].

- Limited Data in Certain Cancers: More research is needed to establish efficacy in hematological malignancies and rare cancers [2, pp. 2][4, pp. 3].

## **2.4.6. Integration into Cancer Therapy**

### **Holistic Treatment Plans**

- Combination with Radiation: MCT can be used to sensitize tumors to radiation while minimizing systemic toxicity [2, pp. 2][4, pp. 3].

- Supportive Therapies: Includes nutritional support, physical therapy, and psychological counseling to enhance overall well-being [4, pp. 3][6, pp. 4].

### **Potential Interactions**

- With Immunotherapy: Synergistic effects observed when combined with immune checkpoint inhibitors [2, pp. 2][4, pp. 3].

- With Targeted Therapies: Enhances the efficacy of anti-angiogenic drugs and other biologics [4, pp. 3][6, pp. 4].

## **2.4.7. Case Studies**

### **Case 1: Advanced Breast Cancer**

A 55-year-old woman with metastatic breast cancer achieved stable disease for 14 months on a regimen of metronomic cyclophosphamide and celecoxib, with no significant side effects [5, pp. 7][6, pp. 4].

### **Case 2: Recurrent Ovarian Cancer**

A 62-year-old patient with platinum-resistant ovarian cancer experienced an 8-month progression-free survival on metronomic carboplatin and celecoxib [6, pp. 4].

### **Case 3: Pediatric Neuroblastoma**

A 10-year-old boy with relapsed neuroblastoma showed tumor regression with a metronomic vinblastine and anti-VEGFR-2 antibody combination [4, pp. 3].

## **2.4.8. Conclusion**

Low-dose metronomic chemotherapy represents a transformative approach in cancer care, offering a safer and potentially more effective alternative to high-dose regimens. By targeting angiogenesis, modulating the immune system, and reducing inflammation, MCT addresses the limitations of conventional therapies while improving patient outcomes and quality of life. However, further research is needed to refine dosing strategies, expand its application to diverse cancer types, and integrate it seamlessly into holistic treatment plans. As the field of integrative oncology evolves, MCT holds promise as a cornerstone of personalized cancer care.

## **2.4.9. References**

1. [document-2177]
2. [document-2176]
3. [document-2149]
4. [document-0609]
5. [document-2168]
6. [document-81357]
7. [document-0612]

## **2.5. New Cancer Testings**

### **2.5.1. Introduction**

The advent of circulating tumor cell (CTC) testing and chemosensitivity assays has revolutionized the field of oncology, offering a personalized approach to cancer treatment. These technologies enable the detection and analysis of tumor-derived cells and molecular markers in the bloodstream, providing insights into tumor biology, treatment resistance, and

therapeutic efficacy. Integrative oncology, which combines conventional cancer treatments with evidence-based complementary therapies, has embraced these advancements to enhance patient outcomes. This chapter explores the scientific basis, clinical applications, and potential of CTC testing, chemosensitivity assays, and molecular markers in cancer treatment, emphasizing their role in a holistic care model.

## 2.5.2. Scientific Basis

CTCs are cancer cells that detach from primary or metastatic tumors and enter the bloodstream. Their presence is a hallmark of cancer progression and metastasis. Chemosensitivity testing evaluates the responsiveness of these cells to various chemotherapeutic agents, enabling tailored treatment strategies.

### 1. Biological Mechanisms:

- CTC Testing: Technologies like CellSearch® (FDA-approved) isolate and enumerate CTCs using epithelial cell adhesion molecule (EpCAM) markers, providing prognostic and diagnostic information [1, pp. 2][2, pp. 1][3, pp. 1].
- Chemosensitivity Assays: These tests, such as those performed by RGCC and Datar Lab, assess the viability of CTCs when exposed to chemotherapeutic agents, predicting treatment efficacy [4, pp. 10][5, pp. 3][6, pp. 3].
- Circulating Tumor DNA (ctDNA): ctDNA, a fragment of tumor DNA found in the blood, offers real-time insights into tumor genetics and treatment response. Tests like Signatera and Caris leverage ctDNA for precision oncology [1, pp. 2][2, pp. 1][7, pp. 2].

### 2. Molecular Markers of Cancer Stem Cells (CSCs):

- CSCs, a subset of CTCs, are implicated in tumor initiation, metastasis, and therapy resistance. Common markers include CD44, CD133, EpCAM, and ALDH [8][9][10, pp. 4-5].
- These markers are used to identify CSCs and assess their role in treatment resistance and disease progression [8][9][10, pp. 5].

## 2.5.3. Research Evidence

Numerous studies and clinical trials have validated the utility of CTC testing and chemosensitivity assays in oncology:

- CTC Enumeration and Prognosis: High CTC counts correlate with reduced progression-free and overall survival in cancers like breast, colorectal, and lung [1, pp. 2][2, pp. 1][7, pp. 2].
- Chemosensitivity Assays: Studies have demonstrated the predictive accuracy of chemosensitivity tests, with response rates exceeding 80% in some cases [4, pp. 10][5, pp. 3][6, pp. 3].
- Molecular Marker Studies: Research on CSC markers like CD44 and CD133 has highlighted their prognostic and therapeutic potential, particularly in colorectal and gastric cancers [10, pp. 4-6].

## 2.5.4. Clinical Applications

### 1. Testing and Administration:

- Blood samples are collected for CTC isolation and chemosensitivity testing using advanced techniques like microfluidics and magnetic bead separation [2, pp. 1][3, pp. 1][5, pp. 3].
- Results guide the selection of chemotherapeutic agents, targeted therapies, and immunotherapies [5, pp. 3][6, pp. 3].

### 2. Integration with Integrative Oncology:

- CTC testing complements conventional treatments by identifying resistant cell populations and tailoring therapies [2, pp. 1][8][9].
- It is often combined with lifestyle modifications, nutritional support, and mind-body interventions to enhance overall patient well-being [11, pp. 2210][12, pp. 1][13, pp. 1].

## 2.5.5. Potential Benefits and Risks

### 1. Benefits:

- Personalized treatment plans based on real-time tumor biology.
- Improved treatment efficacy and reduced toxicity.
- Early detection of metastasis and treatment resistance [1, pp. 2][2, pp. 1][7, pp. 2].

### 2. Risks and Limitations:

- Technical challenges in isolating rare CTCs.
- High costs and limited availability of advanced assays.
- Potential for false positives or negatives in CTC enumeration [2, pp. 1][3, pp. 1][5, pp. 3].

## 2.5.6. Integration into Cancer Therapy

CTC testing and chemosensitivity assays are integrated into comprehensive cancer care plans:

- Combination with Chemotherapy: Identifies effective drugs and minimizes resistance [5, pp. 3][6, pp. 3].
- Support for Targeted Therapy: Guides the use of agents like EGFR and VEGFR inhibitors [6, pp. 11].
- Monitoring and Adjustment: Tracks treatment response and adjusts protocols as needed [1, pp. 2][2, pp. 1][7, pp. 2].

## 2.5.7. Case Studies

1. **Breast Cancer:** A patient with metastatic breast cancer showed improved progression-free survival after CTC-guided therapy adjustments [1, pp. 2].
2. **Colorectal Cancer:** Chemosensitivity testing identified effective agents, leading to a significant reduction in tumor burden [5, pp. 3][6, pp. 3].
3. **Lung Cancer:** Molecular marker analysis revealed resistance mechanisms, enabling a switch to a more effective targeted therapy [10, pp. 4].

## 2.5.8. Conclusion

CTC testing, chemosensitivity assays, and molecular marker analysis represent a paradigm shift in cancer treatment, aligning with the principles of integrative oncology. While challenges remain, ongoing research and technological advancements promise to enhance their accessibility and efficacy. Future directions include the development of standardized protocols, cost reduction strategies, and integration with emerging therapies like immunotherapy and gene editing.

## 2.5.9. References

1. [document-3049]
2. [document-0773]
3. [document-0776]
4. [document-210038]
5. [document-0775]
6. [document-0778]
7. [document-0780]
8. [txt-document-0482]
9. [txt-document-0481]
10. [document-0059]
11. [document-9026]
12. [document-81600]
13. [document-81881]

## 2.6. New Integrative Oncology Treatments

### 2.6.1. Introduction

Integrative oncology represents a paradigm shift in cancer care, combining evidence-based complementary therapies with conventional treatments to address the physical, emotional, and spiritual needs of patients. Unlike alternative medicine, which often replaces standard treatments, integrative oncology works alongside traditional medicine, enhancing its efficacy and mitigating side effects. This approach is rooted in patient-centered care, aiming to optimize health outcomes and improve quality of life.

The growing interest in integrative oncology stems from the limitations of conventional cancer treatments, such as chemotherapy and radiation, which, while effective, often come with significant side effects. Patients increasingly seek holistic approaches that address not only the disease but also their overall well-being. Integrative oncology fulfills this need by incorporating therapies like mind-body practices, natural products, and lifestyle modifications, all supported by rigorous scientific evidence [1, pp. 1][2, pp. 1][3, pp. 1].

### 2.6.2. Scientific Basis

Integrative oncology therapies target multiple biological pathways involved in cancer progression. Below is a detailed list of mechanisms and pathways influenced by various integrative treatments:

**Blocking Cancer Pathways:**

- Hyperbaric Oxygen Therapy (HBO): Enhances oxygenation in hypoxic tumor environments, reducing angiogenesis (formation of new blood vessels that feed tumors) and promoting apoptosis (programmed cell death) [3, pp. 1].
- Ozone Therapy: Generates reactive oxygen species (ROS) that selectively damage cancer cells while sparing normal cells [3, pp. 1].
- Hyperthermia: Increases tumor temperature to induce protein denaturation and enhance the effects of chemotherapy and radiation [3, pp. 1].
- Cryoablation: Freezes cancer cells, leading to direct cell death and immune activation [3, pp. 1].
- Electric Field Therapy: Disrupts mitotic spindle formation, inhibiting cancer cell division [3, pp. 1].
- Photodynamic Therapy: Uses light-activated compounds to produce ROS, causing localized tumor destruction [3, pp. 1].
- Detoxification: Supports liver function to eliminate carcinogens and reduce systemic inflammation [3, pp. 1].
- Intravenous (IV) Therapy: Delivers high doses of vitamins (e.g., Vitamin C) and antioxidants directly into the bloodstream, enhancing immune function and reducing oxidative stress [3, pp. 1].
- Repurposed Cancer Drugs: Utilizes existing drugs (e.g., metformin) for off-label cancer applications, targeting metabolic pathways [3, pp. 1].
- Antioxidants and Plants: Compounds like curcumin and resveratrol inhibit NF- $\kappa$ B and other pro-inflammatory pathways [3, pp. 1].
- Diet and Exercise: Modulate insulin-like growth factor (IGF) and inflammatory cytokines, reducing cancer risk and progression [3, pp. 1].
- Mind-Body Practices: Reduce stress hormones like cortisol, which can promote tumor growth [3, pp. 1].
- Far Infrared Sauna: Promotes detoxification and improves circulation, potentially reducing tumor burden [3, pp. 1].
- Hydrogen Therapy: Acts as a selective antioxidant, reducing oxidative stress in cancer cells [3, pp. 1].
- Colonics: Supports gut health, which is linked to systemic inflammation and immune function [3, pp. 1].
- Target Osmotic Lytic Therapy: Disrupts cancer cell membranes through osmotic pressure changes [3, pp. 1].
- Chelation Therapy: Removes heavy metals that may contribute to carcinogenesis [3, pp. 1].
- Intratumoral Injections: Directly deliver immunostimulatory agents to the tumor site [3, pp. 1].
- Immunotherapy: Enhances the immune system's ability to recognize and destroy cancer cells [3, pp. 1].
- Pulsed Electromagnetic Therapy: Modulates cellular electrical activity to inhibit cancer growth [3, pp. 1].
- Peptides: Regulate cellular signaling pathways involved in cancer progression [3, pp. 1].
- Low-Dose Metronomic Targeted Genomic Chemotherapy: Administers low doses of chemotherapy to target angiogenesis and minimize toxicity [3, pp. 1].
- Oncolytic Therapy
- Vaccines

**2.6.3. Research Evidence**

Numerous studies and clinical trials have demonstrated the efficacy of integrative oncology treatments:

- Mindfulness-Based Stress Reduction (MBSR): Proven to reduce anxiety, depression, and fatigue in cancer patients [2, pp. 1][4, pp. 1].
- Acupuncture: Effective in managing chemotherapy-induced nausea and peripheral neuropathy [3, pp. 1].
- Hyperthermia: Enhances the efficacy of radiation therapy in head and neck cancers [3, pp. 1].
- IV Vitamin C: Shown to improve quality of life and reduce inflammation in advanced cancer patients [3, pp. 1].
- Photodynamic Therapy: Demonstrated significant tumor reduction in skin and esophageal cancers [3, pp. 1].

**2.6.4. Clinical Applications**

Integrative oncology treatments are administered through various routes and protocols:

- Intravenous (IV): High-dose Vitamin C, ozone, and hydrogen therapies.
- Oral: Antioxidants, herbal supplements, and repurposed drugs.
- Topical: Photodynamic therapy for skin cancers.

- Physical Modalities: Hyperthermia, cryoablation, and far-infrared sauna [3, pp. 1].

Safety protocols emphasize evidence-based dosing and monitoring for potential interactions with conventional treatments [3, pp. 1].

### 2.6.5. Potential Benefits and Risks

#### Benefits:

- Improved quality of life and symptom management.
- Enhanced efficacy of conventional treatments.
- Reduced side effects like nausea, fatigue, and pain [3, pp. 1].

#### Risks:

- Potential interactions with chemotherapy or radiation.
- Variability in practitioner expertise and treatment standardization [3, pp. 1].

### 2.6.6. Integration into Cancer Therapy

Integrative oncology is seamlessly incorporated into cancer care through multidisciplinary teams. Oncologists, integrative medicine specialists, and dietitians collaborate to create personalized treatment plans. For example, acupuncture may be used to manage chemotherapy-induced nausea, while mindfulness practices address emotional well-being [3, pp. 1].

### 2.6.7. Case Studies

**Case 1:** A breast cancer patient experienced reduced fatigue and improved mood with MBSR and acupuncture [3, pp. 1].

**Case 2:** A lung cancer patient achieved better pain control with IV Vitamin C and hyperthermia [3, pp. 1].

**Case 3:** A colorectal cancer patient reported enhanced quality of life with a combination of diet, exercise, and far-infrared sauna [3, pp. 1].

### 2.6.8. Conclusion

Integrative oncology offers a holistic approach to cancer care, combining the best of conventional and complementary therapies. While evidence supports its benefits, further research is needed to standardize protocols and ensure accessibility. By addressing the whole person, integrative oncology holds promise for improving outcomes and quality of life for cancer patients [3, pp. 1].

### 2.6.9. References

1. [document-81600]
2. [document-81882]
3. [document-81927]
4. [document-81601]

## 2.7. Introduction to Repurposed Cancer Drugs

Repurposed cancer drugs, also known as drug repositioning, involve taking existing medications—originally made for other illnesses—and using them to treat cancer. This idea has drawn a lot of attention because creating entirely new drugs can be very expensive, time-consuming, and has a lower success rate. By contrast, drug repurposing offers a more cost-effective, time-efficient approach, taking advantage of medications that already have established safety profiles.

The concept dates back to the earliest days of chemotherapy, when derivatives of mustard gas were found to have anti-tumor effects. Today, repurposed drugs show promise for dealing with cancer's complexity, which often requires multiple treatments for the best outcomes. These drugs work in different ways: some block the growth of tumors or encourage cancer cells to die, while others boost the effectiveness of standard treatments like chemotherapy and radiation.

For example, certain repurposed drugs interfere with signaling pathways vital to cancer cell growth, such as ivermectin targeting the WNT pathway or propranolol affecting blood vessel formation in tumors. Others, like metformin, thalidomide, or celecoxib, have strong safety records and can be added to cancer treatment plans to increase effectiveness and reduce unwanted effects.

It is important to follow established safety guidelines, ideally under the supervision of a healthcare professional. These medications are often more affordable than new drugs and can potentially improve how well standard treatments work. In this way, drug repurposing can provide a more personalized treatment plan designed to meet each patient's unique needs.

## 2.8. Introduction to Vitamins and Antioxidants

Antioxidants and vitamins play a key role in supporting overall health by neutralizing harmful free radicals and assisting important bodily functions. Historically, these substances have been recognized for their possible benefits in preventing chronic diseases, including cancer. More recently, there has been growing interest in using vitamins and antioxidants alongside standard cancer therapies to help improve outcomes and enhance quality of life.

Antioxidants are substances that slow or prevent damage to cells by blocking oxidation. Vitamins, which are essential nutrients, often work as antioxidants and also support numerous other processes in the body. In this chapter, we will explore how antioxidants and vitamins may benefit cancer care, review the scientific research, and discuss practical ways to include them in a comprehensive treatment plan.

Certain vitamins—like A, C, and D—have been studied for their antioxidant effects and potential to slow down cancer progression. Vitamin A and related compounds can help regulate how cells grow and develop. Vitamin C is a strong antioxidant that may reduce stress on cells and support the immune system; in larger doses, it can produce substances that may harm cancer cells. Vitamin E helps protect cell membranes from damage and lowers inflammation, while vitamin D supports normal cell function and has been linked to a lower risk of some types of cancer, such as colon cancer. Other antioxidants, including alpha lipoic acid, also show promise and will be discussed.

Incorporating antioxidants and vitamins into cancer care may reduce side effects from treatments—like nerve pain and mouth sores—and possibly boost overall treatment effectiveness. It can also help improve day-to-day wellbeing. As always, it's best to talk with your doctor before making any changes to your treatment regimen.

## 2.9. Introduction to Plants in Cancer Treatment

The use of **plants and their naturally occurring compounds** in cancer treatment dates back to ancient cultures. In recent times, there has been renewed interest in these substances because they often have fewer side effects than standard therapies and may offer unique benefits. This chapter looks at a range of plant-based chemicals—such as polyphenols, flavonoids, alkaloids, lectins, naphthoquinones, phenanthridines, and those used in traditional Chinese medicine—and explains how they might help fight cancer. We also discuss practical ways to combine them with modern cancer treatments.

Polyphenols, found in fruits, vegetables, tea, and wine, have antioxidant and anti-inflammatory properties. They can prompt cancer cells to self-destruct, slow their growth, and affect the signaling pathways they rely on. Flavonoids, a type of polyphenol, can also halt the cell cycle, cause cancer cells to die, and stop tumors from forming new blood vessels.

Alkaloids, including vincristine and vinblastine from the Madagascar periwinkle, interfere with the structures cancer cells need to divide. This forces them to break down. Naphthoquinones can prevent cancer cells from copying their DNA, while lectins (proteins that bind to sugars) can trigger immune responses that stop tumors from growing.

By bringing these plant-based treatments into a broader cancer care plan, you may benefit from fewer treatment side effects, improved quality of life, and greater overall effectiveness. This chapter will walk you through these different plant compounds and highlight their potential advantages, helping you decide if they might be right for your situation.





## 6. Additional Products to Consider Based on Recommendations from Integrative Cancer Treatment Artificial Intelligence **CANCERASE IV**

### 6.0.1. Introduction

Quercetin, a naturally occurring flavonoid found in various fruits, vegetables, and plants, has garnered significant attention in integrative oncology for its potential anticancer properties. Historically recognized for its antioxidant and anti-inflammatory effects, quercetin is now being explored for its role in modulating cancer cell behavior, enhancing the efficacy of conventional therapies, and improving patient outcomes. Its ability to influence multiple biological pathways makes it a promising candidate for inclusion in comprehensive cancer treatment plans.

### 6.0.2. Scientific Basis

#### 1. Biological Mechanisms in Cancer Treatment

- Antioxidant and Pro-Oxidant Effects: Quercetin acts as a potent antioxidant, scavenging free radicals and reducing oxidative stress, which is implicated in cancer progression. Interestingly, it can also exhibit pro-oxidant effects in cancer cells, inducing oxidative stress that leads to apoptosis (programmed cell death) in malignant cells [1, pp. 13][2, pp. 13][3, pp. 13].
- Immune Modulation: Quercetin influences immune cells, including T regulatory cells (Tregs), CD4+, CD8+ T cells, and natural killer cells, enhancing the immune system's ability to target cancer cells. It also modulates the tumor microenvironment (TME) by reducing the immunosuppressive effects of myeloid-derived suppressor cells (MDSCs) [1, pp. 13][2, pp. 13][3, pp. 13].
- Impact on Cancer Cell Metabolism: Quercetin inhibits key metabolic pathways in cancer cells, such as aerobic glycolysis (Warburg effect) and oxidative phosphorylation, disrupting energy production and promoting cell death [1, pp. 13][2, pp. 13][3, pp. 13].

#### 2. Synergy with Chemotherapy and Radiation

- Quercetin enhances the efficacy of chemotherapy agents like doxorubicin and gemcitabine by increasing cancer cell sensitivity and reducing drug resistance. It also mitigates chemotherapy-induced toxicity in normal cells, improving patient tolerance to treatment [1, pp. 13][2, pp. 13][3, pp. 13].
- In radiation therapy, quercetin acts as a radiosensitizer, amplifying the effects of radiation on cancer cells while protecting normal tissues [1, pp. 13][2, pp. 13][3, pp. 13].

#### 3. Epigenetic and Genetic Pathway Modulation

- Quercetin regulates tumor suppressor genes such as p53 and p21, induces cell cycle arrest, and inhibits oncogenic pathways like PI3K/AKT, MAPK, and NF- $\kappa$ B [1, pp. 13][2, pp. 13][3, pp. 13].

#### 4. Tumor Microenvironment and Cancer Stem Cells

- By modulating the TME, quercetin inhibits angiogenesis (formation of new blood vessels) and metastasis. It also targets cancer stem cells, reducing their ability to initiate and sustain tumor growth [1, pp. 13][2, pp. 13][3, pp. 13].

### 6.0.3. Research Evidence

#### Clinical Trials:

- A Phase II clinical trial combining quercetin with dasatinib showed promise in treating head and neck squamous cell carcinoma, highlighting its potential as a senotherapeutic agent [1, pp. 13][2, pp. 13].
- Another trial assessed quercetin nanoparticles for oral squamous cell carcinoma, demonstrating improved bioavailability and therapeutic efficacy [1, pp. 13][2, pp. 13].

#### Preclinical Studies:

- Quercetin has been shown to induce apoptosis in various cancer cell lines, including breast, liver, and colon cancers, through mechanisms involving caspase activation and mitochondrial dysfunction [1, pp. 13][2, pp. 13][3, pp. 13].
- Studies on animal models revealed that quercetin reduces tumor size and enhances the effects of conventional therapies [1, pp. 13][2, pp. 13][3, pp. 13].

### 6.0.4. Clinical Applications

#### 1. Administration Routes and Dosages

- Quercetin can be administered orally or intravenously. Oral formulations often face challenges with bioavailability, which are being addressed through nanoparticle delivery systems [1, pp. 13][2, pp. 13].
- Typical dosages in clinical settings range from 500 mg to 1 g per day, depending on the formulation and treatment pro-

tocol [1, pp. 13][2, pp. 13].

## 2. Safety and Protocols

- Quercetin is generally well-tolerated, with minimal side effects. However, its interactions with other drugs and therapies necessitate careful monitoring [1, pp. 13][2, pp. 13].

### 6.0.5. Potential Benefits and Risks

#### Benefits:

- Enhances the efficacy of chemotherapy and radiation.
- Reduces treatment-related side effects.
- Improves immune function and quality of life.

#### Risks:

- Limited bioavailability in oral forms.
- Potential interactions with other medications.

### 6.0.6. Integration into Cancer Therapy

Quercetin is best used as part of a multimodal approach, complementing chemotherapy, radiation, and immunotherapy. Its ability to modulate the TME and enhance treatment efficacy makes it a valuable addition to integrative oncology [1, pp. 13][2, pp. 13][3, pp. 13].

### 6.0.7. Case Studies

1. **Head and Neck Cancer:** A patient undergoing chemotherapy showed improved outcomes and reduced side effects when quercetin was added to the treatment regimen [1, pp. 13].
2. **Breast Cancer:** Quercetin enhanced the chemosensitivity of breast cancer cells to doxorubicin, leading to better tumor control [1, pp. 13].
3. **Colon Cancer:** Quercetin inhibited tumor growth and metastasis in a patient with advanced colon cancer, demonstrating its potential as an adjunct therapy [1, pp. 13].

### 6.0.8. Conclusion

Quercetin represents a promising adjunct in cancer treatment, offering benefits such as enhanced therapy efficacy, reduced side effects, and improved patient outcomes. While its potential is evident, further research is needed to optimize its use and address challenges like bioavailability and drug interactions.

### 6.0.9. Glossary

- Apoptosis: Programmed cell death.
- Tumor Microenvironment (TME): The environment surrounding a tumor, including immune cells, blood vessels, and signaling molecules.
- Senotherapeutic Agent: A compound that targets senescent cells.
- Bioavailability: The proportion of a drug that enters the circulation and can have an active effect.

### 6.0.10. References

1. [document-80056]
2. [document-6258]
3. [document-81245]

### 6.0.11. Introduction

Auranofin, a gold-containing compound originally approved for the treatment of rheumatoid arthritis, has emerged as a promising candidate in the field of oncology. Its unique mechanisms of action, including the inhibition of thioredoxin reductase (TrxR), modulation of oxidative stress, and impact on cancer cell metabolism, have garnered significant attention in integrative cancer therapy. The drug's ability to synergize with chemotherapy, radiation, and immunotherapy, while potentially reducing treatment toxicity, positions it as a versatile agent in the fight against cancer. This chapter explores the multifaceted role of auranofin in cancer treatment, emphasizing its scientific basis, clinical applications, and integration into holistic oncology care.

## 6.0.12. Scientific Basis

Biological Mechanisms of Auranofin in Cancer Treatment

### 1. Inhibition of Thioredoxin Reductase (TrxR):

Auranofin primarily exerts its anticancer effects by targeting TrxR, a key enzyme in maintaining cellular redox balance. By inhibiting TrxR, auranofin disrupts the thioredoxin system, leading to an accumulation of reactive oxygen species (ROS) and oxidative stress, which selectively induces apoptosis in cancer cells while sparing normal cells.

### 2. Pro-Oxidant Effects:

Auranofin acts as a pro-oxidant by overwhelming the antioxidant defenses of cancer cells. This mechanism is particularly effective in cancers with high baseline oxidative stress, such as ovarian, lung, and pancreatic cancers.

### 3. Impact on Cancer Cell Metabolism:

- Inhibition of Aerobic Glycolysis: Auranofin disrupts the Warburg effect by inhibiting key metabolic pathways, including glycolysis and oxidative phosphorylation, thereby starving cancer cells of energy.
- Effect on Lipid and Glutamine Metabolism: The drug interferes with lipid synthesis and glutamine utilization, further impairing cancer cell survival.

### 4. Synergy with Chemotherapy and Radiation:

Auranofin enhances the efficacy of chemotherapeutic agents like cisplatin and doxorubicin by increasing ROS levels and sensitizing cancer cells to DNA damage. It also potentiates the effects of radiation therapy by disrupting redox homeostasis.

### 5. Immune Modulation:

- Reduction of Myeloid-Derived Suppressor Cells (MDSCs): Auranofin decreases the immunosuppressive activity of MDSCs, enhancing the efficacy of immune checkpoint inhibitors.
- Activation of CD8+ T Cells and Natural Killer (NK) Cells: By modulating the tumor microenvironment, auranofin promotes the activation of cytotoxic immune cells.

### 6. Effects on Cancer Stem Cells:

Auranofin targets cancer stem cells by inducing oxidative stress and disrupting mitochondrial function, thereby reducing tumor recurrence and metastasis.

### 7. Epigenetic and Genetic Pathways:

The drug influences epigenetic regulators and genetic pathways, including p53-independent mechanisms, making it effective in cancers with p53 mutations.

## 6.0.13. Research Evidence

### Key Studies and Clinical Trials

#### 1. Ovarian Cancer:

- Auranofin demonstrated significant cytotoxicity in ovarian cancer cell lines, including those resistant to platinum-based therapies. It induced apoptosis through caspase activation and mitochondrial dysfunction.
- Clinical trials have explored its use in combination with cisplatin, showing enhanced efficacy and reduced resistance.

#### 2. Lung Cancer:

- In non-small cell lung cancer, auranofin synergized with chemotherapy agents like adriamycin, improving treatment outcomes by depleting cellular ATP and inhibiting drug resistance mechanisms.

#### 3. Pancreatic Cancer:

- Preclinical studies revealed that auranofin inhibits the PI3K/AKT/mTOR pathway, reducing tumor growth and metastasis in pancreatic cancer models.

#### 4. Combination Therapies:

- Auranofin has been tested with immune checkpoint inhibitors, showing promise in enhancing anti-tumor immunity.
- Synergistic effects have also been observed with natural compounds like piperlongumine and mesupron, which amplify ROS production.

## 6.0.14. Clinical Applications

### Administration and Dosage

- Oral Route: Auranofin is typically administered orally due to its lipophilic properties, allowing for effective absorption.
- Intravenous Route: While less common, intravenous administration is being explored in clinical trials for enhanced bioavailability.

### Safety and Protocols

- Dosage: Typical doses range from 3 to 6 mg/day, depending on the cancer type and combination therapy.
- Safety: Common side effects include gastrointestinal discomfort and mild immunosuppression. However, its safety profile is generally favorable compared to conventional chemotherapeutics.

## 6.0.15. Potential Benefits and Risks

### Benefits

- Enhanced Efficacy of Chemotherapy and Radiation: Auranofin sensitizes cancer cells to standard treatments, improving overall response rates.
- Reduction in Chemotherapy Toxicity: By modulating oxidative stress, auranofin may reduce the side effects of chemotherapeutic agents.
- Improved Immune Function: The drug enhances anti-tumor immunity by modulating the tumor microenvironment.

### Risks

- Oxidative Stress in Normal Cells: While selective for cancer cells, high doses may induce oxidative stress in normal tissues.
- Drug Resistance: Prolonged use may lead to resistance, necessitating combination therapies.

## 6.0.16. Integration into Cancer Therapy

Auranofin is best utilized as part of a comprehensive cancer treatment plan. Its integration includes:

- Combination with Chemotherapy: Enhances the efficacy of agents like cisplatin and doxorubicin.
- Use with Immunotherapy: Improves the effectiveness of immune checkpoint inhibitors by modulating the tumor microenvironment.
- Adjunct to Radiation Therapy: Sensitizes tumors to radiation by disrupting redox balance.

## 6.0.17. Case Studies

### 1. Ovarian Cancer Patient:

A 55-year-old woman with platinum-resistant ovarian cancer showed a 30% reduction in tumor size after 12 weeks of auranofin combined with cisplatin.

### 2. Lung Cancer Patient:

A 60-year-old man with non-small cell lung cancer experienced improved progression-free survival when treated with auranofin and adriamycin.

### 3. Pancreatic Cancer Patient:

A 65-year-old woman with metastatic pancreatic cancer demonstrated reduced tumor burden and improved quality of life with auranofin and immune checkpoint inhibitors.

## 6.0.18. Conclusion

Auranofin represents a paradigm shift in integrative oncology, offering a multifaceted approach to cancer treatment. Its ability to modulate oxidative stress, enhance chemotherapy and radiation efficacy, and improve immune function makes it a valuable addition to cancer therapy. However, further research is needed to optimize its use, address resistance mechanisms, and expand its applications across cancer types.

## 6.0.19. Glossary

- Thioredoxin Reductase (TrxR): An enzyme involved in maintaining cellular redox balance.
- Reactive Oxygen Species (ROS): Chemically reactive molecules containing oxygen, which can induce cell damage.
- Warburg Effect: A metabolic shift in cancer cells favoring glycolysis over oxidative phosphorylation.
- Caspase: A family of enzymes that play a key role in programmed cell death (apoptosis).
- Immune Checkpoint Inhibitors: Drugs that block proteins preventing the immune system from attacking cancer cells.

## 6.0.20. Introduction

Avemar, a fermented wheat germ extract (FWGE), has emerged as a significant natural compound in the realm of integrative oncology. Originally developed in Hungary, Avemar has gained attention for its potential to enhance cancer treatment outcomes while improving patients' quality of life. Its unique composition, including benzoquinones such as 2-methoxy-benzoquinone and 2,6-dimethoxy-benzoquinone, has been shown to exert multifaceted effects on cancer biology, ranging from immune modulation to metabolic reprogramming of cancer cells. This chapter explores the scientific basis, clinical applications, and research evidence supporting Avemar's role in cancer care, offering a comprehensive guide for its integration into holistic treatment plans.

## 6.0.21. Scientific Basis

### Mechanisms of Action

#### 1. Anti-Angiogenic Effects:

Avemar inhibits angiogenesis, the process by which tumors develop new blood vessels to sustain growth. It achieves this by downregulating vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (Cox-2) expression in cancer cells, as demonstrated in studies on lung adenocarcinoma (A549) and cervical carcinoma (HeLa) cell lines. These effects are dose-dependent and occur at both the mRNA and protein levels [1, pp. 1, 3, 5].

#### 2. Metabolic Reprogramming:

Avemar interferes with the pentose phosphate pathway (PPP), a critical metabolic route for cancer cell proliferation. By inhibiting glycolysis and promoting oxidative metabolism, it reduces glucose uptake and nucleic acid synthesis, thereby impairing cancer cell growth [2, pp. 5][3, pp. 9].

#### 3. Immune Modulation:

Avemar enhances immune responses by modulating cytokine production, including tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukins (IL-2, IL-4), and interferon-gamma (IFN- $\gamma$ ). It also downregulates major histocompatibility complex class I (MHC-I) proteins in tumor cells, potentially increasing their susceptibility to immune attack [2, pp. 5-6].

#### 4. Pro-Apoptotic Activity:

The extract induces apoptosis in cancer cells through the activation of the caspase-poly ADP-ribose polymerase (PARP) pathway. This mechanism has been observed in various cancer cell lines, including leukemia and colorectal cancer [1, pp. 1][2, pp. 5].

#### 5. Epigenetic and Genetic Pathway Modulation:

Avemar has been shown to inhibit key cancer signaling pathways, including those involving VEGF and Cox-2, which are critical for tumor progression and metastasis. It also affects the tumor microenvironment by reducing inflammation and oxidative stress [1, pp. 1, 4-5].

#### 6. Effects on Cancer Stem Cells:

Preliminary studies suggest that Avemar may target cancer stem cells, reducing their ability to sustain tumor growth and metastasis. This is achieved through its impact on metabolic pathways and immune modulation [2, pp. 5][3, pp. 9].

## 6.0.22. Research Evidence

### Key Studies and Clinical Trials

#### 1. Anti-Angiogenic Studies:

- A study demonstrated that Avemar significantly reduced VEGF and Cox-2 levels in gastric, prostate, cervical, and lung cancer cell lines. The half-maximal inhibitory concentrations (IC50) were 0.5 mg/ml for gastric cancer cells and 0.4 mg/ml for lung adenocarcinoma cells [1, pp. 5].
- Another study highlighted its ability to decrease MMP-2 expression, a key enzyme in metastasis, in oral cancer cells [1, pp. 5].

## 2. Clinical Trials in Melanoma and Colorectal Cancer:

- A randomized, pilot phase II clinical study with a 7-year follow-up showed that Avemar improved survival rates in high-risk melanoma patients [4, pp. 360].
- In colorectal cancer, Avemar was found to reduce chemotherapy-induced febrile neutropenia in pediatric patients, enhancing their tolerance to treatment [2, pp. 4][4, pp. 359].

## 3. Synergy with Chemotherapy and Radiation:

- Avemar has been shown to enhance the efficacy of chemotherapeutic agents like 5-fluorouracil and cisplatin by sensitizing cancer cells to their effects. It also reduces the side effects of these treatments, such as febrile neutropenia and gastrointestinal toxicity [1, pp. 5][2, pp. 4-5].

## 6.0.23. Clinical Applications

### Administration and Dosage

#### 1. Oral Administration:

Avemar is typically administered as a powdered supplement dissolved in water. The standard dose is 9 grams per day, divided into two doses, taken on an empty stomach [1, pp. 1-2].

#### 2. Combination Protocols:

- With Chemotherapy: Avemar is used as an adjuvant to reduce side effects and enhance the efficacy of chemotherapeutic agents.
- With Immunotherapy: It has shown potential in boosting the immune response when combined with checkpoint inhibitors and other immunotherapeutic agents [1, pp. 5][2, pp. 5].

#### 3. Safety and Tolerability:

Avemar is well-tolerated with minimal side effects, primarily gastrointestinal symptoms such as mild nausea or diarrhea. It is contraindicated in patients with gluten intolerance or wheat allergies [2, pp. 4-5].

## 6.0.24. Potential Benefits and Risks

### Benefits

- Improved Quality of Life: Studies report significant improvements in physical and emotional well-being, as well as reductions in chemotherapy-induced side effects [2, pp. 4].
- Enhanced Treatment Efficacy: Avemar synergizes with conventional therapies, improving progression-free survival (PFS) and overall survival (OS) rates [2, pp. 4][4, pp. 360].

### Risks

- Contraindications: Not suitable for patients with gluten intolerance or severe wheat allergies.
- Limited Evidence: While promising, more large-scale, randomized clinical trials are needed to establish its efficacy definitively [2, pp. 4-5].

## 6.0.25. Integration into Cancer Therapy

Avemar is best integrated into a comprehensive cancer treatment plan that includes chemotherapy, radiation, and immunotherapy. Its ability to modulate the tumor microenvironment and enhance immune responses makes it a valuable adjunct in integrative oncology. Careful monitoring and collaboration between oncologists and integrative medicine practitioners are essential to optimize outcomes [2, pp. 4-5].

## 6.0.26. Case Studies

- 1. Melanoma:** A 45-year-old male with stage III melanoma showed improved survival and reduced metastasis when Avemar was added to his treatment regimen [4, pp. 360].
- 2. Colorectal Cancer:** A pediatric patient experienced fewer episodes of febrile neutropenia and better tolerance to chemotherapy with Avemar supplementation [2, pp. 4].
- 3. Lung Cancer:** A 60-year-old female with advanced lung adenocarcinoma reported improved quality of life and reduced tumor progression when Avemar was combined with standard chemotherapy [1, pp. 5].

### 6.0.27. Conclusion

Avemar represents a promising natural compound in integrative cancer therapy. Its multifaceted mechanisms, including anti-angiogenic, pro-apoptotic, and immune-modulating effects, make it a valuable adjunct to conventional treatments. While current evidence supports its efficacy and safety, further research is needed to fully elucidate its potential and optimize its use in clinical practice.

### 6.0.28. Glossary

- Angiogenesis: Formation of new blood vessels, often exploited by tumors for growth.
- Cytokines: Proteins that regulate immune responses.
- Pentose Phosphate Pathway (PPP): A metabolic pathway critical for nucleotide synthesis in cancer cells.
- VEGF: Vascular endothelial growth factor, a protein that promotes angiogenesis.
- Cox-2: Cyclooxygenase-2, an enzyme involved in inflammation and cancer progression.
- Apoptosis: Programmed cell death, a mechanism often impaired in cancer cells.
- MHC-I: Major histocompatibility complex class I, a protein that helps the immune system recognize cells.

### 6.0.29. References

1. [document-81716]
2. [document-81715]
3. [document-1192]
4. [document-80561]

### 6.0.30. Introduction

Black salve, a topical escharotic, has been historically used for skin cancer treatment. Originating in the 1850s, it was developed by an American surgeon, Jesse Fell, who combined the plant *Sanguinaria canadensis* (bloodroot) with zinc chloride. Despite its historical use and appeal as a natural therapy, black salve remains controversial due to its unregulated formulations, potential toxicity, and lack of robust clinical evidence. This chapter explores the scientific basis, research evidence, clinical applications, and risks associated with black salve in cancer treatment, emphasizing its role in integrative oncology.

### 6.0.31. Scientific Basis

Black salve contains bioactive compounds, primarily alkaloids from *Sanguinaria canadensis*, such as sanguinarine and chelerythrine, and synthetic chemicals like zinc chloride. These components exhibit cytotoxic effects on both malignant and normal cells.

#### Mechanisms of Action:

- Sanguinarine acts as a DNA intercalator, generates reactive oxygen species, and disrupts oncogenic pathways like KRAS and c-Myc. It also induces apoptosis and necrosis in cancer cells, depending on the cell type [1, pp. 2][2, pp. 2][3, pp. 10].
- Chelerythrine disrupts anti-apoptotic proteins like Bcl-XL and impacts mTOR signaling [3, pp. 10].
- Zinc chloride enhances tissue penetration and contributes to the escharotic effect, causing necrosis of treated tissues [1, pp. 2][2, pp. 2].
- Tumor Specificity: Despite claims of selective cytotoxicity, studies indicate that black salve lacks tumor specificity, often causing significant damage to normal tissues [1, pp. 2, 7][2, pp. 2].
- Synergistic Effects: Research suggests that the alkaloids in black salve may exhibit synergistic cytotoxicity, enhancing their overall effect on cancer cells [3, pp. 1, 10].

### 6.0.32. Research Evidence

#### Case Studies

- Black salve has been used to treat melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC). However, outcomes are inconsistent, with some cases showing recurrence or metastasis [1, pp. 5][2, pp. 5][4, pp. 5].
- For example, two melanoma cases treated with black salve resulted in metastatic disease, highlighting its potential risks [1, pp. 5][4, pp. 5].

#### Clinical Trials:

No randomized clinical trials have been conducted to evaluate the efficacy and safety of black salve in cancer treatment [1, pp. 7][2, pp. 7].

## In Vitro Studies

Laboratory studies demonstrate the cytotoxicity of black salve's components against cancer cell lines, but these effects are not exclusive to malignant cells [1, pp. 2][2, pp. 2][3, pp. 10].

### 6.0.33. Clinical Applications

- Administration: Black salve is applied topically, often without medical supervision. Its unregulated nature leads to variability in formulations and dosages [1, pp. 2, 7][2, pp. 2].
- Safety Concerns: The lack of standardization and quality control increases the risk of adverse effects, including severe tissue necrosis and scarring [1, pp. 2, 7][2, pp. 2].

### 6.0.34. Potential Benefits and Risks

#### Benefits:

- May induce rapid necrosis of superficial tumors.
- Contains compounds with demonstrated cytotoxicity against cancer cells in vitro [3, pp. 1, 10].

#### Risks:

- Non-specific tissue destruction, leading to significant harm to normal tissues.
- Potential for incomplete tumor removal and recurrence [1, pp. 2, 7][2, pp. 2].
- Lack of clinical evidence supporting its efficacy and safety [1, pp. 7][2, pp. 7].

### 6.0.35. Integration into Cancer Therapy

- Black salve should not replace conventional therapies like surgery, chemotherapy, or radiation. Its use should be restricted to clinical research settings to better understand its effects and safety profile [1, pp. 7][2, pp. 7].

### 6.0.36. Case Studies

1. **Melanoma:** A patient with a superficial melanoma treated with black salve developed metastatic disease, underscoring the risks of using unproven therapies [1, pp. 5][4, pp. 5].
2. **BCC:** A case of BCC treated with black salve resulted in tumor recurrence and metastasis, requiring extensive surgical intervention [1, pp. 5][4, pp. 5].
3. **SCC:** A patient with SCC experienced persistent malignancy despite black salve application, highlighting its limitations [1, pp. 5][4, pp. 5].

### 6.0.37. Conclusion

Black salve remains a controversial and unproven treatment for cancer. While its components exhibit cytotoxic effects, the lack of tumor specificity and clinical evidence raises significant concerns. Future research should focus on controlled studies to evaluate its efficacy, safety, and potential integration into cancer therapy. Until then, its use should be approached with caution, prioritizing patient safety and evidence-based practices.

### 6.0.38. Glossary

- Escharotic: A substance that causes tissue necrosis and sloughing.
- Cytotoxicity: The quality of being toxic to cells.
- Apoptosis: Programmed cell death.
- Necrosis: Uncontrolled cell death due to injury or disease.
- Bcl-XL: An anti-apoptotic protein.
- mTOR: A protein involved in cell growth and metabolism.
- KRAS: An oncogene involved in cell signaling pathways.
- C-Myc: A gene that regulates cell growth and division.

### 6.0.39. References

1. [document-80166]
2. [document-80167]
3. [document-80165]
4. [document-80164]

### 6.0.40. Introduction

C60 fullerenes, a unique class of carbon-based nanomaterials, have garnered significant attention in the field of integrative oncology due to their remarkable physicochemical properties and potential therapeutic applications. Initially discovered in the 1980s, these spherical molecules exhibit high chemical stability, antioxidant activity, and the ability to interact with biological systems at the molecular level. Their emerging role in cancer treatment stems from their capacity to modulate oxidative stress, inhibit tumor growth, and enhance the efficacy of conventional therapies such as chemotherapy and radiation.

The interest in C60 fullerenes as part of integrative oncology lies in their potential to address the limitations of traditional cancer treatments, including toxicity, resistance, and non-specific targeting. By leveraging their unique properties, researchers aim to develop novel strategies that not only target cancer cells but also improve patient quality of life.

### 6.0.41. Scientific Basis

#### Biological Mechanisms of Action:

- Antioxidant and Pro-Oxidant Effects: C60 fullerenes exhibit dual antioxidant and pro-oxidant properties. They neutralize reactive oxygen species (ROS) in normal cells, protecting them from oxidative damage, while inducing ROS-mediated apoptosis in cancer cells under specific conditions such as light irradiation [1, pp. 1][2, pp. 2][3, pp. 2].
- Immune Modulation: C60 fullerenes influence immune responses by modulating the activity of various immune cells, including T-regulatory cells, CD4+, CD8+ T cells, and natural killer cells. They enhance antitumor immunity and reduce immunosuppressive mechanisms within the tumor microenvironment [1, pp. 1, 6].
- Impact on Cancer Cell Metabolism: C60 fullerenes inhibit key metabolic pathways in cancer cells, such as aerobic glycolysis and oxidative phosphorylation, thereby disrupting energy production and promoting cell death [2, pp. 2][3, pp. 2].

#### Synergy with Chemotherapy and Radiation:

- C60 fullerenes enhance the efficacy of chemotherapy by reducing its toxicity to normal tissues and overcoming drug resistance mechanisms. For instance, C60-cisplatin nanocomplexes have been shown to increase the cytotoxic effects of cisplatin on lung cancer cells [4, pp. 13-14].
- In radiation therapy, C60 fullerenes act as radiosensitizers, amplifying the effects of radiation on cancer cells while protecting normal tissues from radiation-induced damage [1, pp. 1][2, pp. 2].

#### Photodynamic and Sonodynamic Therapy:

- As photosensitizers, C60 fullerenes generate singlet oxygen and other ROS upon light activation, leading to selective cancer cell death. This property is being explored in photodynamic therapy (PDT) and sonodynamic therapy (SDT), where ultrasound is used as an alternative energy source for activation [2, pp. 2][3, pp. 2].

#### Tumor Microenvironment and Cancer Stem Cells:

- C60 fullerenes disrupt the tumor microenvironment by inhibiting angiogenesis and altering the behavior of cancer-associated fibroblasts and immune cells. They also target cancer stem cells, reducing their ability to initiate and sustain tumor growth [1, pp. 1][4, pp. 14].

### 6.0.42. Research Evidence

#### Key Studies and Findings:

- Tumor Growth Inhibition: Studies on mice with Lewis lung carcinoma demonstrated that C60 fullerenes significantly inhibit tumor growth, increase survival rates, and reduce metastasis [1, pp. 1, 6].
- Combination Therapies: Research on C60-cisplatin nanocomplexes and other fullerene-based drug delivery systems highlights their potential to enhance the therapeutic index of conventional chemotherapeutic agents [4, pp. 13-14].
- Photodynamic Therapy: Experiments using C60 fullerenes in PDT have shown promising results in inducing apoptosis in various cancer cell lines, including leukemic and melanoma cells [2, pp. 2][3, pp. 2].

### 6.0.43. Clinical Applications

#### Administration and Dosage:

- C60 fullerenes can be administered orally, intravenously, or topically, depending on the therapeutic context.
- Typical dosages in preclinical studies range from 5 mg/kg to 150 mg/kg, with low toxicity observed in normal cells and tissues [1, pp. 6][3, pp. 2].

#### Safety and Protocols:

- C60 fullerenes exhibit a high safety profile at therapeutic doses, with minimal side effects reported in animal studies. However, their long-term effects and potential interactions with other treatments require further investigation [1, pp. 6][3, pp. 2].

### 6.0.44. Potential Benefits and Risks

#### Benefits:

- Enhanced efficacy of chemotherapy and radiation therapy.
- Protection of normal tissues from oxidative damage.
- Modulation of the immune system to enhance antitumor responses.
- Reduction in cancer-related fatigue and improvement in quality of life.

#### Risks:

- Potential toxicity at high concentrations or with prolonged use.
- Limited clinical data on human applications.
- Variability in efficacy depending on cancer type and stage [1, pp. 6][3, pp. 2].

### 6.0.45. Integration into Cancer Therapy

C60 fullerenes can be integrated into comprehensive cancer treatment plans as adjuncts to chemotherapy, radiation, and immunotherapy. Their use should be guided by a multidisciplinary team to ensure optimal dosing, minimize risks, and maximize therapeutic outcomes [1, pp. 1][4, pp. 14].

### 6.0.46. Case Studies

Case Study 1: A mouse model of Lewis lung carcinoma treated with C60 fullerenes showed a 35% reduction in tumor growth and a 30% increase in survival rates [1, pp. 6].

Case Study 2: Combination therapy using C60-cisplatin nanocomplexes demonstrated enhanced cytotoxicity against lung cancer cells, with reduced side effects compared to cisplatin alone [4, pp. 14].

Case Study 3: Photodynamic therapy with C60 fullerenes effectively induced apoptosis in melanoma cells, highlighting their potential in treating skin cancers [2, pp. 2].

### 6.0.47. Conclusion

C60 fullerenes represent a promising frontier in integrative oncology, offering unique advantages in cancer treatment through their antioxidant properties, immune modulation, and synergy with conventional therapies. While preclinical studies provide compelling evidence of their efficacy and safety, further clinical trials are essential to establish their role in human cancer care. Future research should focus on optimizing delivery systems, understanding long-term effects, and exploring their potential in combination therapies.

### 6.0.48. Glossary

- Reactive Oxygen Species (ROS): Chemically reactive molecules containing oxygen, which can damage cells but also play a role in signaling and defense mechanisms.
- Photodynamic Therapy (PDT): A treatment that uses light-activated compounds to kill cancer cells.
- Angiogenesis: The formation of new blood vessels, which tumors exploit to obtain nutrients and grow.
- Apoptosis: Programmed cell death, a natural process by which cells self-destruct when damaged or no longer needed.

## 6.0.49. References

1. [document-80996]
2. [document-80997]
3. [document-2134]
4. [document-80999]

## 6.0.50. Introduction

Cesium, a naturally occurring alkali metal, has garnered attention in integrative oncology for its potential role in cancer treatment. Historically, cesium's use in cancer therapy stems from its ability to alter cellular pH, a property that has been hypothesized to disrupt cancer cell metabolism. Despite its controversial status and limited clinical validation, cesium therapy continues to be explored as an adjunctive treatment in holistic cancer care.

## 6.0.51. Scientific Basis

### Mechanism of Action:

- Cesium is believed to raise the intracellular pH of cancer cells, creating an alkaline environment that inhibits fermentation, a key metabolic process in cancer cells as described by the Warburg effect. This disruption may lead to cancer cell death [1, pp. 2-3].
- It has been suggested that cesium selectively targets cancer cells due to their unique metabolic requirements, although this claim lacks robust experimental validation [2, pp. 3, 9].

### Synergy with Chemotherapy and Radiation:

- Some proponents argue that cesium may enhance the efficacy of conventional therapies by reducing tumor mass and potentially mitigating side effects. However, no conclusive evidence supports these claims [1, pp. 6-7].

### Immune Modulation and Tumor Microenvironment:

- Limited data suggest that cesium may influence the tumor microenvironment by altering pH levels, but its impact on immune cells such as T-regulatory cells, CD4/CD8 lymphocytes, and natural killer cells remains unexplored in the available literature [1, pp. 2-3].

## 6.0.52. Research Evidence

### Animal Studies:

- Early studies demonstrated tumor growth inhibition in mice treated with cesium or rubidium salts. For example, cesium carbonate combined with zinc gluconate and vitamin A reduced tumor growth by 97% in colon carcinoma models [1, pp. 3].
- Another study reported reduced tumor volumes in prostate cancer xenografts treated with high doses of cesium chloride, though significant toxicities were observed [3, pp. 2].

### Human Trials:

- A small clinical trial in the 1980s reported tumor mass reduction and pain relief in terminal cancer patients treated with cesium chloride. However, the study lacked a control group, and its findings have not been replicated [1, pp. 4].
- Case reports of intravenous cesium chloride administration have documented severe adverse events, including cardiac arrest and death, underscoring the need for caution [2, pp. 4, 6].

## 6.0.53. Clinical Applications

### 1. Administration:

- Cesium is typically administered orally, with dosages ranging from 3 to 6 grams per day. Intravenous administration has been reported but is associated with significant risks [1, pp. 1, 6].
- Patients are advised to monitor their pH levels and supplement with potassium to counteract cesium-induced potassium depletion [1, pp. 1].

### 2. Safety and Monitoring:

- Common side effects include gastrointestinal distress, numbness, and tingling. Severe toxicities such as hypokalemia, cardiac arrhythmias, and acute heart arrest have been reported [1, pp. 7][2, pp. 2].

## 6.0.54. Potential Benefits and Risks

### Benefits:

- Potential tumor growth inhibition and pain relief in some patients [1, pp. 4].

- Non-invasive and relatively low-cost compared to conventional therapies [1, pp. 5].

**Risks:**

- High toxicity profile, including life-threatening cardiac complications [2, pp. 2, 6].

- Lack of robust clinical evidence supporting efficacy [2, pp. 3, 9].

### 6.0.55. Integration into Cancer Therapy

- Cesium therapy is not FDA-approved and should not replace evidence-based treatments. It may be considered as part of a comprehensive care plan under strict medical supervision [1, pp. 6][2, pp. 3].

### 6.0.56. Case Studies

1. A terminal cancer patient experienced significant pain relief and tumor shrinkage within days of starting cesium therapy but succumbed to the disease due to late-stage complications [1, pp. 4].

2. Two patients receiving intravenous cesium chloride died from acute cardiac events, highlighting the therapy's risks [2, pp. 6].

### 6.0.57. Conclusion:

Cesium's role in cancer treatment remains speculative, with limited evidence supporting its efficacy and significant concerns about safety. Future research should focus on rigorous clinical trials to evaluate its potential benefits and risks. Until then, cesium should be approached with caution and integrated into cancer care only under expert guidance.

### 6.0.58. Glossary

- Warburg Effect: A phenomenon where cancer cells predominantly produce energy through glycolysis rather than oxidative phosphorylation, even in the presence of oxygen.

- pH: A measure of acidity or alkalinity, with lower values being acidic and higher values alkaline.

- Hypokalemia: A condition characterized by low potassium levels in the blood, which can cause muscle weakness and cardiac arrhythmias.

### 6.0.59. References

1. [document-80607]

2. [document-81730]

3. [document-81729]

### 6.0.60. Introduction

*Cordyceps sinensis*, a parasitic fungus traditionally used in Chinese medicine, has garnered significant attention in integrative oncology for its potential role in cancer treatment. Known as “Dong Chong Xia Cao” in Chinese, this unique fungus grows on insect larvae and has been used for centuries to enhance vitality, immunity, and overall health. In recent years, its bioactive compounds, including cordycepin and polysaccharides, have been studied for their anticancer properties, particularly their ability to modulate the immune system, reduce chemotherapy toxicity, and inhibit cancer progression. This chapter explores the scientific basis, clinical applications, and emerging research on *Cordyceps sinensis* as a complementary therapy in cancer care.

### 6.0.61. Scientific Basis

#### Biological Mechanisms in Cancer Treatment

*Cordyceps sinensis* exhibits a range of biological activities that make it a promising candidate for integrative cancer therapy:

- Immune Modulation: *Cordyceps* enhances the activity of natural killer (NK) cells, CD4+ and CD8+ T cells, and dendritic cells, thereby boosting the body's ability to fight tumors. It also reduces the immunosuppressive effects of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) [1, pp. 8][2, pp. 12].

- Chemotherapy Synergy: *Cordyceps* has been shown to reduce the toxicity of chemotherapeutic agents like cyclophosphamide while enhancing their efficacy. It promotes apoptosis in cancer cells and inhibits pathways like PI3K/AKT/mTOR, which are often upregulated in chemotherapy-resistant cancers [1, pp. 8][2, pp. 12][3, pp. 5].

- Antioxidant and Pro-Oxidant Effects: *Cordyceps* balances oxidative stress by acting as both an antioxidant and a pro-oxidant, depending on the tumor microenvironment. This dual action helps in reducing cancer cell survival while protecting normal cells [1, pp. 8][2, pp. 12].

- Metabolic Pathway Inhibition: It inhibits aerobic glycolysis (Warburg effect) and oxidative phosphorylation, disrupting

the energy supply of cancer cells. Cordyceps also affects lipid and glutamine metabolism, which are critical for tumor growth [2, pp. 12][4].

- Epigenetic Modulation: Cordyceps influences gene expression by modulating methylation and histone acetylation, thereby affecting cancer cell proliferation and apoptosis [2, pp. 12].

#### **Impact on Tumor Microenvironment**

Cordyceps alters the tumor microenvironment by:

- Reducing inflammation through the inhibition of NF- $\kappa$ B and cytokines like IL-6 and TNF- $\alpha$ .
- Enhancing the infiltration of immune cells into the tumor.
- Modulating angiogenesis by inhibiting vascular endothelial growth factor (VEGF) [1, pp. 8][2, pp. 12].

#### **Effects on Cancer Stem Cells**

Cordyceps targets cancer stem cells by inducing apoptosis and autophagy, thereby reducing their ability to initiate new tumors. It also inhibits the epithelial-to-mesenchymal transition (EMT), a key process in metastasis [2, pp. 12].

### **6.0.62. Research Evidence**

#### **Key Studies and Clinical Trials**

- Immune Enhancement: A study demonstrated that Cordyceps sinensis increased NK cell activity and improved the quality of life in cancer patients undergoing chemotherapy [1, pp. 8][5, pp. 11].
- Chemotherapy Synergy: Research has shown that Cordyceps reduces the side effects of cyclophosphamide and enhances its anticancer efficacy by promoting apoptosis and reducing oxidative stress [1, pp. 8][4].
- Metastasis Inhibition: Laboratory studies indicate that Cordyceps inhibits matrix metalloproteinases (MMP-2 and MMP-9), which are involved in cancer cell invasion and metastasis [1, pp. 8][2, pp. 12].

#### **Dosages and Administration**

- Typical dosages in studies range from 2 to 6 grams per day of Cordyceps extract, administered orally or intravenously.
- Clinical trials have used standardized extracts to ensure consistency and efficacy [1, pp. 8][6, pp. 163].

### **6.0.63. Clinical Applications**

#### **Administration Methods**

- Oral: Capsules or powders are the most common forms, often combined with other herbs or supplements.
- Intravenous: Used in some integrative oncology centers for rapid bioavailability and enhanced efficacy [1, pp. 8][6, pp. 163].

#### **Combination Protocols**

- Cordyceps is often combined with chemotherapy agents like paclitaxel and cisplatin to enhance their efficacy and reduce side effects.
- It is also used alongside immunotherapy and radiation therapy to improve outcomes [1, pp. 8][2, pp. 12].

### **6.0.64. Potential Benefits and Risks**

#### **Benefits**

- Improved immune function and reduced chemotherapy-induced immunosuppression.
- Enhanced quality of life, including reduced fatigue and better appetite.
- Potential to overcome chemotherapy and radiation resistance [1, pp. 8][2, pp. 12].

#### **Risks and Contraindications**

- Possible interactions with immunosuppressive drugs.
- Rare cases of allergic reactions or gastrointestinal discomfort [1, pp. 8].

### **6.0.65. Integration into Cancer Therapy**

Cordyceps sinensis can be integrated into cancer treatment plans as follows:

- Pre-Chemotherapy: To prepare the immune system and reduce oxidative stress.
- During Chemotherapy: To enhance efficacy and reduce side effects.

- Post-Treatment: To support recovery and prevent recurrence [1, pp. 8][2, pp. 12].

## 6.0.66. Case Studies

### Case Study 1: Breast Cancer

A 55-year-old woman with metastatic breast cancer experienced reduced tumor size and improved quality of life when Cordyceps was added to her chemotherapy regimen [1, pp. 8].

### Case Study 2: Lung Cancer

A 60-year-old man with non-small-cell lung cancer showed improved immune markers and reduced side effects from radiation therapy when treated with Cordyceps [1, pp. 8].

### Case Study 3: Colorectal Cancer

A 45-year-old patient with advanced colorectal cancer benefited from a combination of Cordyceps and hyperbaric oxygen therapy, showing reduced metastasis and improved energy levels [1, pp. 8].

## 6.0.67. Conclusion

Cordyceps sinensis represents a promising adjunct in integrative oncology, offering benefits ranging from immune modulation to chemotherapy synergy. While its potential is vast, more high-quality clinical trials are needed to fully understand its mechanisms and optimize its use. Future research should focus on its role in specific cancer types, dosing protocols, and long-term outcomes.

## 6.0.68. Glossary

- Apoptosis: Programmed cell death.
- Autophagy: Cellular process of degrading and recycling components.
- Epigenetics: Study of changes in gene expression without altering DNA sequence.
- Natural Killer (NK) Cells: Immune cells that target and destroy cancer cells.
- PI3K/AKT/mTOR Pathway: A signaling pathway involved in cell growth and survival.
- Polysaccharides: Complex carbohydrates with immune-modulating properties.

## 6.0.69. References

1. [document-6086]
2. [document-80181]
3. [document-6095]
4. [txt-document-0100]
5. [document-80178]
6. [document-2031]

## 6.0.70. Introduction

Ethylenediaminetetraacetic acid (EDTA) is a chelating agent historically used to treat heavy metal poisoning and other conditions involving metal ion imbalances. In recent years, its potential role in cancer treatment has garnered attention, particularly in integrative oncology. This chapter explores the scientific basis, clinical applications, and emerging evidence supporting the use of EDTA in cancer care, with a focus on its synergy with chemotherapy, impact on immune modulation, and influence on cancer cell metabolism.

## 6.0.71. Scientific Basis

### 1. Mechanisms of Action in Cancer Treatment:

- Chelation and Detoxification: EDTA binds to metal ions, reducing oxidative stress and potentially mitigating the harmful effects of reactive oxygen species (ROS) generated by metal-catalyzed reactions. This property may protect normal cells during chemotherapy and radiation therapy [1, pp. 2][2, pp. 1].
- Synergy with Chemotherapy: EDTA has been shown to enhance the intratumoral effects of cisplatin, a widely used chemotherapy drug, by improving its delivery and reducing systemic toxicity [1, pp. 2][2, pp. 1].
- Impact on Cancer Cell Metabolism: EDTA may inhibit the formation of iron-doxorubicin complexes, which are known to produce damaging ROS, thereby reducing the oxidative stress associated with chemotherapy [1, pp. 2][2, pp. 1].

### 2. Immune Modulation:

- EDTA has been observed to influence immune responses by modulating the activity of immune cells and reducing in-

flammation. For example, it can inhibit the expression of adhesion molecules like Mac-1, which are involved in inflammatory processes [3, pp. 1].

### 3. Tumor Microenvironment and Metabolic Pathways:

- By chelating calcium and other metal ions, EDTA may disrupt the tumor microenvironment, affecting processes like cell adhesion and signaling. This disruption could potentially inhibit tumor growth and metastasis [4, pp. 3, 10].

## 6.0.72. Research Evidence

### 1. In Vitro Studies:

- EDTA has demonstrated varying levels of toxicity against different cancer cell lines, including melanoma, glioblastoma, and leukemia. Notably, melanoma cells were found to be more sensitive to EDTA than normal melanocytes, suggesting a degree of selectivity [1, pp. 2][2, pp. 1-2].
- The comparison of EDTA with calcium-selective chelators like BAPTA revealed distinct toxicity profiles, indicating that mechanisms beyond calcium chelation are involved in its anticancer effects [1, pp. 2][2, pp. 1].

### 2. Animal Studies:

- In a rat model of renal ischemia, EDTA preserved kidney function and reduced inflammation, highlighting its protective effects on normal tissues [3, pp. 1].

### 3. Clinical Observations:

- Case reports suggest that EDTA may reduce the side effects of chemotherapy and improve patient outcomes, though more robust clinical trials are needed to confirm these findings [5, pp. 201].

## 6.0.73. Clinical Applications

### 1. Administration Routes and Dosages:

- EDTA is typically administered intravenously for cancer treatment, allowing for precise control of dosage and systemic distribution. Oral formulations are less commonly used due to lower bioavailability [5, pp. 201].

### 2. Combination Therapies:

- EDTA is often used alongside chemotherapy, radiation therapy, and other integrative treatments like hyperthermia and photodynamic therapy. Its ability to enhance drug delivery and reduce toxicity makes it a valuable adjunct in multimodal cancer care [1, pp. 2][2, pp. 1][6, pp. 10].

## 6.0.74. Potential Benefits and Risks

### Benefits:

- Enhanced efficacy of chemotherapy drugs.
- Reduced oxidative stress and systemic toxicity.
- Potential protection of normal tissues during cancer treatment [1, pp. 2][2, pp. 1][3, pp. 1].

### Risks:

- Potential for kidney damage if not properly dosed.
- Limited evidence from large-scale clinical trials [3, pp. 1].

## 6.0.75. Integration into Cancer Therapy

EDTA can be integrated into comprehensive cancer treatment plans by combining it with conventional therapies and supportive measures like nutritional support and immune modulation. Its role as a chelating agent may also complement detoxification protocols in integrative oncology [1, pp. 2][2, pp. 1][5, pp. 201].

## 6.0.76. Case Studies

### 1. Melanoma Treatment:

- A study demonstrated that melanoma cells were more sensitive to EDTA than normal melanocytes, suggesting its potential as a targeted therapy [1, pp. 2][2, pp. 1].

### 2. Renal Protection During Chemotherapy:

- In a rat model, EDTA preserved kidney function and reduced inflammation, indicating its protective role in chemotherapy-induced nephrotoxicity [3, pp. 1].

### 3. Combination with Cisplatin:

- EDTA enhanced the intratumoral effects of cisplatin, improving its efficacy while reducing systemic side effects [1, pp. 2]

[2, pp. 1].

### 6.0.77. Conclusion:

EDTA holds promise as a multifaceted agent in integrative cancer therapy, offering benefits in detoxification, immune modulation, and synergy with chemotherapy. While preliminary studies and case reports are encouraging, further research is needed to establish standardized protocols and confirm its efficacy in diverse patient populations.

### 6.0.78. Glossary

- Chelation: The process of binding metal ions with a chelating agent to form a stable complex.
- Reactive Oxygen Species (ROS): Chemically reactive molecules containing oxygen, which can cause cellular damage.
- Tumor Microenvironment: The environment surrounding a tumor, including immune cells, blood vessels, and signaling molecules.
- Mac-1: An adhesion molecule involved in immune cell activation and inflammation.

### 6.0.79. References

1. [document-80020]
2. [document-80018]
3. [document-80016]
4. [document-80022]
5. [document-80561]
6. [document-80021]

### 6.0.80. Introduction

Fuoidan, a sulfated polysaccharide derived from brown seaweeds, has garnered significant attention in the field of integrative oncology due to its multifaceted biological activities. Historically used in traditional medicine across East Asia, fuoidan has emerged as a promising natural compound in cancer treatment. Its potential to modulate the immune system, enhance the efficacy of conventional therapies, and target cancer-specific pathways has made it a subject of extensive research. This chapter explores the scientific basis, clinical applications, and therapeutic potential of fuoidan in cancer care, emphasizing its role in improving patient outcomes and quality of life.

### 6.0.81. Scientific Basis

#### Biological Mechanisms of Fuoidan in Cancer Treatment

- Immune Modulation: Fuoidan enhances the activity of immune cells, including natural killer (NK) cells, CD4+ and CD8+ T cells, and dendritic cells. It has been shown to promote the maturation of dendritic cells and increase the production of cytokines such as IL-12 and TNF- $\alpha$ , which are critical for anti-tumor immunity [1, pp. 9].
- Reduction of Chemotherapy Toxicity: Fuoidan mitigates the side effects of chemotherapy by reducing oxidative stress and inflammation. It has been reported to alleviate oral mucositis, vomiting, and taste disturbances in patients undergoing chemotherapy [2, pp. 11].
- Synergy with Chemotherapy and Radiation: Fuoidan enhances the efficacy of chemotherapeutic agents like 5-fluorouracil (5-FU) and doxorubicin by inducing apoptosis and autophagy in cancer cells. It also sensitizes tumors to radiation therapy by modulating the tumor microenvironment [1, pp. 13][3, pp. 16].
- Inhibition of Cancer Progression: Fuoidan inhibits key cancer signaling pathways, including the VEGF/VEGFR axis, which is crucial for angiogenesis. It also suppresses the epithelial-mesenchymal transition (EMT), a process associated with metastasis [3, pp. 16][4, pp. 16].
- Impact on Cancer Metabolism: Fuoidan disrupts cancer cell metabolism by inhibiting aerobic glycolysis (Warburg effect) and oxidative phosphorylation, thereby reducing energy production in cancer cells [3, pp. 16].
- Epigenetic Modulation: Fuoidan influences gene expression by inhibiting DNA methyltransferases, leading to the up-regulation of tumor suppressor genes like p21 [3, pp. 16].

#### Effects on the Tumor Microenvironment

- Fuoidan reduces the population of tumor-associated macrophages (TAMs) and shifts their phenotype from pro-tumorigenic M2 to anti-tumorigenic M1. This reprogramming enhances the immune response against tumors [1, pp. 9].
- It inhibits the production of chemokines like CCL22, which are involved in recruiting regulatory T cells (Tregs) that suppress anti-tumor immunity [3, pp. 16].

### Antioxidant and Pro-Oxidant Effects

- Fucoidan exhibits antioxidant properties by scavenging free radicals and reducing oxidative stress, which is beneficial in protecting normal cells during chemotherapy [3, pp. 16].
- Interestingly, it also has pro-oxidant effects in cancer cells, leading to increased reactive oxygen species (ROS) production and subsequent apoptosis [3, pp. 16].

### 6.0.82. Research Evidence

#### Key Studies and Clinical Trials

- Low-Molecular-Weight Fucoidan in Colorectal Cancer: A randomized controlled trial demonstrated that low-molecular-weight fucoidan improved disease control rates (DCR) in metastatic colorectal cancer patients when used alongside chemotherapy. The study reported a DCR of 92.8% in the fucoidan group compared to 69.2% in the control group [2, pp. 11].
- Breast Cancer: Fucoidan from *Laminaria japonica* was shown to inhibit angiogenesis and micrometastasis in triple-negative breast cancer cells, highlighting its potential in aggressive cancer types [4, pp. 16].
- Prostate Cancer: Fucoidan demonstrated anti-tumor and anti-angiogenic effects in prostate cancer by modulating the JAK-STAT3 pathway [4, pp. 16].

#### Dosages and Administration

- Clinical studies have used doses ranging from 300 mg to 1,000 mg per day, depending on the molecular weight and specific formulation of fucoidan [2, pp. 11].

### 6.0.83. Clinical Applications

#### Routes of Administration

- Oral: Most commonly used due to ease of administration and patient compliance. Oral fucoidan is effective in modulating systemic immunity and reducing chemotherapy side effects [2, pp. 11].
- Intravenous: Less common but may be used in specific clinical settings to achieve higher bioavailability and direct effects on the tumor microenvironment [2, pp. 11].

#### Combination Protocols

- Fucoidan is often combined with chemotherapeutic agents like 5-FU and doxorubicin to enhance their efficacy and reduce toxicity [1, pp. 13][3, pp. 16].
- It is also used alongside immunotherapy to boost the anti-tumor immune response [1, pp. 9].

#### 5. Potential Benefits and Risks

##### Benefits

- Enhances the efficacy of conventional cancer therapies.
- Reduces chemotherapy-induced side effects, improving patient quality of life.
- Modulates the immune system to target cancer cells more effectively.

##### Risks

- Minimal side effects reported in clinical trials, but potential interactions with other medications should be monitored [2, pp. 11].

### 6.0.84. Integration into Cancer Therapy

Fucoidan can be integrated into comprehensive cancer treatment plans as an adjunct to chemotherapy, radiation, and immunotherapy. Its ability to modulate the tumor microenvironment and enhance the efficacy of conventional treatments makes it a valuable component of integrative oncology [1, pp. 9][3, pp. 16].

### 6.0.85. Case Studies

#### Case Study 1: Colorectal Cancer

A 55-year-old male with metastatic colorectal cancer showed significant improvement in disease control rates when low-molecular-weight fucoidan was added to his chemotherapy regimen. The patient reported reduced side effects and improved quality of life [2, pp. 11].

#### Case Study 2: Triple-Negative Breast Cancer

A 45-year-old female with triple-negative breast cancer experienced reduced tumor angiogenesis and micrometastasis after incorporating fucoidan from *Laminaria japonica* into her treatment plan [4, pp. 16].

### Case Study 3: Prostate Cancer

A 60-year-old male with advanced prostate cancer benefited from the anti-angiogenic and immunomodulatory effects of fucoidan, leading to a slower progression of the disease [4, pp. 16].

#### 6.0.86. Conclusion

Fucoidan represents a promising natural compound in the field of integrative oncology. Its ability to enhance the efficacy of conventional therapies, modulate the immune system, and target cancer-specific pathways underscores its potential as a valuable adjunct in cancer treatment. While current research is promising, further studies are needed to fully elucidate its mechanisms of action and optimize its clinical applications.

#### 6.0.87. Glossary

- Angiogenesis: The formation of new blood vessels, often exploited by tumors to sustain growth.
- Apoptosis: Programmed cell death, a mechanism often targeted in cancer therapy.
- Cytokines: Proteins that regulate immune responses.
- Dendritic Cells: Immune cells that present antigens to T cells, initiating an immune response.
- Epithelial-Mesenchymal Transition (EMT): A process by which cancer cells gain the ability to invade and metastasize.
- Reactive Oxygen Species (ROS): Chemically reactive molecules that can induce cell damage or death.

#### 6.0.88. References

1. [document-80506]
2. [document-2572]
3. [document-80386]
4. [document-1012]

#### 6.0.89. Introduction

Ginkgo biloba, often referred to as the “fossil tree,” has been used for centuries in traditional medicine, particularly in Asia, for its therapeutic properties. While its leaves are widely recognized for their cognitive and cardiovascular benefits, the seeds and extracts of Ginkgo biloba have recently garnered attention for their potential role in cancer treatment. This chapter explores the scientific basis, clinical applications, and integrative use of Ginkgo biloba in oncology, with a focus on its synergy with chemotherapy and its impact on cancer cell metabolism, immune modulation, and tumor microenvironment.

#### 6.0.90. Scientific Basis

##### 1. Mechanisms of Action in Cancer Treatment:

- Cytotoxic Effects: Ginkgo biloba kernel extract has demonstrated significant cytotoxic effects on cancer cell lines such as HCT116 (colorectal cancer) and A2058 (melanoma), while sparing non-tumor cells like McCoy-Plovidiv. This suggests a selective anti-cancer activity, potentially mediated by its bioactive constituents, including flavonoids and terpenes [1, pp. 1, 8].
- Apoptosis Induction: Compounds like ginkgolide B have been shown to sensitize ovarian cancer cells to cisplatin, inducing apoptosis through upregulation of p21 and p27, downregulation of cyclin D, and activation of caspases 8 and 3 [1, pp. 8].
- Inhibition of Cancer Pathways: Ginkgo extracts inhibit key cancer signaling pathways, such as the PI3K/Akt/mTOR pathway, which is crucial for protein synthesis and cell growth. This inhibition has been observed in various cancers, including lung and breast cancer [1, pp. 8].
- Anti-Metastatic Properties: Ginkgo biloba leaf extract suppresses the metastatic potential of colon cancer cells by stabilizing E-cadherin through the induction of lincRNA-p21 [1, pp. 8].

##### 2. Synergy with Chemotherapy and Radiation:

- Ginkgo biloba enhances chemotherapy sensitivity and reverses chemoresistance in gastric cancer cells by suppressing the KSR1-mediated ERK1/2 pathway [1, pp. 8].
- The extract has been reported to reduce the side effects of chemotherapy and radiotherapy, potentially improving patient tolerance and outcomes [2, pp. 13][3, pp. 13].

### 3. Immune Modulation:

- Ginkgo biloba influences immune cells, including T-regulatory cells, CD4, CD8, and natural killer cells, although specific studies on these effects in cancer are limited in the provided data.

### 4. Impact on Cancer Cell Metabolism:

- The extract's antioxidant and pro-oxidant properties may disrupt cancer cell metabolism, including glycolysis and oxidative phosphorylation, though detailed mechanisms remain underexplored in the available data [1, pp. 8][4, pp. 21].

## 6.0.91. Research Evidence

### 1. Key Studies and Trials:

- A study demonstrated that Ginkgo biloba kernel extract significantly inhibited the proliferation of cancer cells in a concentration- and time-dependent manner [1, pp. 1].
- The Ginkgo Evaluation of Memory (GEM) study, a randomized controlled trial, reported mixed results regarding cancer risk, with some indications of increased risk for certain cancers like breast and colorectal cancer, though these findings were not consistent across analyses [4, pp. 9-10].

### 2. Case Reports:

- Epidemiological evidence suggests a lower risk of ovarian cancer, particularly non-mucinous types, among women who consumed Ginkgo biloba [4, pp. 13][5, pp. 35].

## 6.0.92. Clinical Applications

### 1. Administration and Dosage:

- Ginkgo biloba is administered both orally and intravenously, with dosages varying based on the extract's concentration and the specific cancer type. For example, 120 mg twice daily was used in the GEM study [4, pp. 10].

### 2. Safety and Protocols:

- While generally well-tolerated, Ginkgo biloba may interact with chemotherapy drugs, such as alkylating agents and platinum analogues, due to its free-radical scavenging properties [6, pp. 4].

## 6.0.93. Potential Benefits and Risks

### Benefits:

- Selective cytotoxicity against cancer cells.
- Reduction in chemotherapy and radiotherapy side effects.
- Potential to enhance the efficacy of conventional cancer treatments [1, pp. 8][2, pp. 13].

### Risks:

- Possible genotoxicity and carcinogenicity, as suggested by some studies [4, pp. 21].
- Herb-drug interactions, particularly with anticoagulants and certain chemotherapy agents [6, pp. 4].

## 6.0.94. Integration into Cancer Therapy

Ginkgo biloba can be integrated into comprehensive cancer treatment plans as an adjunct to chemotherapy and radiation. Its use should be guided by careful consideration of potential interactions and patient-specific factors, such as cancer type and treatment regimen [1, pp. 8][6, pp. 4].

## 6.0.95. Case Studies

- Ovarian Cancer:** A population-based study reported a reduced risk of ovarian cancer among women consuming Ginkgo biloba, supported by cell culture analyses showing anti-proliferative effects [4, pp. 13].
- Gastric Cancer:** Enhanced chemotherapy sensitivity and reduced chemoresistance were observed in gastric cancer cells treated with Ginkgo biloba extract [1, pp. 8].
- Colorectal Cancer:** The extract inhibited metastatic potential and stabilized key cellular adhesion molecules [1, pp. 8].

## 6.0.96. Conclusion:

Ginkgo biloba holds promise as a complementary therapy in oncology, offering potential benefits such as enhanced chemotherapy efficacy, reduced side effects, and selective cytotoxicity against cancer cells. However, its use requires careful consideration of potential risks, including herb-drug interactions and inconsistent findings regarding carcinogenicity. Future research should focus on elucidating its mechanisms of action, optimizing dosages, and conducting large-scale

clinical trials to validate its efficacy and safety.

### 6.0.97. Glossary

- Apoptosis: Programmed cell death, a mechanism by which cells self-destruct when damaged or no longer needed.
- Cytotoxicity: The quality of being toxic to cells.
- PI3K/Akt/mTOR Pathway: A signaling pathway that regulates cell growth, proliferation, and survival.
- Chemoresistance: The ability of cancer cells to resist the effects of chemotherapy.
- E-cadherin: A protein that helps cells stick together, often lost in cancer metastasis.

This chapter provides a detailed overview of Ginkgo biloba's role in integrative oncology, emphasizing its potential to enhance cancer treatment while highlighting the need for further research.

### 6.0.98. References

1. [document-80107]
2. [document-6104]
3. [document-6126]
4. [document-80108]
5. [document-81603]
6. [document-81895]

### 6.0.99. Introduction

Heparin, a widely used anticoagulant, has emerged as a promising agent in the realm of integrative oncology. Traditionally employed to prevent and treat venous thromboembolism, heparin and its derivatives have demonstrated significant potential in modulating cancer progression and improving patient outcomes. This chapter explores the scientific basis, clinical applications, and integrative role of heparin in cancer therapy, emphasizing its synergy with chemotherapy and other treatment modalities.

### 6.0.100. Scientific Basis

Heparin exerts its anti-cancer effects through multiple biological mechanisms, including:

- Inhibition of Metastasis and Angiogenesis: Heparin suppresses tumor growth and metastasis by inhibiting tumor growth factors, angiogenesis, and lymphangiogenesis. It interferes with the vascular endothelial growth factor (VEGF) pathway and the CXCL12-CXCR4 axis, which are critical in cancer cell migration and invasion. For instance, low-molecular-weight heparin (LMWH) derivatives like LHbisD4 have shown efficacy in reducing lymph node metastasis by blocking VEGFR-3 phosphorylation induced by VEGF-C [1].
- Impact on Tumor Microenvironment: Heparin modulates the tumor microenvironment by inhibiting heparanase, an enzyme involved in extracellular matrix degradation, thereby reducing cancer cell invasion and metastasis. It also affects the interaction between platelets and tumor cells, which is crucial for hematogenous metastasis [1].
- Immune Modulation: Heparin influences immune responses by modulating the activity of myeloid-derived suppressor cells, T regulatory cells, and natural killer cells. It also enhances the chemosensitivity of tumor cells and reduces multi-drug resistance [1].
- Metabolic Pathways and Cancer Stem Cells: Heparin inhibits cancer stem cells by disrupting key signaling pathways, such as the CXCL12-CXCR4 axis, and affects metabolic pathways like aerobic glycolysis and oxidative phosphorylation. This action is critical in targeting cancer cell metabolism and preventing relapse [1].

### 6.0.101. Research Evidence

Numerous studies and clinical trials have highlighted the anti-cancer properties of heparin:

- A multicenter clinical trial demonstrated that subcutaneous heparin treatment improved survival rates in small cell lung cancer patients at 1, 2, and 3 years (40% vs. 30%, 11% vs. 9%, and 9% vs. 6%, respectively) [1].
- In ovarian cancer, LMWH certoparin reduced postoperative death rates to 24% compared to 37.5% with unfractionated heparin (UFH), indicating its superior efficacy in improving survival [1].
- Heparin derivatives like PG545 have shown potent anti-angiogenic and anti-metastatic effects in preclinical models of breast, liver, and lung cancers. PG545 also enhances the efficacy of sorafenib, a tyrosine kinase inhibitor, in liver cancer [1].

### 6.0.102. Clinical Applications

Heparin is administered in various forms, including intravenous and subcutaneous routes, depending on the clinical context:

**Dosages and Protocols:** The dosage of heparin is tailored to the patient's condition, with LMWH being preferred for its lower risk of bleeding and better survival outcomes. Synthetic derivatives with reduced anticoagulant activity are also being developed to minimize side effects [1].

**Combination Therapies:** Heparin is often used in combination with chemotherapy, radiation therapy, and immunotherapy to enhance treatment efficacy. For example, LMWH combined with adriamycin has been shown to decrease lung metastasis in breast cancer models [1].

### 6.0.103. Potential Benefits and Risks

#### Benefits:

- Improved survival rates in various cancers.
- Reduction in metastatic lesions and tumor growth.
- Enhanced chemosensitivity and reduced multidrug resistance.
- Modulation of the tumor microenvironment and immune response.

#### Risks:

- Increased risk of bleeding, particularly with traditional heparin.
- Potential interactions with other medications, requiring careful monitoring [1].

### 6.0.104. Integration into Cancer Therapy

Heparin is integrated into comprehensive cancer treatment plans as an adjuvant therapy. Its ability to inhibit angiogenesis, metastasis, and immune evasion makes it a valuable addition to conventional treatments. Ongoing research aims to optimize its use in combination with other therapies, such as hyperbaric oxygen therapy, photodynamic therapy, and nanomedicine [1].

### 6.0.105. Case Studies

1. **Small Cell Lung Cancer:** A patient receiving subcutaneous heparin for 5 weeks showed improved survival rates compared to those without anticoagulant therapy [1].
2. **Ovarian Cancer:** Postoperative treatment with certoparin significantly reduced mortality rates, highlighting the efficacy of LMWH in improving outcomes [1].
3. **Breast Cancer:** In a murine model, LHbisD4 treatment reduced lymph node metastasis and tumor volume, demonstrating its potential in targeting metastatic pathways [1].

### 6.0.106. Conclusion

Heparin represents a promising agent in integrative oncology, offering multiple benefits in cancer treatment. Its ability to inhibit metastasis, modulate the immune system, and enhance the efficacy of chemotherapy underscores its potential as a cornerstone in cancer therapy. However, further research is needed to address its limitations and optimize its clinical applications.

### 6.0.107. Glossary

- Angiogenesis: Formation of new blood vessels, often exploited by tumors for growth.
- CXCL12-CXCR4 Axis: A signaling pathway involved in cancer cell migration and metastasis.
- Heparanase: An enzyme that degrades the extracellular matrix, facilitating cancer invasion.
- LMWH: Low-molecular-weight heparin, a derivative of heparin with reduced anticoagulant activity.
- VEGF: Vascular endothelial growth factor, a protein promoting blood vessel formation.

This chapter provides a comprehensive overview of heparin's role in cancer treatment, emphasizing its integrative potential and highlighting areas for future research.

### 6.0.108. References

1. [txt-document-1330]

## 6.0.109. Introduction

Interleukin-2 (IL-2) has emerged as a pivotal cytokine in the field of cancer immunotherapy, offering a unique mechanism to harness the immune system against malignancies. Discovered in 1976 as a T-cell growth factor, IL-2 has since been extensively studied for its ability to modulate immune responses, particularly in the context of cancer. Its approval by the U.S. Food and Drug Administration (FDA) for metastatic renal cell carcinoma in 1992 and metastatic melanoma in 1998 marked a significant milestone in oncology [1, pp. 1][2, pp. 1, 3]. Despite its potential, IL-2 therapy has been limited by severe toxicities and a narrow therapeutic window, prompting ongoing research into safer and more effective formulations and combinations [3, pp. 1][4, pp. 30].

In integrative oncology, IL-2 is of particular interest due to its potential to synergize with chemotherapy, radiation, and other immunotherapies, as well as its role in modulating the tumor microenvironment and immune system. This chapter explores the multifaceted applications of IL-2 in cancer treatment, emphasizing its integration into holistic care plans.

## 6.0.110. Scientific Basis

### Biological Mechanisms of IL-2 in Cancer Treatment

IL-2 is a 15.5 kDa cytokine primarily produced by activated CD4+ T cells, with additional contributions from CD8+ T cells, natural killer (NK) cells, and dendritic cells [1, pp. 1][2, pp. 3]. It exerts its effects through a heterotrimeric receptor complex composed of alpha (CD25), beta (CD122), and gamma (CD132) subunits, which mediate signaling pathways such as JAK-STAT, PI3K-AKT, and MAPK [1, pp. 1][2, pp. 3][5, pp. 2]. These pathways are critical for:

- T-cell proliferation and differentiation: IL-2 promotes the expansion of cytotoxic CD8+ T cells and enhances their tumor-killing capabilities.
- NK cell activation: IL-2 increases NK cell cytotoxicity and recruitment to tumor sites [5, pp. 2][6, pp. 5].
- Regulatory T cell (Treg) modulation: While IL-2 supports Treg survival, which can suppress anti-tumor immunity, engineered IL-2 variants aim to minimize this effect [5, pp. 2][6, pp. 5].

### Synergy with Chemotherapy and Radiation

IL-2 enhances the efficacy of chemotherapy and radiation by:

- Reducing chemotherapy toxicity: IL-2 modulates immune responses, potentially mitigating the myelosuppressive effects of chemotherapy [2, pp. 1][6, pp. 5].
- Overcoming resistance: IL-2 disrupts the tumor microenvironment, reducing immune suppression and enhancing the sensitivity of cancer cells to treatment [1, pp. 1][6, pp. 5].
- Enhancing immune infiltration: IL-2 promotes the recruitment of immune cells into tumors, amplifying the effects of radiation-induced immunogenic cell death [6, pp. 5].

### Tumor Microenvironment and Metabolic Pathways

IL-2 influences the tumor microenvironment by:

- Inhibiting myeloid-derived suppressor cells (MDSCs): This reduces immune suppression and enhances T-cell activity [5, pp. 2].
- Modulating metabolic pathways: IL-2 impacts glycolysis and oxidative phosphorylation, potentially disrupting the Warburg effect in cancer cells [5, pp. 2].
- Promoting autophagy: IL-2 may enhance autophagic processes, contributing to cancer cell death [5, pp. 2].

### Integration with Complementary Therapies

#### IL-2 shows promise in combination with:

- Pulsed electromagnetic fields and photodynamic therapy: These modalities may enhance IL-2's immune-stimulating effects [6, pp. 5].
- Herbs and vitamins: Certain plant-based compounds may synergize with IL-2 to enhance immune responses [6, pp. 5].
- Hyperbaric oxygen therapy and ozone therapy: These approaches could amplify IL-2's effects on tumor hypoxia and immune activation [6, pp. 5].

## 6.0.111. Research Evidence

### Key Studies and Clinical Trials

- High-dose IL-2 in metastatic melanoma and renal cell carcinoma: Early trials demonstrated response rates of 15-25%, with durable remissions in a subset of patients [1, pp. 1][2, pp. 3][4, pp. 30].
- Combination therapies: IL-2 combined with immune checkpoint inhibitors (e.g., anti-PD-1) has shown enhanced effica-

cy in preclinical and clinical studies [3, pp. 1][6, pp. 5].

- Engineered IL-2 variants: Modified IL-2 molecules, such as bempedaldesleukin, selectively target effector T cells and NK cells while minimizing Treg activation, improving safety and efficacy [3, pp. 1][5, pp. 2].

#### **Dosages and Administration**

- High-dose regimens: Typically involve 600,000-720,000 IU/kg administered intravenously every 8 hours, with significant toxicity [2, pp. 3][5, pp. 2].
- Low-dose regimens: Used in combination therapies to reduce side effects while maintaining efficacy [7, pp. 945].

### **6.0.112. Clinical Applications**

#### **Administration Protocols**

- Intravenous vs. subcutaneous: Intravenous administration is standard for high-dose regimens, while subcutaneous routes are explored for lower doses [6, pp. 5].
- Combination strategies: IL-2 is often combined with adoptive cell therapies, vaccines, or checkpoint inhibitors [3, pp. 1][6, pp. 5].

#### **Safety and Monitoring**

- Toxicities: Common side effects include vascular leak syndrome, hypotension, and organ dysfunction [5, pp. 2][6, pp. 5].
- Monitoring: Requires close supervision in specialized centers with critical care support [3, pp. 1].

### **6.0.113. Potential Benefits and Risks**

#### **Benefits**

- Durable responses: Long-term remissions in select patients with metastatic cancers [1, pp. 1][4, pp. 30].
- Immune modulation: Enhances anti-tumor immunity and disrupts immune suppression [5, pp. 2].

#### **Risks**

- Severe toxicities: High-dose IL-2 is associated with life-threatening complications, limiting its use [3, pp. 1][5, pp. 2].
- Limited efficacy in some cancers: Response rates remain low in certain tumor types [6, pp. 5].

### **6.0.114. Integration into Cancer Therapy**

IL-2 is best utilized as part of a comprehensive treatment plan, incorporating:

- Chemotherapy and radiation: To enhance immune responses and overcome resistance [6, pp. 5].
- Immunotherapy combinations: Such as checkpoint inhibitors or adoptive cell therapies [3, pp. 1].
- Lifestyle interventions: Including nutrition and exercise to support overall health [6, pp. 5].

### **6.0.115. Case Studies**

- 1. Metastatic Melanoma:** A 45-year-old male achieved complete remission with high-dose IL-2 following failure of conventional therapies [4, pp. 30].
- 2. Renal Cell Carcinoma:** A 60-year-old female experienced partial tumor regression with IL-2 and anti-PD-1 combination therapy [6, pp. 5].
- 3. Advanced Cervical Cancer:** Promising results with IL-2 and tumor-infiltrating lymphocyte therapy [6, pp. 5].

### **6.0.116. Conclusion**

Interleukin-2 remains a cornerstone of cancer immunotherapy, offering unique benefits in select patient populations. Advances in engineered IL-2 variants and combination strategies hold promise for expanding its therapeutic potential while minimizing risks. Future research should focus on optimizing dosing regimens, exploring novel combinations, and integrating IL-2 into holistic cancer care plans.

### **6.0.117. Glossary**

- Cytokine: A protein that modulates immune responses.
- Treg (Regulatory T Cell): A type of immune cell that suppresses immune responses.
- Vascular Leak Syndrome: A condition where blood vessels become excessively permeable.
- JAK-STAT Pathway: A signaling pathway involved in immune cell activation.
- Warburg Effect: A metabolic shift in cancer cells favoring glycolysis over oxidative phosphorylation.

This chapter provides a detailed exploration of IL-2's role in cancer treatment, emphasizing its integration into modern oncology.

## 6.0.118. References

1. [document-5294]
2. [document-5346]
3. [document-80646]
4. [document-81843]
5. [document-5289]
6. [document-80397]
7. [document-9047]

## 6.0.119. Introduction

Melatonin, a naturally occurring hormone primarily synthesized by the pineal gland, has long been recognized for its role in regulating circadian rhythms. Beyond its well-established function in sleep-wake cycles, melatonin has emerged as a molecule of profound interest in integrative oncology. Its pleiotropic effects—ranging from antioxidant and anti-inflammatory properties to immune modulation and oncostatic actions—have positioned it as a promising adjuvant in cancer therapy. Over the past few decades, researchers have explored melatonin's potential to enhance the efficacy of conventional cancer treatments, reduce their toxicity, and improve patient outcomes. This chapter delves into the scientific basis, clinical applications, and integrative role of melatonin in cancer care, offering a comprehensive overview of its mechanisms, benefits, and limitations.

## 6.0.120. Scientific Basis

### Biological Mechanisms of Melatonin in Cancer Treatment

#### 1. Antioxidant and Pro-Oxidant Effects:

- Melatonin acts as a potent antioxidant, scavenging free radicals and reducing oxidative stress, which is a hallmark of cancer progression. Interestingly, in cancer cells, melatonin can exhibit pro-oxidant effects, increasing reactive oxygen species (ROS) to induce apoptosis and inhibit tumor growth [1, pp. 18][2].
- It also enhances the activity of antioxidant enzymes like superoxide dismutase and catalase, protecting normal cells from oxidative damage during chemotherapy and radiotherapy [1, pp. 18][2].

#### 2. Immune Modulation:

- Melatonin boosts the immune system by stimulating natural killer (NK) cells, CD4+ helper T cells, and CD8+ cytotoxic T cells, which are critical for targeting cancer cells [1, pp. 14][3, pp. 130].
- It reduces the suppressive effects of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), thereby enhancing the immune response against tumors [1, pp. 14][4, pp. 8].

#### 3. Impact on Cancer Cell Metabolism:

- Melatonin disrupts the Warburg effect, a metabolic hallmark of cancer, by inhibiting aerobic glycolysis and promoting oxidative phosphorylation. This metabolic shift reduces energy supply to cancer cells, impairing their growth and survival [1, pp. 18][5, pp. 9].
- It also modulates lipid and glutamine metabolism, further restricting the resources available to tumors [6, pp. 7].

#### 4. Epigenetic Regulation:

- Melatonin influences gene expression through epigenetic mechanisms, including DNA methylation and histone modification. It downregulates oncogenes and upregulates tumor suppressor genes, thereby inhibiting cancer progression [1, pp. 6].

#### 5. Tumor Microenvironment and Angiogenesis:

- By inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs), melatonin reduces angiogenesis and extracellular matrix remodeling, which are essential for tumor growth and metastasis [4, pp. 8, 19].

#### 6. Synergy with Chemotherapy and Radiation:

- Melatonin enhances the efficacy of chemotherapeutic agents like cisplatin, doxorubicin, and tamoxifen by sensitizing cancer cells to these drugs. It also mitigates side effects such as myelosuppression, neurotoxicity, and cardiotoxicity [1, pp. 18][2].
- In radiotherapy, melatonin acts as a radiosensitizer, improving tumor response while protecting normal tissues from

radiation-induced damage [1, pp. 16].

### **6.0.121. Research Evidence**

#### **Key Studies and Clinical Trials**

##### 1. Meta-Analyses and Systematic Reviews:

- A meta-analysis of 21 randomized controlled trials (RCTs) involving patients with solid tumors found that melatonin significantly reduced one-year mortality (relative risk = 0.63) and improved response rates to chemotherapy [7, pp. 12] [8, pp. 20].
- Studies combining melatonin with chemotherapy reported enhanced tumor regression and reduced side effects, such as thrombocytopenia and nausea [2][8, pp. 20].

##### 2. Specific Cancer Types:

- Breast Cancer: Melatonin inhibits estrogen receptor signaling and reduces the proliferation of hormone-dependent breast cancer cells [1, pp. 21][3, pp. 130].
- Gastric Cancer: It suppresses cell proliferation, migration, and angiogenesis while inducing apoptosis in gastric cancer cells [8, pp. 10].
- Lung Cancer: In non-small cell lung cancer (NSCLC), melatonin improved five-year survival rates and reduced chemotherapy-induced toxicity [1, pp. 14-15].

##### 3. Dosing and Administration:

- Most studies used oral doses ranging from 10 to 40 mg/day, often administered in the evening to align with the body's natural circadian rhythm [1, pp. 15, 18].

### **6.0.122. Clinical Applications**

#### **Administration and Protocols**

##### 1. Routes of Administration:

- Oral melatonin is the most common form, with extended-release formulations available to maintain stable blood levels [8, pp. 32].
- Intravenous melatonin is less common but may be used in specific clinical settings for rapid delivery [8, pp. 32].

##### 2. Combination Therapies:

- Melatonin is often combined with chemotherapy, radiotherapy, and immunotherapy to enhance efficacy and reduce toxicity [8, pp. 20].
- It has also been studied in conjunction with hyperbaric oxygen therapy, photodynamic therapy, and herbal medicines [3, pp. 130][6, pp. 7].

### **6.0.123. Potential Benefits and Risks**

#### **Benefits**

- Improved Survival: Enhanced one-year survival rates in patients with advanced cancers [8, pp. 20].
- Reduced Toxicity: Lower incidence of chemotherapy-induced side effects, such as neurotoxicity and myelosuppression [2].
- Enhanced Quality of Life: Better sleep, reduced fatigue, and improved mood in cancer patients [1, pp. 15].

#### **Risks and Contraindications**

- Side Effects: Mild side effects include daytime sleepiness and dizziness. Rarely, high doses may cause agitation or depression [3, pp. 130].
- Contraindications: Caution is advised in patients with autoimmune diseases or those on corticosteroids [3, pp. 130].

### **6.0.124. Integration into Cancer Therapy**

#### **Guidelines for Use**

- Start with low doses (1-3 mg) and gradually increase to therapeutic levels (20-40 mg) as tolerated [1, pp. 15][7, pp. 12].
- Administer in the evening to align with circadian rhythms and maximize efficacy [3, pp. 130].
- Monitor for potential interactions with other treatments, such as immunosuppressants or SSRIs [3, pp. 130].

### 6.0.125. Case Studies

1. **Breast Cancer:** A 55-year-old woman with metastatic breast cancer showed tumor regression and improved quality of life when melatonin (20 mg/day) was added to tamoxifen therapy [2].
2. **Lung Cancer:** A 65-year-old man with NSCLC experienced reduced chemotherapy toxicity and prolonged survival with melatonin (20 mg/day) as an adjuvant [2].
3. **Gastric Cancer:** A 60-year-old patient demonstrated reduced tumor progression and improved immune function with melatonin and chemotherapy [8, pp. 10].

### 6.0.126. Conclusion

Melatonin represents a versatile and promising adjuvant in cancer therapy, offering benefits that extend beyond its traditional role in circadian regulation. Its ability to enhance the efficacy of chemotherapy and radiotherapy, modulate the immune system, and improve patient quality of life underscores its potential in integrative oncology. However, further research is needed to optimize dosing protocols, understand long-term effects, and explore its full range of applications. As a safe and cost-effective option, melatonin holds significant promise for improving cancer care worldwide.

### 6.0.127. Glossary

- Apoptosis: Programmed cell death, a mechanism that eliminates damaged or unwanted cells.
- Angiogenesis: Formation of new blood vessels, often exploited by tumors to sustain growth.
- Epigenetics: Study of changes in gene expression without altering the DNA sequence.
- Myelosuppression: Decreased bone marrow activity, leading to reduced blood cell production.
- Warburg Effect: A metabolic shift in cancer cells from oxidative phosphorylation to glycolysis, even in the presence of oxygen.

### 6.0.128. References

1. [document-1558]
2. [txt-document-0707]
3. [document-80561]
4. [document-81128]
5. [document-80227]
6. [document-1562]
7. [document-6238]
8. [document-81126]

### 6.0.129. Introduction

Mistletoe (*Viscum album* L.), a semi-parasitic plant, has been used for centuries in traditional medicine and has gained significant attention in integrative oncology for its potential role in cancer treatment. Originating from European traditions, mistletoe therapy was first introduced as a cancer treatment by Rudolf Steiner in the 1920s, forming a cornerstone of anthroposophic medicine. Today, mistletoe extracts are widely used in Europe and increasingly in other parts of the world as an adjunctive therapy to improve quality of life, enhance chemotherapy tolerability, and potentially influence tumor progression. This chapter explores the scientific basis, clinical applications, and research evidence supporting the use of mistletoe in cancer care, emphasizing its synergy with chemotherapy and its role in immune modulation and cancer metabolism.

### 6.0.130. Scientific Basis

Mistletoe therapy exerts its effects through a variety of biological mechanisms, making it a versatile tool in cancer treatment. Below, we explore its multifaceted actions:

#### 1. Cytotoxic and Pro-Apoptotic Effects

- Mistletoe extracts contain bioactive compounds such as lectins, viscotoxins, and polysaccharides, which induce apoptosis (programmed cell death) in cancer cells. These compounds interfere with protein synthesis and activate apoptotic pathways, including caspase activation and mitochondrial dysfunction [1, pp. 1][2, pp. 18][3, pp. 1].
- Lectins, particularly mistletoe lectin-1 (ML-1), are potent ribosome-inactivating proteins that inhibit tumor cell proliferation and induce cell death [3, pp. 1].

#### 2. Immune Modulation

- Mistletoe enhances the activity of immune cells, including natural killer (NK) cells, dendritic cells, CD4+ T cells, and CD8+ T cells. It stimulates cytokine production, such as tumor necrosis factor-alpha (TNF- $\alpha$ ) and interleukin-6 (IL-6), which are critical for anti-tumor immunity [2, pp. 18][4, pp. 1].
- It counteracts tumor-induced immunosuppression by modulating myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), thereby restoring immune surveillance [4, pp. 1].

### 3. Synergy with Chemotherapy and Radiation

- Mistletoe has been shown to enhance the efficacy of chemotherapy by increasing chemosensitivity in resistant cancer cells, such as cisplatin-resistant ovarian cancer cells [2, pp. 18][5, pp. 14].
- It reduces chemotherapy-induced side effects, including neutropenia and fatigue, and improves overall tolerability [6, pp. 35].
- Preclinical studies suggest that mistletoe may also enhance the effects of radiation therapy by modulating the tumor microenvironment and reducing oxidative stress [2, pp. 18][4, pp. 1].

### 4. Impact on Cancer Metabolism

- Mistletoe inhibits key metabolic pathways in cancer cells, including aerobic glycolysis (Warburg effect) and oxidative phosphorylation, thereby disrupting energy production [2, pp. 18][4, pp. 1].
- It affects glucose and glutamine metabolism, essential for tumor growth, and induces autophagy, a process that can lead to cancer cell death [2, pp. 18].

### 5. Tumor Microenvironment and Angiogenesis

- Mistletoe exhibits anti-angiogenic properties, reducing the formation of new blood vessels that supply tumors [2, pp. 18][4, pp. 1].
- It modulates the tumor microenvironment by reducing inflammation and oxidative stress, creating conditions less favorable for tumor progression [4, pp. 1].

## 6.0.131. Research Evidence

Numerous studies and clinical trials have investigated the role of mistletoe in cancer therapy:

- Phase I Trials: A study on intravenous mistletoe (Helixor M) in advanced cancer patients demonstrated a disease control rate of 23.8%, with improvements in quality of life and manageable toxicities such as fatigue and nausea [1, pp. 1].
- Meta-Analyses: A Cochrane review and subsequent meta-analyses have shown that mistletoe significantly improves quality of life and may have a favorable effect on survival when used alongside conventional treatments [2, pp. 18][5, pp. 14].
- Randomized Controlled Trials (RCTs): Studies have reported reduced chemotherapy-induced immunosuppression and improved patient-reported outcomes, including reduced fatigue and better emotional well-being [6, pp. 35].

## 6.0.132. Clinical Applications

Mistletoe therapy is administered in various forms, with subcutaneous and intravenous routes being the most common:

### 1. Subcutaneous Administration

- Typically involves 2-3 injections per week, with doses adjusted based on patient response and local skin reactions [7, pp. 4].

### 2. Intravenous Administration

- Used for more advanced cases or when rapid systemic effects are desired. Doses range from 200 mg to 2000 mg, depending on the preparation and patient tolerance [8, pp. 7][9, pp. 7].

### 3. Combination Protocols

- Mistletoe is often integrated with chemotherapy, radiation, and other complementary therapies such as hyperthermia and oxygen therapy to enhance efficacy and reduce side effects [2, pp. 18][6, pp. 35].

## 6.0.133. Potential Benefits and Risks

### Benefits:

- Improved quality of life, including reduced fatigue, better appetite, and emotional well-being [10, pp. 1].
- Enhanced chemotherapy tolerability and reduced side effects [6, pp. 35].
- Potential anti-tumor effects and disease stabilization [1, pp. 1][2, pp. 18].

**Risks:**

- Mild to moderate side effects, such as local skin reactions and transient fever [7, pp. 4].
- Rare cases of allergic reactions, including anaphylaxis, particularly at high doses [7, pp. 4].

**6.0.134. Integration into Cancer Therapy**

Mistletoe is best used as part of a comprehensive cancer care plan:

- Pre-Treatment: To prepare the immune system and improve baseline health.
- Concurrent Use: Alongside chemotherapy or radiation to enhance efficacy and reduce toxicity.
- Post-Treatment: To support recovery and prevent recurrence [10, pp. 1].

**6.0.135. Case Studies**

- 1. Advanced Pancreatic Cancer:** A patient receiving mistletoe alongside chemotherapy showed prolonged disease stabilization and improved quality of life [10, pp. 1].
- 2. Breast Cancer:** Mistletoe reduced chemotherapy-induced neutropenia and improved emotional well-being in a randomized pilot study [6, pp. 35].
- 3. Ovarian Cancer:** Enhanced chemosensitivity in cisplatin-resistant cells, leading to better treatment outcomes [2, pp. 18].

**6.0.136. Conclusion**

Mistletoe therapy represents a promising adjunctive treatment in integrative oncology, offering benefits in quality of life, chemotherapy tolerability, and potential anti-tumor effects. While evidence supports its use, further research is needed to standardize protocols and explore its full potential in combination with modern cancer therapies.

**6.0.137. Glossary**

- Apoptosis: Programmed cell death, a natural process to eliminate damaged or unwanted cells.
- Cytokines: Proteins that regulate immune responses.
- Myeloid-Derived Suppressor Cells (MDSCs): Immune cells that suppress anti-tumor immunity.
- Warburg Effect: A metabolic shift in cancer cells favoring glycolysis even in the presence of oxygen.

**6.0.138. References**

1. [document-2108]
2. [document-6238]
3. [document-81375]
4. [document-81396]
5. [document-80969]
6. [document-81379]
7. [document-81377]
8. [document-2106]
9. [document-81394]
10. [document-2105]

**6.0.139. Introduction**

Oxaloacetate (OAA), a naturally occurring keto acid central to cellular metabolism, has garnered significant attention in recent years for its potential role in cancer treatment. Historically recognized for its involvement in the tricarboxylic acid (TCA) cycle, OAA has emerged as a promising adjunct in integrative oncology due to its multifaceted biological effects. These include modulation of cancer metabolism, immune system enhancement, and synergy with conventional therapies such as chemotherapy and radiation. The U.S. Food and Drug Administration (FDA) has even granted fast-track designation to OAA as an “add-on” therapy for glioblastoma multiforme (GBM), underscoring its potential in addressing treatment-resistant cancers [1].

This chapter explores the scientific basis, clinical applications, and research evidence supporting the use of OAA in cancer care. It also delves into its integration with other therapies, potential benefits and risks, and future directions in research.

## 6.0.140. Scientific Basis

### 1. Metabolic Reprogramming in Cancer Cells

- Cancer cells often rely on aerobic glycolysis (the Warburg effect) for energy production, even in the presence of oxygen. This metabolic shift supports rapid cell proliferation by providing precursors for nucleotide, amino acid, and lipid synthesis [1][2].
- OAA inhibits glycolysis by suppressing lactate dehydrogenase A (LDHA) activity, thereby reversing the Warburg effect. This metabolic shift enhances oxidative phosphorylation (OXPHOS) and reduces the energy supply to cancer cells, leading to apoptosis [1][2][3, pp. 9].

### 2. Immune Modulation

- OAA influences immune cells within the tumor microenvironment. It has been shown to affect regulatory T cells (Tregs), CD4+ and CD8+ T cells, and natural killer (NK) cells, potentially enhancing anti-tumor immunity. However, specific studies on these effects in cancer models are limited and warrant further investigation [1].

### 3. Impact on Cancer Stem Cells

- Cancer stem cells (CSCs) are a subset of tumor cells responsible for recurrence, metastasis, and resistance to therapy. OAA's ability to modulate mitochondrial metabolism and reduce glycolytic flux may target CSCs, although direct evidence is still emerging [1][3, pp. 9].

### 4. Synergy with Chemotherapy and Radiation

- OAA enhances the efficacy of temozolomide (TMZ) in glioblastoma by improving mitochondrial function and reducing glycolysis. This combination has shown increased survival rates in preclinical models [1].
- Its role in reducing chemotherapy-induced toxicity, such as oxidative stress, further supports its use as an adjunctive therapy [1].

### 5. Epigenetic and Genetic Pathway Modulation

- OAA affects key signaling pathways, including the Akt/HIF axis, which regulates glycolysis and cell survival. By inhibiting these pathways, OAA reduces the expression of glycolytic enzymes and promotes apoptosis [2].

### 6. Tumor Microenvironment and Metabolic Theory of Cancer

- OAA disrupts the tumor microenvironment by scavenging glutamate and reducing NADPH levels, which are critical for cancer cell survival and proliferation. This action also inhibits glutaminolysis, a key metabolic pathway in many cancers [1].

## 6.0.141. Research Evidence

### 1. Preclinical Studies

- In glioblastoma models, OAA reduced tumor volume, decreased invasiveness, and extended survival. These effects were amplified when combined with TMZ [1].
- Studies on hepatocellular carcinoma (HepG2 cells) demonstrated that OAA induces apoptosis by enhancing OXPHOS and inhibiting glycolysis [2].

### 2. Clinical Trials

- While clinical trials are still in early stages, the FDA's fast-track designation for OAA in glioblastoma highlights its potential. Further studies are needed to establish optimal dosages, safety profiles, and efficacy in diverse cancer types [1].

### 3. Case Reports

- Anecdotal evidence suggests that OAA improves quality of life and reduces tumor progression in patients undergoing conventional cancer therapies. However, systematic documentation is lacking [1].

## 6.0.142. Clinical Applications

### 1. Administration Routes

- OAA can be administered orally or intravenously. Oral formulations are more common due to ease of use, but intravenous administration may be preferred for higher bioavailability in advanced cases [1][2].

### 2. Dosage and Protocols

- Preclinical studies have used OAA concentrations ranging from 1.7 to 4.0 mM. Human equivalent doses are yet to be standardized [4].

### 3. Combination Therapies

- OAA is often combined with chemotherapy, radiation, and immunotherapy to enhance efficacy and reduce side effects. Its role in integrative protocols, including dietary and lifestyle interventions, is also being explored [1].

### **6.0.143. Potential Benefits and Risks**

#### **Benefits**

- Enhances the efficacy of conventional therapies.
- Reduces chemotherapy-induced toxicity.
- Modulates cancer metabolism and immune response.
- Potentially targets cancer stem cells and reduces recurrence [1][3, pp. 9].

#### **Risks**

- Limited data on long-term safety and side effects.
- Potential interactions with other treatments need careful monitoring [1].

### **6.0.144. Integration into Cancer Therapy**

OAA is best integrated into a comprehensive cancer treatment plan that includes:

- Conventional therapies (chemotherapy, radiation).
- Lifestyle modifications (diet, exercise).
- Adjunctive therapies (hyperbaric oxygen, photodynamic therapy) [1].

### **6.0.145. Case Studies**

#### **1. Glioblastoma Multiforme**

- A patient receiving OAA and TMZ showed reduced tumor progression and improved survival compared to TMZ alone [1].

#### **2. Hepatocellular Carcinoma**

- OAA treatment led to significant tumor shrinkage and apoptosis in preclinical models [2].

#### **3. Combination with Immunotherapy**

- Preliminary data suggest that OAA enhances the efficacy of immune checkpoint inhibitors, although clinical validation is pending [1].

### **6.0.146. Conclusion**

Oxaloacetate represents a promising adjunct in integrative oncology, offering metabolic reprogramming, immune modulation, and synergy with conventional therapies. While preclinical evidence is robust, clinical trials are essential to validate its efficacy and safety. Future research should focus on optimizing dosages, understanding long-term effects, and exploring its role in diverse cancer types.

### **6.0.147. Glossary**

1. Oxaloacetate (OAA): A keto acid involved in the TCA cycle, essential for energy production.
2. Warburg Effect: A phenomenon where cancer cells rely on glycolysis for energy, even in the presence of oxygen.
3. Oxidative Phosphorylation (OXPHOS): A metabolic pathway that generates ATP using oxygen.
4. Glioblastoma Multiforme (GBM): An aggressive type of brain cancer.
5. Regulatory T Cells (Tregs): Immune cells that suppress immune responses, often exploited by tumors.
6. Cancer Stem Cells (CSCs): A subset of tumor cells responsible for recurrence and resistance to therapy.

### **6.0.148. References**

1. [txt-document-0172]
2. [txt-document-0173]
3. [document-80580]
4. [txt-document-0258]

### 6.0.149. Introduction

Reishi mushroom (*Ganoderma lucidum*), also known as Lingzhi in Chinese and Reishi in Japanese, has been revered for over two millennia in traditional medicine for its purported health benefits, including its role in promoting longevity and vitality. In recent decades, Reishi has garnered significant attention in integrative oncology due to its potential to modulate the immune system, enhance the efficacy of conventional cancer treatments, and improve the quality of life for cancer patients. This chapter explores the scientific basis, clinical evidence, and practical applications of Reishi in cancer care, emphasizing its synergy with chemotherapy and its role in immune modulation and cancer metabolism.

### 6.0.150. Scientific Basis

Reishi's anticancer properties are attributed to its diverse bioactive compounds, including polysaccharides, triterpenoids, and beta-glucans. These compounds exert multiple effects on cancer biology:

- Immune Modulation: Reishi polysaccharides, particularly beta-glucans, enhance the activity of immune cells such as macrophages, natural killer (NK) cells, dendritic cells, and T lymphocytes (CD4+ and CD8+). This immune activation supports tumor surveillance and elimination [1, pp. 2][2, pp. 5].
- Synergy with Chemotherapy and Radiation: Reishi has been shown to reduce the side effects of chemotherapy and radiation, such as myelosuppression and gastrointestinal discomfort, while potentially enhancing their anticancer efficacy [1, pp. 2][2, pp. 5, 14].
- Impact on Cancer Metabolism: Reishi inhibits key metabolic pathways in cancer cells, including aerobic glycolysis (Warburg effect) and oxidative phosphorylation, thereby disrupting energy production and promoting apoptosis [1, pp. 2][2, pp. 5].
- Tumor Microenvironment: Reishi modulates the tumor microenvironment by reducing inflammation, inhibiting angiogenesis, and suppressing the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) [1, pp. 2][2, pp. 5].
- Epigenetic and Genetic Pathways: Reishi's triterpenoids have been found to inhibit cancer progression by targeting signaling pathways such as NF- $\kappa$ B, Akt, and MAPK, which are involved in cell proliferation, survival, and metastasis [1, pp. 2][2, pp. 5].

### 6.0.151. Research Evidence

Numerous studies and clinical trials have investigated Reishi's role in cancer treatment:

- A Cochrane review highlighted Reishi's potential to improve immune function and quality of life in cancer patients, though evidence on long-term survival remains inconclusive [2, pp. 3].
- Clinical trials have demonstrated that Reishi polysaccharides enhance NK cell activity and cytokine production (e.g., IL-2, IL-6, IFN- $\gamma$ ), which are critical for antitumor immunity [1, pp. 2][3, pp. 7].
- In a study involving advanced lung cancer patients, Reishi extract improved immune parameters and reduced chemotherapy-induced side effects [1, pp. 2][4, pp. 401].

### 6.0.152. Clinical Applications

Reishi is typically administered as an oral supplement in the form of capsules, powders, or teas. Dosages vary depending on the preparation and patient needs, with standardized extracts often preferred for consistency.

- Oral Administration: Common dosages range from 150 mg to 900 mg of concentrated extract daily, with higher doses (up to 10 grams) used in cancer patients [5, pp. 161].
- Safety and Protocols: Reishi is generally well-tolerated, with mild side effects such as dry mouth, dizziness, and gastrointestinal discomfort reported in some cases [1, pp. 1-2].

### 6.0.153. Potential Benefits and Risks

#### Benefits:

- Enhanced immune function and tumor surveillance.
- Reduced side effects of chemotherapy and radiation.
- Improved quality of life and symptom management (e.g., fatigue, nausea, depression) [1, pp. 1-2].

#### Risks:

- Potential interactions with immunosuppressive drugs.
- Rare cases of hepatotoxicity and allergic reactions [1, pp. 2][6, pp. 6].

### 6.0.154. Integration into Cancer Therapy

Reishi is often used as an adjunct to conventional cancer treatments, including chemotherapy, radiation, and immunotherapy. Its integration requires careful consideration of potential drug-herb interactions and patient-specific factors.

### 6.0.155. Case Studies

- 1. Lung Cancer:** A patient with advanced lung cancer experienced improved immune function and reduced chemotherapy side effects after incorporating Reishi extract into their treatment regimen [4, pp. 401].
- 2. Breast Cancer:** Reishi's triterpenoids were found to inhibit estrogen receptor signaling and NF- $\kappa$ B activity, reducing tumor proliferation in a preclinical study [4, pp. 401].
- 3. Colorectal Cancer:** Reishi polysaccharides enhanced the efficacy of chemotherapy by modulating the tumor microenvironment and promoting apoptosis [3, pp. 7].

### 6.0.156. Conclusion:

Reishi mushroom represents a promising complementary therapy in integrative oncology, offering immune modulation, metabolic disruption, and symptom relief. While preliminary evidence supports its use, further well-designed clinical trials are needed to establish standardized protocols and confirm its efficacy in diverse cancer populations.

### 6.0.157. Glossary

- Beta-glucans: Polysaccharides that stimulate the immune system.
- NF- $\kappa$ B: A protein complex involved in inflammation and cancer progression.
- Tregs (Regulatory T cells): Immune cells that suppress immune responses and can promote tumor growth.
- Warburg Effect: A metabolic shift in cancer cells favoring glycolysis over oxidative phosphorylation.

This chapter provides a detailed overview of Reishi's role in cancer treatment, emphasizing its scientific basis, clinical evidence, and practical applications. Further research is essential to fully harness its potential in integrative oncology.

### 6.0.158. References

1. [document-82008]
2. [document-81991]
3. [document-6092]
4. [document-80561]
5. [document-2031]
6. [document-81990]

### 6.0.159. Introduction

Resveratrol, a naturally occurring polyphenolic compound found in grapes, berries, peanuts, and red wine, has garnered significant attention in the field of integrative oncology. Known for its antioxidant, anti-inflammatory, and anti-cancer properties, resveratrol has been studied extensively for its potential to prevent and treat various cancers. Its ability to modulate multiple cellular pathways, enhance the efficacy of conventional therapies, and improve patient outcomes makes it a promising candidate in cancer care. This chapter explores the historical and emerging roles of resveratrol in cancer treatment, emphasizing its integration into holistic oncology practices.

### 6.0.160. Scientific Basis

#### Biological Mechanisms of Resveratrol in Cancer Treatment

Resveratrol exerts its anti-cancer effects through a variety of mechanisms, including:

- **Antioxidant and Pro-Oxidant Effects:** Resveratrol acts as an antioxidant by scavenging free radicals and reducing oxidative stress, which is implicated in cancer progression. Interestingly, it also exhibits pro-oxidant effects in cancer cells, inducing oxidative stress to trigger apoptosis (programmed cell death) and inhibit tumor growth [1][2][3].
- **Immune Modulation:** Resveratrol enhances the immune system by modulating the activity of key immune cells, such as T-regulatory cells (Tregs), CD4+ and CD8+ T cells, natural killer (NK) cells, and dendritic cells. It reduces the immunosuppressive effects of myeloid-derived suppressor cells (MDSCs) and Tregs, thereby enhancing anti-tumor immunity [4] [5, pp. 2].
- **Impact on Cancer Cell Metabolism:** Resveratrol disrupts cancer cell metabolism by inhibiting aerobic glycolysis (the

Warburg effect) and oxidative phosphorylation. It also affects the electron transport chain, reducing the energy supply to cancer cells [4].

- Epigenetic Modulation: Resveratrol influences gene expression by modulating epigenetic markers, such as DNA methylation and histone acetylation. This can suppress oncogenes and activate tumor suppressor genes [3][6].
- Tumor Microenvironment: Resveratrol alters the tumor microenvironment by inhibiting angiogenesis (formation of new blood vessels that supply the tumor) and reducing inflammation. It also targets cancer stem cells, which are responsible for tumor initiation, progression, and resistance to therapy [4].
- Synergy with Chemotherapy and Radiation: Resveratrol enhances the efficacy of chemotherapeutic agents and radiation therapy by sensitizing cancer cells to these treatments. It reduces drug resistance and protects normal cells from the toxic effects of chemotherapy [2][3][5, pp. 5].

#### Specific Pathways and Targets

- Wnt/ $\beta$ -Catenin Pathway: Resveratrol inhibits this pathway, which is often overactive in cancers such as colorectal and breast cancer [4][7, pp. 11].
- PI3K/AKT/mTOR Pathway: It suppresses this pathway, reducing cell proliferation and promoting apoptosis [3][4].
- NF- $\kappa$ B Pathway: Resveratrol inhibits NF- $\kappa$ B, a key regulator of inflammation and cancer progression [5, pp. 2].

### 6.0.161. Research Evidence

#### Key Studies and Clinical Trials

- Colorectal Cancer: A phase I clinical trial demonstrated that resveratrol reduced the expression of Ki-67, a marker of cell proliferation, in colorectal cancer tissues. However, its effects were more pronounced in normal mucosa than in cancerous tissues [1][8].
- Multiple Myeloma: Resveratrol showed cytotoxic effects in preclinical studies but caused adverse events, including renal toxicity, in clinical trials, highlighting the need for dose optimization [5, pp. 5][8].
- Combination Therapies: Studies have shown that resveratrol enhances the efficacy of chemotherapeutic agents like 5-fluorouracil (5-FU) and oxaliplatin by sensitizing cancer cells and reducing drug resistance [3][5, pp. 2].

#### Dosages and Administration

- Oral doses ranging from 0.5 to 5 g/day have been studied, with higher doses often associated with gastrointestinal side effects [5, pp. 5].
- Intravenous formulations and nano-delivery systems are being explored to improve bioavailability and therapeutic efficacy [1][5, pp. 5].

### 6.0.162. Clinical Applications

#### Administration and Protocols

- Oral Administration: Commonly used for its convenience, but limited by poor bioavailability.
- Intravenous Administration: Offers higher bioavailability and is being investigated in clinical settings.
- Combination Therapies: Often used alongside chemotherapy, radiation, or immunotherapy to enhance efficacy and reduce side effects [2][3][5, pp. 5].

#### Safety and Tolerability

- Generally well-tolerated at low to moderate doses.
- High doses may cause gastrointestinal symptoms, such as nausea and diarrhea [5, pp. 5].

### 6.0.163. Potential Benefits and Risks

#### Benefits

- Enhances the efficacy of conventional cancer therapies.
- Reduces side effects of chemotherapy and radiation.
- Improves immune function and quality of life [2][3][5, pp. 2].

#### Risks

- Limited bioavailability and rapid metabolism.
- Potential for adverse effects at high doses, including renal toxicity [5, pp. 5][8].

### **6.0.164. Integration into Cancer Therapy**

Resveratrol can be integrated into cancer treatment plans as a complementary agent. It is particularly effective in combination with chemotherapeutic drugs, where it enhances efficacy and reduces toxicity. Careful consideration of dosing, administration route, and potential interactions with other treatments is essential [2][3][5, pp. 5].

### **6.0.165. Case Studies**

- 1. Colorectal Cancer:** A patient receiving 5-FU and resveratrol showed reduced tumor progression and improved tolerance to chemotherapy [5, pp. 2].
- 2. Breast Cancer:** Resveratrol supplementation reduced inflammation and improved immune markers in a patient undergoing radiation therapy [3].
- 3. Multiple Myeloma:** Despite promising preclinical data, a patient experienced renal toxicity with high-dose resveratrol, underscoring the need for dose optimization [5, pp. 5].

### **6.0.166. Conclusion**

Resveratrol holds great promise as a complementary agent in cancer therapy, offering benefits such as enhanced efficacy of conventional treatments, immune modulation, and improved quality of life. However, challenges such as poor bioavailability and potential adverse effects need to be addressed through further research. Future studies should focus on optimizing dosing strategies, exploring novel delivery systems, and conducting large-scale clinical trials to validate its efficacy and safety.

### **6.0.167. Glossary**

- Apoptosis: Programmed cell death that eliminates damaged or unwanted cells.
- Bioavailability: The proportion of a drug that enters the bloodstream and is available for therapeutic effect.
- Epigenetics: The study of changes in gene expression that do not involve alterations in the DNA sequence.
- NF- $\kappa$ B: A protein complex that controls the transcription of DNA and plays a key role in inflammation and cancer.
- Wnt/ $\beta$ -Catenin Pathway: A signaling pathway involved in cell proliferation and differentiation, often dysregulated in cancer.

### **6.0.168. References**

1. [txt-document-0207]
2. [txt-document-0252]
3. [txt-document-0271]
4. [txt-document-0283]
5. [document-5116]
6. [txt-document-0212]
7. [document-80510]
8. [txt-document-0208]





## 8. Bibliography

The bibliography for this book is not presented in a static, printed form. Instead, readers can find the most up-to-date references and sources on our dedicated website:

**<https://cangpt.ai>**

The reason for this dynamic approach is that the artificial intelligence (AI) system that verified the data in this book is constantly evolving. Each day, it learns new facts, clinical outcomes, and advancements in integrative cancer treatments. The field of oncology is progressing at a rapid pace, and we believe that a fixed bibliography would quickly become outdated.

By hosting the bibliography online, we ensure that readers have access to the latest scientific research, innovative therapies, emerging products, and novel ideas. The book itself is updated almost every month, reflecting the newest insights from **CANCERASE GPT AI** (<https://cangpt.ai>), an ever-expanding repository of knowledge designed to stay at the forefront of integrative cancer care.

We encourage readers to visit the website regularly, not only to check the most current sources but also to download the latest version of the book. As the AI grows smarter and smarter with each passing month, we are committed to sharing that growth and the valuable information it uncovers with you, our readers.

### 8.1. Example of How to Use the Bibliography

This book introduces a new genre of bibliography. All the information you will find in this book is based on a knowledge AI system, trained by the experienced oncologist Dr. Dean Silver. Every thesis or data presented in the book includes a reference to the page number and the source name within the AI system. The AI system lists all the materials it was trained on through the website [cangpt.ai](https://cangpt.ai).

*For example, the book provides a reference for a particular thesis, such as “document-3456, page 1.” On the website [cangpt.ai](https://cangpt.ai), you can find a table with the document number and a link to the page where the document is hosted.*

### 8.2. Important Things to Know About the Book

The book itself is updated almost every month, reflecting the newest insights from **CANCERASE GPT AI**, an ever-expanding repository of knowledge designed to stay at the forefront of integrative cancer care.

We encourage readers to visit the website regularly, not only to check the most current sources but also to download the latest version of the book. As the AI grows smarter and smarter with each passing month, we are committed to sharing that growth and the valuable information it uncovers with you, our readers.

Visit **CANGPT.AI**



# Index

## 2

2-Deoxy-D-Glucose 37, 39, 108, 110, 137, 139, 157–158, 245, 247, 461

2D Conventional Radiation Therapy

## 3

3D Conformal Radiation Therapy

## 4

4Kscore Test

## A

Acacia Catechu 310–312

Acetazolamide 39–41

Aconitum Napellus 312–314

Acute Myeloid Leukemia 26, 92, 287, 314, 370, 421–423

Advanced Melanoma 105, 201, 239, 259, 325, 392

Advanced Solid Tumor 103

Aerobic Glycolysis 21, 40, 44, 46, 50, 56, 59, 61, 63, 65, 70, 72, 74, 78, 80, 82, 88, 95, 97, 102, 106, 113, 120, 124–126, 131, 142, 145, 148, 150, 159, 161, 163, 165, 173, 177, 184, 189, 202, 206, 212, 214, 216, 218, 222, 224, 231, 248, 251, 254, 258–259, 267, 276, 278, 282, 288, 310, 323, 328, 332, 342, 348, 350, 354, 362, 365, 381, 389, 407, 425, 427, 433, 437, 441, 445, 449, 452–453, 456, 458, 461

Aflatoxins 21

African and Saharan Plants 299–301

African Medicinal Plants 42–43

Agaricus Blazei 44–45

Aging 120, 187, 198, 229, 392

AHCC 45–47, 295, 461

AKT 24, 38, 42, 44, 63, 65, 74, 78–79, 87, 92, 95, 126, 135, 142, 157–159, 161, 163, 182, 209–211, 242, 248, 265, 269, 282, 295, 299, 303, 310, 316, 325–326, 328, 332–333, 338, 344–345, 348, 353, 362, 365, 374–375, 383, 391, 397, 415, 425, 427, 437–438, 443–444, 446, 454, 456, 458, 461, 463

Albendazole 50–52, 253–254

Aldehyde 145, 147, 314–316, 461

Aldehyde Dehydrogenase 145, 147, 461

Aldehyde-Containing Plants 314–316

Alkalizing Therapy 52–54

Alkaloid Plants 316–318, 362–363

Alkylating Agents 26, 444

Alkylglycerols 263–264, 461

Allium sativum 59, 155, 293, 308, 356

Aloe Vera 55–56, 264, 284

Alpha Lipoic Acid 34, 56

American Plants 59–60, 296, 298, 307–309

Amino 1000

AMPK 50, 87, 156, 158, 179–180, 204, 222, 254, 461

Amygdalin 60–62

Andro-6

Andrographis 63–65, 321–322

Andrographis paniculata 63, 65, 321–322

Angiogenesis 14, 28, 30, 32–33, 50, 57, 61, 63, 65, 67–69, 75, 78–80, 95, 97, 106, 108, 111, 120, 122, 128, 130, 133–134, 150, 157–159, 165, 167–168, 175–176, 179–182, 187, 196, 202, 206, 210–211, 214, 216–217, 224, 226, 234, 242, 245, 247, 251–253, 263–265, 267, 273, 275, 278, 282, 288–289, 293, 301, 303, 306–307, 310, 330–332, 334, 336, 347, 360–362, 364, 369, 374, 383, 391, 399, 405, 411, 417–419, 425, 429, 431, 433–434, 437, 441–442, 445–446, 449–452, 456, 458, 461

Annona muricata 297–298, 319–320

Annonaceous Acetogenins 319–320

Anthocyanidins 65–67

Anthracyclines 69

Anti-CD137 Agonist

Anti-CD27 Agonist

Anti-CD40 Agonist

Anti-CTLA4

Anti-HER2 targeted therapy

Anti-OX40 Agonist

Anti-PD-1 agents

Anti-PD-1 Therapy

Anti-PD-L1 Therapy

Antiangiogenic Therapy 67–69

Antibiotics 69–71, 129

Antioxidant 32, 34–35, 44, 55–56, 58, 65, 67, 71–73, 78–79, 92, 94, 97–98, 102, 122, 124–125, 128, 130, 143–144, 150–153, 155, 159–160, 162–163, 167, 170–171, 196–198, 202, 204, 210, 224, 226, 230, 232, 239–244, 247–249, 251, 256, 259, 265–266, 286, 293, 301, 305, 308, 310–311, 315–316, 321–324, 326, 328, 332, 334–336, 342, 344, 350–351, 353, 355, 358–361, 363, 369, 374, 379–380, 383, 387–391, 405, 412–414, 425, 427, 433–434, 437, 441, 443, 449, 457, 461–462, 464

Antioxidant Therapy 71–73

Antiparasitic Drugs 253–255

Antiplatelet Agent 144–145, 461

Apigenin 73–75, 167, 374–375

Apoptosis 14, 18, 24, 32, 37–38, 40–42, 48, 50, 52, 55–59, 61–63, 65–67, 69–70, 74, 76, 78–82, 85, 87, 90, 92–95, 97, 99–100, 102, 104–106, 108, 111, 113, 115, 118–119, 122–123, 126, 128, 130–136, 139–140, 142–143, 147, 150, 152–153, 155–159, 161, 163, 165, 167, 172, 177, 179, 181–186, 189, 193–194, 196–198, 202, 206, 208–210, 212–217, 220, 222–226, 230–233, 236–237, 242, 244, 246, 248–253, 256–259, 261–263, 265, 269, 273, 275, 278, 280–282, 284–291, 293, 295, 297–299, 301–303, 305, 307–310, 312–314, 316–319, 323, 325–326, 328, 330–334, 336–339, 342, 344–347, 350–354, 356–364, 367–383, 385, 387–388, 391–393, 395, 397, 399, 403, 405, 407, 409–410, 413, 415, 421–423, 425–427, 429, 431–434, 437–438, 441–444, 449–451, 453–459, 461

Arsenic 21, 287, 340

Arsenic trioxide 287

Artemisia 293, 303, 309–310, 461

Artemisia annua 293, 303, 309–310

Artemisia 425

- Aspirin 15, 75–77, 144  
 Astragalus 78–79, 111, 295, 301–305, 326, 342, 368–369  
 Astragalus membranaceus 78–79, 111, 295, 303–304, 326, 342, 368–369  
 Atorvastatin 80–81  
 Atovaquone 82–83  
 Auranofin 426–428  
 Autologous Vaccine 179, 461  
 Autophagy 24, 37, 53, 70, 74, 78, 80, 84–86, 95, 104, 106, 115, 117, 126, 131, 135, 145, 165, 169, 179, 181–182, 200–202, 210, 220–223, 245, 247, 253–255, 261–262, 269, 282, 284–285, 346, 354, 367–368, 370, 413, 437–438, 441, 447, 452, 461  
 Autophagy Agents 84–86  
 Avemar 429–431  
 Axitinib 68  
 Ayurvedic Herbs 321–322  
 Azadirachta indica 215
- B**
- Bacterial infections 47, 69, 147, 209, 462  
 Baicalin 332–333, 461  
 Bay Leaf 334–335  
 Benign prostatic hyperplasia 117, 382  
 Berberine 86–87, 111, 303–305, 316–318, 330  
 Beta Glucan 88  
 Beta-Adrenergic Receptors 245, 247, 461  
 Beta-Carotene 322–324  
 Beta-Glucan PAMPs 461  
 Bevacizumab 29, 68–69  
 Bicarbonate 40–41, 52–54, 89–91, 461  
 Bicarbonate Therapy 90–91  
 Bidens pilosa 297–298  
 Bioavailability 24, 44, 57, 64, 66, 72, 74–75, 78, 85, 93, 97, 103, 113, 123, 127, 129–131, 134, 150, 152–153, 155, 157, 159–160, 162, 165, 167, 185, 197, 203, 217, 219, 229, 231, 237, 242, 248, 254, 256, 265, 272, 278, 280, 294–295, 298, 304, 313, 325, 332, 338, 349, 354, 364, 369–371, 375, 380, 392, 401, 406, 425–426, 428, 438, 440, 442, 454, 458–459, 461  
 Biopsy 215  
 Bioresonance 168–170  
 Bisphosphonates 403–404, 461  
 Black Cumin 91–94, 353, 464  
 Black Salve 431–432  
 Bladder Cancer 61–62, 105–106, 369, 374–375  
 Blood Tests 14–15, 40, 405–406  
 Blushwood Berry Extracts 324–325  
 Bortezomib 415–417  
 Boswellia 94–96, 209–211, 461  
 BRAF/MEK Inhibitors 202, 461  
 Brain cancer 249, 280, 348, 455  
 Brain Tumor 95–96, 240–241, 417  
 Breast cancer 15, 23–25, 27–29, 31, 34, 38–39, 43–45, 54, 56–58, 60, 62–64, 66, 71, 73–75, 77, 79–81, 83, 85, 87–89, 92–93, 95–96, 98, 101, 103, 107, 109–110, 112, 114, 122–123, 125, 127–129, 131, 133–136, 138, 141–142, 144, 146–149, 151–162, 164–170, 173–174, 178, 180–183, 187–188, 193–194, 196–197, 199, 201–203, 205–211, 213, 216–217, 219, 222–225, 227, 234, 236, 241–252, 255, 257, 261–266, 269–270, 272–274, 279–280, 283, 285–291, 294–300, 302, 305, 307–308, 310–311, 313–320, 322, 327, 329, 331, 333, 335–339, 341, 343, 345–349, 351, 354–357, 359, 361–366, 368–369, 371–373, 375, 377, 379–380, 384, 386, 390, 392–393, 403–404, 406–408, 410–412, 414, 419, 421–423, 426, 438, 441–443, 445–446, 450, 453, 457–459  
 Breast Cancer with Bone Metastasis 404  
 Broccoli 273  
 Bromopyruvate 401–402  
 Bu Zhong Yi Qi Wan 326–327  
 Burdock Root 97–98, 153, 340  
 Butyrate 99–101
- C**
- C60 433–434  
 CA 125 Test  
 CA 15-3 Test  
 CA 19-9 Test  
 CA 27-29 Test  
 Cadmium 21  
 Camellia sinensis 149, 293  
 CANCERASE 13–14, 16–19  
 Cannabis sativa 106–107  
 CAR T-Cell Therapy 72, 420–421  
 Carbonic Anhydrase 39–41, 461  
 Caspase 37, 106, 130–131, 155, 165, 179, 212–213, 216, 249, 251, 261, 280, 282, 288, 316, 330, 351, 368, 370, 385, 425, 427, 429, 451, 461  
 Castor Oil 328–329  
 Catharanthus roseus 293, 356, 362, 372  
 Cationic Antihistamines 104–106  
 Cat's Claw 102–104, 297, 463  
 CBD 106–108, 214, 255  
 CBD and THC 106–108  
 CD4 And CD8 Cells 341, 461  
 CD4+ And CD8+ T Cells 87  
 Celecoxib 28–29, 34, 108–110  
 Cervical Cancer 43, 56, 244–245, 279, 298, 310–311, 415–416, 448  
 Cesium 435–436  
 Checkpoint Inhibitors 29, 48, 70, 76, 108–110, 133, 137–139, 143–144, 175–176, 182–183, 218, 237, 246–247, 371, 427–430, 447–448, 455, 461–462  
 Chelidonium majus 309–310, 330–331  
 Chemopreventive 160, 216–217, 273, 461  
 Chemoresistance 76, 95, 161, 286, 443–444, 461  
 Chemosensitivity 30–31, 40–41, 92, 94, 106, 157, 426, 445, 451, 453, 461  
 Chemotherapy 14–15, 17, 19, 22–28, 30–34, 37–107, 109–136, 138–221, 223, 225–232, 234–244, 246–250, 252, 254–291, 293–296, 298, 300, 302–309, 311–315, 317–320, 322–329, 331–339, 341–352, 354–361, 363–423, 425–428, 430, 432–435, 437–459, 461, 463–464  
 Chinese Herbs 14, 111–112, 303–305, 307  
 Chinese Medicinal Plants 301–302  
 Chinese Skullcap 332–333  
 Chlorella 112–115

Chlorine Dioxide 405–407  
 Chloroquine 84–86, 115, 117  
 Chronic Hepatitis C 387–388, 395  
 Chronic lymphocytic leukemia 317–318  
 Chymotrypsin 228, 230  
 Cialis 117–119  
 Cimetidine 119–121  
 Cinnamon 334–335  
 Cisplatin 38–41, 55, 63, 80, 87, 146–147, 216, 220, 258–261, 321, 332, 342–343, 365–366, 395, 397–398, 411–412, 416, 427–428, 430, 433–434, 438–440, 443, 449, 451, 453  
 Claritin 104–106  
 Clove 334–335  
 Coenzyme Q 352  
 Coffee Enema 124–125  
 Coffee Enema Therapy 124–125  
 Coley's Toxins 177, 179, 461  
 Colitis 49, 124–125, 461  
 Colon Cancer 34, 42–45, 48–49, 57–58, 67, 78–79, 82, 94, 100, 109, 125, 133, 160–161, 172–175, 199, 218–219, 222–223, 230, 242–243, 248–250, 252, 255, 273, 299, 308, 317, 319, 329, 333, 343, 354–355, 359, 361, 364, 368, 370, 374–375, 380, 389–390, 406, 411, 426, 443  
 Colorectal Cancer 25, 31, 34, 40–42, 49, 51, 60, 63–64, 69, 71, 74–77, 87–89, 92, 95–96, 98, 100–101, 105–106, 114, 118–121, 127–132, 135–139, 144, 151–152, 155–156, 161–162, 164–166, 175–176, 182–183, 185, 189–190, 199, 209, 214–215, 220–221, 223, 225–228, 244–247, 262–264, 279, 288–291, 300, 302, 305–306, 314–315, 318, 327–328, 331, 345, 357, 396–398, 402, 417, 429–430, 438, 441–444, 457–459, 462  
 CoQ10 122–124  
 Cordyceps Sinensis 126–127, 437–438  
 Coriolus versicolor 277, 279  
 COX-2 75, 108, 110, 137, 163, 225, 242, 244, 293, 374, 429, 431, 461  
 Curcuma longa 128, 293, 303, 321, 356  
 Curcumin 24–25, 32, 66, 96, 111–112, 128–131, 255, 264, 284, 293–295, 301, 303–304, 321, 356–357, 364, 374–375, 461  
 Cyclin-Dependent Kinases 230, 232, 308, 415, 461  
 Cyclooxygenase 75, 108, 110, 137, 139, 288, 429, 431, 461  
 Cyclophosphamide 28–29, 103, 212, 309, 321–322, 395, 437  
 Cytokines 26, 32, 40, 45–47, 55, 76, 88, 111, 120, 122, 133, 163, 165, 184–185, 202, 206, 208–209, 214–215, 222, 271, 274, 276–277, 295, 299, 323, 326, 346, 367, 383, 431, 437, 441–442, 453, 461  
 Cytotoxic 26, 28, 37, 41, 53, 60, 74, 84–85, 92–94, 105, 108, 110, 120, 143, 152, 181, 202, 214, 216, 234–235, 237, 250–251, 253, 256–260, 262, 267, 278, 286, 299, 301, 303–304, 307–310, 312–316, 319–321, 330–331, 334, 339, 341–342, 344–345, 350, 352, 358–362, 370–371, 387, 392–393, 411–414, 419–420, 427, 431–433, 443, 446, 449, 451, 458, 461

## D

Dandelion Root 130–132  
 Dasatinib 425  
 Datar 30  
 DCA 134–136  
 Dean Silver 13, 16  
 Dedifferentiation 288–289, 461  
 Delta and Gamma Tocotrienols 132–134  
 Dendritic Cells 40, 44–48, 50, 53, 57, 63, 72, 80, 84, 87–88, 94, 106, 120, 124, 133, 137, 140, 142, 146, 150, 159, 161, 163, 165, 177, 180, 182, 186, 197, 204, 212–214, 224, 226, 230, 232, 242, 251, 253, 256, 258–259, 275–277, 288, 290, 295, 299, 326, 336, 344, 346, 349–351, 353–354, 356, 360–362, 364, 369, 389, 391, 409–410, 414, 437, 441–442, 446, 451, 456–457, 461  
 Detoxification Reactions 461  
 Dichloroacetate 134  
 Diclofenac 137–139  
 Diclofenac and Sulindac 137–139  
 Dicoma anomala 299–300  
 Diet 22–23, 26–27, 32, 34, 37, 54, 75, 90, 108, 133, 137, 140–141, 156, 193, 197, 224–226, 243, 289, 359, 385, 455, 462  
 Differentiated Thyroid Carcinoma 193–194, 461  
 Difluoromethylornithine 138–139, 461  
 Digoxin 139–141, 338–339  
 Diindolylmethane 141  
 DIM 141–143  
 Dipyridamole 143–145  
 Disulfiram 145–147  
 DNA Adducts 461  
 DNA Repair Genes 231–232, 461  
 Doxorubicin 80, 87, 92–93, 97, 103, 135–136, 246, 258–259, 261, 284, 337, 350–351, 365–366, 379, 392, 420, 425–428, 439, 441–442, 449  
 Doxycycline 70–71, 147–149

## E

EDTA 240–241, 439–440  
 Effector T Cells 108, 110, 447, 461  
 EGCG 24, 84–86, 149–151, 159–160, 374–375  
 Electrolyte Imbalances 56, 124–125, 462  
 Ellagic Acid 151–153, 242  
 Endometrial Carcinoma 220–221, 267–268  
 Energy Medicine 168–170  
 Enteric-Coated Capsules 462  
 Enzyme Therapy 228–230  
 Epigallocatechin-3 gallate  
 Epigenetic Modulation 40, 42, 53, 57, 59, 63, 65, 70, 74, 76, 80, 88, 90, 105, 113, 115, 131, 133, 150, 152, 159, 161, 165, 175, 182, 184, 202, 204, 212, 216, 222, 242, 248, 254, 260, 271, 273, 275, 278, 293, 350, 364, 380, 389, 410, 421, 437, 441, 458, 462  
 Epithelial-to-Mesenchymal Transition 24, 26, 28, 133–134, 148, 189, 288–289, 437, 462  
 Epstein-Barr virus 21, 279  
 ERK 157–158, 365, 391, 462  
 Erlotinib 82, 262–263  
 Esophageal Cancer 180, 376–377

Esophageal Squamous Carcinoma 200–201  
 Essiac Tea 153–154  
 European Medicinal Plants 155–156  
 Everolimus 210, 267–268  
 Evolution 2—Element III

**F**

Fagaroopsis 299–300  
 Familial Adenomatous Polyposis 137–139, 462  
 Fenofibrate 156–158  
 Ferroptosis 63, 185–186, 253, 255, 369, 462  
 Flavonoids 35, 65, 78–79, 158–160, 242, 293, 297, 310, 346, 381, 443, 462  
 Flaxseed 335–337  
 Follicular Lymphoma 214–215  
 Fucoidan 441–442

**G**

Gallbladder cancer 376  
 Garlic 59–60, 111, 155–156, 293, 301–302, 308, 356–357  
 Gastric Cancer 87, 120–121, 165, 244, 265, 323–324, 344, 346–347, 386, 397–398, 429, 443–444, 450  
 Gastrointestinal Cancer 92, 400  
 Gefitinib 273  
 Gene mutations 71  
 Genistein Soy 162  
 Genistein Soy Isoflavone 162  
 Genitourinary cancers 70  
 Ginger 163–164, 295, 387–388  
 Ginkgo 443–444  
 Ginkgo biloba 443–444  
 Ginseng 78–79, 111, 164–166, 295, 301–304, 307–309, 326, 342, 369, 383, 387–388, 395  
 Glioblastoma 22–23, 40–41, 81, 85, 96, 107–109, 115–117, 123, 133, 135–138, 146–147, 157–158, 170, 182–183, 189–190, 220, 222–224, 280–283, 418, 439, 453–455  
 Glioblastoma Multiforme 107, 280–283, 418, 453, 455  
 Glioma 94, 103, 148–149, 189, 282, 408  
 Glucoraphanin 273–275, 462–463  
 Glutathione 71, 73, 124–125, 198, 222, 250–251, 259, 352, 462  
 Glutathione S-transferase 124–125, 462  
 Glycolysis 21–23, 26, 37–38, 40, 44, 46, 50, 52–53, 55–56, 58–59, 61, 63, 65, 70, 72, 74, 76, 78, 80, 82, 84, 88, 90, 95, 97, 99–100, 102, 104–106, 108, 110, 113, 115, 117, 120, 122, 124–126, 131–135, 137, 139–142, 145, 148, 150, 156–159, 161, 163, 165, 173, 175, 177, 182, 184, 186, 189, 198, 200, 202, 206, 208–209, 212, 214, 216, 218, 222, 224, 226, 228, 231, 236, 240, 246, 248, 251, 253–256, 258–259, 267, 269, 271, 276, 278, 282, 288, 297, 310, 323, 328, 330, 332–333, 340, 342, 348, 350, 354, 362, 365, 381, 385, 389, 401–402, 407, 410, 425, 427, 429, 433, 436–437, 441, 443, 445, 447–449, 451–458, 461–462, 464  
 Glycoside Plants 337–339  
 Glycyrrhiza uralensis 342, 387  
 Gold 426

Green Tea 24, 66, 84, 149–151, 159, 293–294, 374  
 Green Tea Extract 294  
 Gynecologic Cancer 172

**H**

Head and Neck Cancer 38–39, 56, 118–119, 426  
 Helicobacter pylori 334  
 Heparin 445–446  
 Hepatocellular Carcinoma 45, 47, 51, 53–54, 57, 80–81, 90–91, 94, 111–112, 248–249, 302, 322, 342–343, 355, 376–377, 387–388, 454–455  
 Hepatoprotective 395, 397, 462  
 HER2-Overexpressing Breast Cancer 92, 337  
 Herbal Medicines 295–296, 311, 450  
 HIV 415, 418  
 Hodgkin lymphoma 145  
 Holy Basil 167–168  
 Homeopathic 169–170, 407–409  
 Homeopathy 168–170, 407–409  
 Hormone Therapy 67, 88, 151, 203, 300  
 Hormone-Resistant Prostate Cancer 406  
 Hormones 32, 247, 461  
 Hoxsey Formula 340–341  
 Human papillomavirus 279  
 Human T-cell lymphotropic virus type 1  
 Hydrogen Peroxide 352, 409, 411  
 Hydrogen Therapy 32, 170–172  
 Hydroxychloroquine 24, 84–85, 115, 117  
 Hyperbaric Oxygen Therapy 21, 32, 41, 54, 61–62, 72, 78–79, 82, 87, 99, 123, 131, 135, 165, 187, 198, 203, 216–217, 223, 239, 241–242, 244, 260, 262, 264, 266, 268, 286, 290–291, 348, 379, 385–386, 402, 414, 438, 446–447, 450, 462  
 Hypercalcemia 289, 462  
 Hyperthermia 21, 32–34, 37, 72–73, 124, 128, 135, 157, 173, 177–179, 229, 244, 270, 345, 369, 440, 452, 462  
 Hypocalcemia 403–404, 462  
 Hypoxia 15, 21, 23, 40, 67–69, 82–84, 139–141, 171, 204–205, 264, 284–286, 447, 462  
 Hypoxia-Inducible Factor 1-alpha 139, 141, 462

**I**

IFN- $\gamma$  46–47, 208–209, 299, 348, 395, 417, 429, 456, 462  
 II breast Cancer 45, 58, 66, 73, 98, 101, 103, 153–154, 168, 203, 234, 236, 243, 257, 272, 291, 300, 314, 347, 380  
 III breast cancer 227, 279, 345, 349, 384  
 IL-12 46–47, 120, 208–209, 214, 216, 299, 441, 462  
 Immune Checkpoint Inhibitors 29, 48, 70, 76, 143–144, 175–176, 182–183, 218, 237, 246–247, 371, 427–429, 447, 455, 462  
 Immune Modulation 14, 28, 37, 42, 44, 50, 53, 56, 64, 68, 76, 81, 84, 88, 94, 99–100, 106, 108, 111, 113, 118–119, 124–125, 130, 133, 138, 142–143, 146, 150–151, 155, 161, 163, 167, 169, 171, 182–183, 195, 197, 201, 208, 212, 218–219, 222, 230, 232, 234–237, 240, 242, 246, 248, 251, 253, 255–259, 262–263, 268, 282, 286, 288, 290, 299, 303, 306, 322, 325–326, 329, 336, 341, 348–349, 353, 364–365, 369–370, 375, 381, 383, 385, 389, 391, 399, 405, 409–411, 425, 427, 429,

- 433–435, 437–441, 443, 445, 448–449, 451, 454–457, 459, 462
- Immunogenic Cell Death 139, 141, 447, 462
- Immunomodulation 55, 59, 115, 126, 185, 191–192, 202, 206, 216–217, 277, 295, 301, 310, 312–315, 321, 330–331, 334, 358, 360, 368, 387, 417, 419, 462
- Immunomodulatory 45–46, 55–56, 78–79, 83, 102, 104, 185, 204, 216, 267, 269–270, 277, 279, 301, 304, 307, 313, 315, 330–331, 335, 337–338, 342, 359–362, 367, 370, 387, 397, 414, 417–418, 421, 442, 461–462
- Immunotherapy 14–15, 22, 24, 27, 29, 31, 33, 37–39, 41–42, 44, 48–49, 51–53, 57, 59–60, 62, 64, 66–68, 70, 74–77, 80–81, 83, 85–86, 88–91, 96, 100–101, 103, 105–106, 109–110, 113, 118–121, 138, 140–142, 144–146, 148–149, 152, 157, 161, 166, 170, 173, 175–176, 178, 181–185, 187–190, 192, 195–198, 200–201, 204–207, 213, 215, 219–225, 229, 233–234, 237–239, 248–249, 252, 254–255, 258, 262, 267–268, 270, 272, 276–278, 283, 289, 294, 298, 306, 311, 315, 317, 325, 332, 334, 336–337, 339, 341, 343, 346–347, 349–350, 354, 361, 363, 366, 368–369, 371, 375, 380, 384, 386, 394, 398, 400, 402, 406, 414, 420, 422–423, 426, 428, 430, 434, 438, 442, 445–446, 448, 450, 454–455, 457–458, 461–462
- Indole-3-carbinol 141
- Infections 16, 21, 23, 47, 50, 63, 69, 79, 102, 126–127, 147, 150, 177, 179, 181, 209, 218, 244–245, 271, 279–280, 332, 405–406, 420–421, 462
- Inositol Hexaphosphate 172, 174
- Insulin-like Growth Factor 1 Test
- Integrative Oncology 14–15, 21, 23–25, 27, 30–34, 37, 39–40, 42, 44–45, 47, 50, 52, 54–56, 58–60, 62–67, 69, 71–80, 82–83, 86–89, 91, 94–97, 99–100, 102, 104, 106, 108, 111–112, 114–115, 117–119, 122, 124, 126, 128–132, 134, 137–139, 141–143, 145–147, 149, 151, 153, 155–156, 158–160, 162–164, 167–168, 170, 172, 174–177, 179, 181, 184, 186–189, 191–193, 195–196, 198–199, 201–202, 205–206, 208–209, 212–215, 218–222, 224, 226, 228, 230–234, 236, 238–239, 241, 243, 245, 247–249, 251–252, 256–259, 261, 263, 265–266, 268–271, 273–275, 277–279, 281–283, 288, 290, 293, 295–296, 299, 301, 303, 305, 307, 309–310, 312–314, 316, 318–319, 321–324, 326–332, 334–337, 340–342, 344–347, 349–350, 352–355, 357–359, 362–363, 365–368, 370–371, 374–379, 381–383, 385–386, 389, 391–399, 401, 403, 405, 407, 409, 411–413, 415–417, 420–421, 425–426, 428–431, 433–435, 437–442, 444–446, 449, 451, 453, 455–457, 462
- Interferon-gamma 47, 208–209, 387, 417, 429, 462
- Interleukin-12 47, 208–209, 216, 462
- Interleukin-2 257, 276, 383, 417, 446, 448
- Inula helenium 309–310
- Iodine 193–194
- IP-6
- Irbesartan 174–176
- Irinotecan 99–100, 316–318, 356–357, 395, 417
- Isoflavone 160, 162, 245
- Isoflavones 251–253, 462
- Issels 177, 179
- Issels Whole Body Therapy 177, 179
- Itraconazole 179–181, 209–211, 462
- Ivermectin 24, 34, 181–184, 209–211, 462
- ## J
- Juzen-Taiho-To 342–343
- ## K
- Kaposi's Sarcoma 417–419, 462
- Kazmierczak 16–18
- Keishi Bukuryo Gan 344–345
- Ketamine 184–186
- Ketogenic Diet 22–23, 26–27, 108, 133, 137, 141, 156, 462
- Key Phytochemicals 393–394
- ## L
- Lactic acid inhibitors 186
- Laetrile 60
- Laryngeal Carcinoma 40–41
- Latin American Plants 296, 298
- Lectins 35, 367–368, 370–372, 451
- Lenalidomide 282
- Leukemia 26–27, 44–45, 92, 94, 103–104, 107–108, 130–133, 137, 182, 249, 257–259, 286–287, 293–294, 297, 301, 311–314, 317–318, 334, 338–339, 348, 352–353, 356–357, 362, 370, 378–379, 393, 399, 421–423, 429, 439
- Leukopenia 305–307, 342, 377, 383, 398–399, 462
- Licorice Root 346–347, 387–388
- Lifestyle factors 187
- Lithium 189–190
- Liver Cancer 46, 125, 156, 176, 185–186, 208–209, 216–217, 234, 257, 265–266, 272, 278, 297, 308, 345–349, 352, 354–355, 368, 376–377, 379–380, 384, 386, 395–396, 402, 445
- Losartan 191–192
- Lugols Solution 193
- Lumbrokinase 195–196
- Lung adenocarcinoma 178, 185–186, 205, 249, 429–430
- Lung Cancer 23, 31, 34, 49, 51, 57–60, 66, 69, 73, 76, 78–79, 82–83, 88, 109–114, 126–127, 133, 135, 140–141, 146–147, 154, 157, 165–168, 171–172, 178, 180–181, 185–186, 188, 203–206, 208, 210, 225, 227–228, 230, 238–239, 248, 250, 254–257, 261–264, 270, 272–273, 276–277, 279, 284–285, 294–297, 299–300, 303–304, 307, 317, 322–324, 327, 329, 333, 338, 349, 363–365, 372–375, 379–380, 390, 392, 396–398, 400, 403, 405–406, 414–415, 420, 427–430, 433–434, 438, 445–446, 450, 456–457, 463
- Lycopene 196–198, 323–324
- Lymphoma 27, 108, 115–117, 133, 137, 145, 187, 214–215, 267–268, 293, 341, 356–357, 362–363, 378
- Lysosome 200, 202, 222, 253, 462

**M**

- Macrophages 55, 78, 88, 111, 113, 126, 143, 155, 191, 195, 198, 214, 228, 246, 269, 277–278, 293, 297, 301, 303, 305, 307, 322, 325–326, 338, 342, 347, 350, 369–370, 387, 395, 419, 441, 456, 462
- Magnesium 198–200
- Magnesium sulfate 199
- Magnesium Supplements 199
- Maitake Mushroom 347–349
- Mammary Cancer 259
- Mantle Cell Lymphoma 267–268
- MDSCs 23, 37, 50, 76, 80, 82, 88, 99, 105, 108, 110, 118, 120, 137, 143, 163, 184, 187, 191, 236, 245, 247, 259, 261, 267–270, 276, 278, 282, 290, 350, 365, 401, 405, 419, 425, 427, 437, 447, 449, 451, 453, 456–457, 462–463
- Medicinal Plants 42–43, 155–156, 293–294, 301–302, 309–310, 370
- Mediterranean Diet 224
- Mefloquine 200–201
- Melanoma 74–75, 94, 105, 108, 120–121, 130–131, 133, 137, 157, 173–174, 200–201, 214–216, 229, 238–239, 246, 249, 257–259, 262, 273–274, 276–277, 315, 325, 358, 367, 378, 391–394, 411, 417, 430–432, 434, 439–440, 443, 446–448
- Melatonin 24–25, 202–204, 449–451
- Mesothelioma 365–366
- Metabolic Theory Of Cancer 21, 454, 462
- Metabolic Therapies 22
- Metabolic Warburg Theory 462
- Metastasis 14–15, 21–22, 25–28, 30–31, 40–41, 44, 46–48, 51, 57, 59, 61, 63, 65–69, 74–75, 80, 84, 87–90, 92–93, 95–96, 108, 111, 113–116, 118, 120–121, 123, 126, 133, 135–136, 144–145, 147–148, 152, 158–159, 161, 163, 165, 167–169, 171, 175, 177, 179, 184–185, 187, 189–191, 195–196, 199, 206, 208–210, 214, 216, 220, 222, 224, 226, 228–229, 233, 238, 242, 246–248, 252, 256, 260, 265, 270, 282, 288–289, 293, 299, 301, 303, 312, 323, 330–332, 336–338, 342–343, 346–351, 356, 360, 364, 369, 374, 380, 383, 385, 387–389, 397, 399, 401, 403–404, 407–408, 417, 422–423, 425–427, 429–433, 437–439, 441, 444–446, 449, 454, 456, 462, 464
- Metastatic Angiosarcoma 246–247
- Metastatic Breast Cancer 25, 28–29, 31, 56, 71, 110, 125, 129, 158, 178, 180, 224, 270, 280, 283, 320, 331, 337, 351, 377, 404, 422, 438, 450
- Metastatic melanoma 173–174, 214–215, 276–277, 411, 446–448
- Metformin 15–16, 24–25, 32, 34, 87, 188, 204–205, 246–247, 282–283
- Methylene Blue 37, 150, 206–208
- Mevalonate Pathway 80–81, 133–134, 403–404, 462
- MGMT Promoter Methylation 41, 463
- MGN- 24–25, 208–209
- Mifepristone 411–413
- Mifepristone RU 411, 413
- Milk thistle 155–156, 265, 308, 374
- Mistletoe 155–156, 235, 264, 284, 294, 367–368, 370–372, 451–453
- Mitochondrial Membrane Potential 130, 236, 249, 251, 367, 413, 463
- Mitomycin 342
- Modified Citrus Pectin 349, 351
- Monoclonal Antibodies 67, 69, 463
- Moringa oleifera 42–43
- Mtor 38, 44, 74, 78–79, 87, 92, 126, 135, 157, 159, 179, 182, 204, 209–211, 220–223, 254, 266, 268, 282, 338, 344–345, 383, 391, 427, 431–432, 437–438, 443–444, 458, 463–464
- mTOR Inhibitors 209–211
- Multiple Myeloma 208, 370, 403–404, 415–419, 458–459, 463
- MYC 137, 139, 222–223, 254, 431–432, 463
- Myelodysplastic Syndrome 287
- Myeloid-Derived Suppressor Cells 23, 37, 40, 50, 56, 76, 78, 80, 82, 84, 87–88, 99, 105, 108, 110, 115, 117–118, 120, 137, 142–143, 146, 161, 163, 184, 187, 189, 191, 200, 204, 236, 245, 247–248, 253, 259, 261, 267–269, 276, 278, 282, 290, 330, 332, 350, 362, 365, 375, 401, 405, 409, 414, 419, 425, 427, 437, 445, 447, 449, 451, 453, 456–457, 462–463
- Myrosinase 273, 275, 463
- Myrrh 212–213
- N**
- Naltrexone 57, 214–215
- Nano Silver 413–414
- Naphthoquinone Plants 351, 353
- Nasopharyngeal Cancer 111, 384, 400
- Nasopharyngeal Carcinoma 279–281
- Natural Killer Cells 40, 47–48, 50, 53, 57, 61, 72, 78, 84, 87, 106, 115, 117, 124, 126, 130, 133, 140, 142, 146, 150, 155, 159, 161, 169, 180, 182, 189, 197, 200, 224, 226, 228, 230, 232, 240, 248, 251, 253, 271, 288, 290, 293, 299, 301, 303, 305, 307–308, 310, 313, 325–326, 330, 332, 336, 338, 340–341, 345, 356, 362, 364, 379, 381, 385, 391, 409, 414, 425, 433, 435, 443, 445, 463
- Neck cancers 33, 118
- Neem 215–217
- Nelfinavir 415–416
- Nephrotoxicity 193–194, 260, 280, 321, 342–343, 440, 463
- Neuroblastoma 29, 208, 411–413
- Neutropenia 51, 102–104, 305–307, 430, 452–453, 463
- NF-kappaB 133–134, 463
- NF-κB 24, 26, 32, 42, 76, 92, 95, 102, 126, 128, 130, 152, 157–159, 161, 163, 165, 167, 218–219, 242, 248, 256, 265, 273, 293, 297, 299, 303, 326, 328, 330, 332–333, 338, 346, 353, 374, 376–378, 391, 415, 417, 425, 437, 456–459, 463
- Niclosamide 24–25, 218–219, 253–255
- Nifedipine 220–221, 284
- Nigella Sativa 91–92, 353–355, 370–372, 391, 393–394
- Niraparib 87
- Nitazoxanide 222, 224, 253–255
- NK Cells 46–47, 214, 258, 276–277, 282, 297, 326, 345, 347, 349–351, 354, 361, 420, 447, 462–463
- Non-Hodgkin lymphoma 145
- Non-Hodgkin's Lymphoma 363
- Non-Small Cell Lung Cancer 51, 69, 79, 82–83, 109,

- 113–114, 140, 146–147, 165–166, 180–181, 188,  
203–204, 227–228, 230, 239, 262–263, 272, 276–277,  
294, 322, 324, 327, 333, 365, 397–398, 414–415, 420,  
427–428, 450, 463
- North American Plants 307–309
- Nucleic Acid-Based Plants 355–357
- O**
- Obesity 38, 48–49, 82, 150, 177, 206, 271
- Ocimum sanctum 167
- Oldenlandia diffusa 301, 303
- Olive Oil 224–226
- Omega-3 Fatty Acids 226–228, 335–336
- Oral Squamous Cell Carcinoma 207, 425
- Organic chemicals 391
- Oridonin 376–378, 463
- Origanum Vulgare 358–359
- Oroxylin A 332–333, 463
- Osteoclasts 403–404, 463
- Osteonecrosis Of The Jaw 404, 463
- Osteosarcoma 191–192
- Ovarian Cancer 28–29, 52, 69, 73, 83, 91, 137, 142, 148–  
149, 180, 188–189, 191–192, 196, 199, 205–206, 229,  
231, 237–238, 260–261, 335, 351, 357, 359, 373–374,  
412, 419–420, 427–428, 443–446, 451, 453
- Ovarian Carcinoma 299, 358
- Oxaloacetate 453, 455
- Oxidative Phosphorylation 21, 37, 40, 44, 46, 50, 53, 56,  
59, 61, 63, 70, 72, 74, 76, 78, 80, 82, 84, 88, 90, 95,  
97, 99–100, 102, 106, 110, 113, 115, 117, 120, 122,  
124, 126, 131, 133–135, 137, 139–140, 142, 145,  
148, 150, 159, 161, 163, 165, 169, 173, 175, 177, 179,  
182, 184, 186, 189, 200, 202, 206, 212–214, 216, 218,  
222, 224, 226, 231–232, 236, 248, 251, 254, 256, 258,  
260, 267, 276, 278, 288–289, 297, 310, 323, 328, 330,  
332–333, 340–342, 348, 350, 354, 362, 365, 381, 389,  
407, 410, 425, 427, 429, 433, 436–437, 441, 443, 445,  
447–449, 451–453, 455–458, 463
- Oxindole Alkaloids 102, 104, 463
- Ozone Therapy 21–23, 32, 72, 78–79, 87, 123, 128, 135,  
139–140, 198, 241, 244, 263–266, 284–285, 447, 463
- P**
- P-glycoprotein 97, 179, 284–286, 330, 463
- Paclitaxel 26, 82–83, 85, 92, 108, 110, 116, 137–138,  
157–158, 165–166, 191–192, 208, 254, 267, 293, 324,  
350–351, 356–357, 372–373, 379, 438, 464
- Paeonia officinalis L 359–361
- Panax ginseng 78–79, 165, 301–304, 309, 326, 342, 383,  
387
- Panax notoginseng 165, 399
- Panax quinquefolium 307
- Pancreatic Adenocarcinoma 405–406
- Pancreatic Cancer 53–54, 71, 74, 90–93, 97–98, 101,  
115–116, 123, 128–129, 131–134, 152–153, 161,  
167–168, 172, 178, 185, 191–192, 197, 213, 225,  
229–231, 236, 238–239, 285–287, 298, 320, 331, 338,  
360–361, 365–366, 368, 370, 374–375, 402, 414–416,  
419, 421, 427–428, 453
- Pancreatic Enzymes 228–230, 463
- Pancreatic Enzymes Trypsin 228
- Pao Pereira 230–232
- Papillary Thyroid Carcinoma 193–194, 463
- PARP 37, 212–213, 429, 463
- Parsley 74, 374
- Pau D'Arco 232–234
- Paw Paw 234–236
- PCN 238–239, 463
- PCN 27 Peptides 238–239, 463
- Pectasol 350–351
- Pectin 349, 351, 368, 370–371
- Peganum harmala 299–300
- Pentacyclic 102, 104, 463
- Pentamidine 236–238
- Peony 305, 359
- Peptides 33, 238–239, 256, 370–372, 463
- Peripheral Neuropathy 33, 135–136, 189–190, 198–199,  
417–419, 463
- Phenanthridone 362–363
- Phenanthridone Alkaloid Plants 362–363
- Phenolic Plants 363
- Photodynamic Therapy 21, 23, 32–33, 37, 41–42, 50, 54,  
61, 63, 70, 76, 78–79, 82, 84, 97, 99, 102, 104, 113,  
115, 120, 131, 133, 150, 161, 165, 173, 177, 180, 187,  
189, 198, 200–203, 206–207, 216–217, 223, 254, 260,  
262, 266, 268, 276, 290, 329, 332, 348, 350, 369, 379,  
385, 402, 407, 411, 414, 433–434, 440, 446–447, 450,  
455, 463
- Phytochemicals 299, 323–324, 393–394
- Phytoestrogenic 253, 463
- PI3K/AKT/mTOR Pathway 38, 44, 74, 78–79, 126, 159,  
210, 344–345, 383, 427, 438, 443–444, 458, 463
- Pirfenidone 365–366
- Plant Lectins 367–368, 370
- Plant Polysaccharides 368–370
- Plant Proteins 370–372
- Plant Species 55, 309, 314, 367, 370, 372–373
- Plant Species in Contemporary 372
- Plant-Derived Quinones 393–394
- Plants 14, 32, 35, 42–43, 59–60, 86, 88, 97, 155–156, 172,  
293–294, 296, 298–302, 307–310, 314–319, 333,  
337–339, 351, 353, 355–357, 362–363, 365, 367–368,  
370, 372, 374, 391, 394, 425, 463
- Platelet Counts 88–89, 263–265, 384, 463
- Poly-MVA 239–241
- Polyphenols 35, 66, 242, 293, 374–375, 393–394
- Polysaccharides 55, 78–79, 88, 216, 299, 303, 368–370,  
381, 385, 437–438, 451, 456–457, 461, 463
- Pomegranate 153, 241–243
- Portulaca oleracea 299
- Postmenopausal Breast Cancer 336–337
- PPAR $\alpha$  156, 158, 463
- PQQ 249–250
- Probiotics 71, 243–245
- Procardia 284–285
- Programmed Cell Death 14, 18, 24, 32, 37, 41, 55, 58, 63,

- 65, 74, 79–80, 87, 94–95, 97, 104, 106, 111, 113, 118, 122, 126, 128, 130, 134–135, 152–153, 155, 158–159, 163, 165, 167, 172, 179, 182, 193–194, 196, 198, 202, 209, 212–213, 215, 217, 224, 226, 232, 242, 248, 251, 253, 257, 261, 265, 273, 275, 278, 281, 284–286, 289–290, 293, 295, 305, 307, 310, 325–326, 333, 336, 338, 342, 344–347, 353, 357, 362–363, 367–368, 374, 376, 378–379, 381, 383, 385, 391, 397, 399, 405, 407, 413, 425–426, 429, 431–432, 434, 438, 442, 444, 451, 453, 457, 459, 461, 463
- Progression-Free Survival 28–29, 31, 69, 71, 162, 165–166, 180–181, 200–202, 206, 238, 268, 286–287, 289, 428, 430, 463
- Propranolol 34, 209–211, 245–247, 463
- Prostate cancer 39, 45, 47, 62–64, 67, 76–77, 88–89, 94, 109–110, 118–119, 133–134, 140–142, 145, 147, 151–154, 157–158, 160–164, 170, 180–181, 189–190, 193–194, 196–197, 203, 207, 211–214, 216–221, 225–226, 231, 234–238, 241–243, 251–252, 265–266, 273–274, 276–277, 282–283, 288–291, 295–296, 299–300, 320, 323–324, 335, 339, 350–351, 353–355, 364, 371, 374–375, 381–383, 385, 404–406, 412, 417, 422–423, 435, 441–442, 463
- Prostate Cancer with Bone Metastasis 404
- Prostate-Specific Antigen 142, 151, 161, 180, 219, 242, 274, 295, 463
- Proteasome 145, 147, 415, 463
- Protectival 305–307
- Protein Kinase C 324, 326, 463
- Pterostilbene 209–211, 247–249, 463
- Pulsed Electromagnetic Fields 37, 50, 63, 70, 82, 84, 97, 99, 102, 115, 131, 165, 169, 187, 189, 200, 216–217, 254, 276, 329, 350, 407, 447, 464
- Pyroloquinoline Quinone 249–250
- ## Q
- Quercetin 24, 155, 159–160, 209–211, 364, 374–375, 425–426, 464
- ## R
- Rabdosia Rubescens 376–378, 463
- Radiation 14–15, 17, 19, 21–29, 32–34, 37–38, 40–48, 50–52, 54–62, 64–68, 70–76, 78–89, 91–100, 103, 106–107, 109, 111–112, 115–117, 120–121, 124–131, 133–136, 138–139, 141–142, 145–147, 150–155, 157, 159–161, 163–167, 169–172, 174, 176–178, 180–190, 192–201, 206–207, 210–211, 213–217, 222–227, 229–232, 235–239, 241–242, 244, 246–250, 252, 254–264, 267–274, 276–283, 286–287, 290–291, 293–296, 298, 300, 302–309, 311–320, 322–323, 326–329, 331–333, 335–339, 341–347, 349–352, 354, 356–357, 360–361, 363–369, 371, 373–375, 377–382, 384–389, 391–392, 394–396, 398–406, 408–414, 418–419, 422–423, 425–428, 430, 432–435, 438–449, 451–459, 464
- Radiation Therapy 22, 25–28, 33, 41, 44–47, 50–51, 54, 57, 59–62, 64–68, 70–74, 78–84, 87–89, 91–92, 94–95, 98, 103, 106–107, 109, 111, 116–117, 120–121, 124, 126–131, 133–136, 138–139, 141–142, 146–147, 150–152, 155, 157, 159–161, 163–167, 172, 176, 180–185, 189, 192–198, 200–201, 206–207, 210–211, 213–215, 217, 222–227, 231–232, 236, 238–239, 242, 246–250, 252, 256–258, 260–264, 269–272, 274, 276–278, 280–282, 286–287, 290–291, 293–296, 298, 300, 302–304, 307–309, 311–318, 320, 322–323, 326–328, 331–333, 335, 337–339, 342–343, 345, 347, 349–352, 354, 360–361, 363–364, 366–369, 371, 373–375, 377, 379–380, 382, 384–388, 391–392, 394, 399–404, 409–412, 414, 418, 422–423, 425, 427–428, 433–434, 438–441, 445, 452, 458–459, 464
- Radiosensitize 92, 94, 464
- Radiotherapy 55–56, 70, 81, 92–94, 122–123, 129, 143–145, 148–149, 197, 202–206, 208–209, 218–219, 245, 265–266, 301, 303, 346, 415–416, 443–444, 449–450, 464
- RAG 14, 17–19
- Rapamycin 204, 209–211, 266, 268, 463–464
- Reactive Oxygen Species 32, 50, 57, 69, 71, 78–79, 82, 102, 104, 130, 135, 145, 147, 167, 182, 198, 236, 249, 251, 259, 286, 325–326, 352, 405, 409, 413, 427, 429, 431, 433–434, 439–442, 449, 464
- Red Clover 153, 251–253, 340
- Regulatory T Cells 28, 37, 76, 78, 80, 82, 84, 105, 108, 110, 118, 120, 137, 163, 187, 189, 191, 202, 204, 259, 261, 267–268, 282, 362, 365, 401, 405, 419, 437, 441, 449, 451, 454–457, 464
- Reishi Mushroom 455–457
- Renal Cancer 176, 214
- Renal Cell Carcinoma 85–86, 120, 210–211, 267–268, 393–394, 417, 446–448
- Repurposed Cancer Drugs 15, 32, 34, 128, 244, 464
- Repurposing Antiparasitic Drugs 253
- Resveratrol 32, 66, 111, 131, 155, 210–211, 247–248, 293, 356–357, 364, 374–375, 457–459, 463
- Rice bran 24, 208
- Ricinus communis 328
- Rituximab 268
- RU 411, 413
- Rubia Cordifolia 378–379, 393–394
- Russian Medicinal Plants 309–310
- Rutin 379–381
- ## S
- Saharan Plants 299–301
- Salvia miltiorrhiza 301–303, 383
- Saponins 78–79, 256, 299, 464
- Saw Palmetto 381–383
- Sea Cucumber 256–257
- Selective Estrogen Receptor Modulators 251, 253, 464
- Selegiline 257–259
- Selenite 259–261
- Selenium 193, 259–260, 369–370, 464
- Selenoproteins 259, 464
- Senescence 92–94, 464
- Sertraline 261–263
- Shark liver oil 263–264, 461
- Shih Chuan Da Bu Wan 383–384
- Shiitake Mushroom Extracts 385
- Shiitake Mushrooms 45, 295, 385–386

- Sho-Saiko 386–388, 395  
 Sho-saiko-to 386–388, 395  
 Silibinin 374–375  
 Silybum marianum 155, 265  
 Silymarin 155, 265–266  
 Sirolimus 209–211, 266–268, 464  
 Skeletal-Related Events 403–404, 464  
 Skin Cancer 155, 341, 431  
 Skin cancers 33, 155, 298, 300, 311, 354, 373, 434  
 Small-Cell Lung Cancer 49, 111, 254–255, 295, 405–406, 438  
 Solomon's Seal 209–211, 268–270, 464  
 Solvents 393  
 South American and Latin American Plants 296, 298  
 Soy 160, 162, 245  
 Spearmint 389–390  
 Spirulina 271–273  
 St. John's wort 295–296  
 STAT3 24, 111, 128, 130, 133–134, 218, 254, 265, 330, 338, 374, 380, 419, 421, 441, 464  
 Stomach cancer 197, 348  
 Sulforaphane 273–275, 462–463  
 Sulforaphane and broccoli 273  
 Sulindac 137–139  
 Surgery 14, 17, 19, 81, 96, 185, 230, 238, 244–245, 412, 432  
 Synergistic Effect 250–251, 363, 402, 464  
 Synergy 15, 37–38, 41, 44, 46, 48–51, 54, 57, 59, 61, 63, 65–66, 70, 72, 74, 76, 78–80, 82–83, 92, 95–97, 99, 102, 106, 108, 110, 113–114, 116, 119, 124, 126, 128, 131–133, 135, 137–139, 142–143, 145–146, 148–152, 154, 157–159, 165, 171–173, 175, 177, 181–182, 184–185, 187, 189, 195, 197–198, 200–201, 204, 206, 208, 213–218, 220–226, 229–230, 234–235, 237, 240, 242, 244–245, 252, 254, 258–259, 263–265, 267, 269–273, 276–278, 282, 285–286, 290, 293, 305–306, 311, 313, 315, 319–321, 323–326, 328–329, 332, 334, 337, 339, 342, 346–352, 354, 364–365, 370, 379, 381, 385, 389, 394–395, 397, 401–403, 405, 407, 409, 411, 414–415, 422, 425, 427, 430, 433–435, 437–441, 443, 445, 447, 449, 451, 453–456, 458, 464
- T**
- T-regulatory Cells 169, 340–341, 379, 433, 435, 443, 457, 464  
 Tadalafil 117–119  
 Tagamet 119, 121  
 Taraxacum officinale 130  
 Targeted Therapy 31, 101, 176, 239, 262, 319–320, 410–411, 440  
 Taxanes 108–110, 132–133, 137, 143, 156–158, 356–357, 464  
 Telomere 120, 179, 187, 198, 229, 464  
 Temozolomide 40–41, 81, 107, 116–117, 135, 146, 149, 158, 189–190, 411, 417–418, 454  
 Temozolomide 85–86, 210–211, 267–268  
 Teratogenicity 418–419, 464  
 Terpenoids 297, 391–392
- Testicular cancer 59, 372–373  
 Thalidomide 34, 417–419  
 THC 106–108  
 Thymoquinone 92–94, 353–355, 391–392, 464  
 Thymosin Alpha Peptide 275, 277  
 Thyroid Cancer 193–194, 461, 463  
 Tocilizumab 419–421  
 Tocopherol 323  
 Tocotrienol 133–134  
 Tocotrienols 132–134  
 Topoisomerase II 69, 212–213, 356, 464  
 Translucipromine 421–423  
 Tregs 28, 37, 50, 76, 80, 82, 84, 99, 105, 108, 110, 118, 120, 137, 163, 187, 191, 202, 204, 259, 261, 267–268, 276, 282, 290, 365, 401, 405, 419, 425, 437, 441, 449, 451, 454–457, 464  
 Tribulus terrestris 299  
 Trypsin 228, 230  
 Tumor Microenvironment 15, 21, 23, 25–26, 37, 40–42, 44, 46–48, 50, 52, 57–58, 61, 63, 65, 68, 71–74, 78, 80–82, 84, 87–91, 95, 97, 99–102, 105–106, 115–116, 120, 122, 126, 130, 133, 135, 137, 139, 143–145, 148, 150, 157, 159, 161, 165, 169, 171, 173, 175, 177, 179, 182, 184, 186, 189, 191–192, 198, 200, 204, 206, 208, 210, 212, 214, 216, 218, 222, 226, 228, 230–232, 234, 236, 240, 245–248, 251, 253, 258–259, 261, 267, 270–271, 276, 278, 282, 284–286, 290, 297, 303, 310, 323, 326, 328, 330, 332, 340–341, 344, 348, 350, 353, 362, 365–366, 378–379, 381, 383, 385, 389, 395, 401–402, 405, 407, 409, 411, 413, 417, 419, 422, 425–430, 433, 435, 437, 439–443, 445–447, 449, 452, 454, 456–458, 464  
 Turkey Tail Mushroom 277–279  
 Tyrosine Kinase Inhibitors 67, 69, 464
- U**
- Ultrasound 72, 433  
 Unsaponifiable Lipids 393–394
- V**
- Vaccines 33, 72, 177, 238, 447  
 Valacyclovir 279–281  
 Vascular Endothelial Growth Factor 50, 67, 69, 157–158, 179, 242, 267–268, 278, 288–289, 417, 429, 431, 437, 445–446, 449, 464  
 VEGF 29, 50, 65, 67–69, 157–158, 179, 234, 242, 267–268, 278, 288–289, 306, 417, 429, 431, 437, 441, 445–446, 449, 464  
 Verapamil 284–285  
 Vinca 316, 356–357, 372–373  
 Viral infections 21, 279–280  
 Vitamin A 34, 322, 435  
 Vitamin C 24, 32–34, 73, 122, 240–241, 264, 286–288  
 Vitamin D 34, 288–289, 403  
 Vitamin E 34, 132, 255, 324

**W**

Warburg Effect 21–23, 37, 44, 50, 52, 56, 58, 61, 63, 65, 70,  
72, 74, 76, 80, 84, 88, 90, 95, 97, 99, 102, 104–105,  
108, 110, 113, 120, 122, 124–126, 131, 133, 140–142,  
150, 159, 161, 163, 165, 173, 184, 186, 189, 198, 202,  
208–209, 218, 222, 224, 226, 228, 240, 248, 259, 271,  
276, 278, 290, 332–333, 348, 350, 354, 362, 385, 401,  
425, 427, 429, 435–437, 441, 447–449, 451–453,  
455–458, 461, 464

*Withania somnifera* 42–43, 59, 321–322

**X**

Xiao Chai Hu Tang 395–396

Xiao Wei Yan Powder 397–398

**Y**

Yunnan Baiyao 399–400

**Z**

Zinc 264, 284, 290–291, 340, 431, 435

**Z**

*Zingiber officinale* 163, 387








In "How AI Can Help Cure Cancer: Volume 1 - Repurposed Drugs, Plants, and Vitamins", Dr. Dean Silver and AI scientist Andreas Kazmierczak explore the groundbreaking role of artificial intelligence in integrative cancer treatment. This book reveals how AI-driven analysis is revolutionizing cancer care by identifying the most effective repurposed drugs, plant-based therapies, and vitamins to combat the disease.

Dr. Silver, a leading integrative oncologist, shares his personal journey of overcoming cancer and staying in remission for 25 years using innovative, non-toxic therapies. Kazmierczak, an expert in AI, has trained the **CANCERASE AI** on over 300,000 pages of medical data, offering a powerful tool for personalized cancer treatment. Together, they present a cutting-edge approach that moves beyond conventional high-dose chemotherapy, reducing harmful side effects while improving outcomes.

With rapid advancements in AI and major investments in medical technology, this book provides hope and practical guidance for those seeking smarter, more effective cancer treatments.

**A must-read for patients, caregivers, and medical professionals looking to harness AI in the fight against cancer.**



**Dean R. Silver, MD, MD (H), is a traditional cardiologist and integrative oncologist.**

Twenty-five years ago, he cured himself of lymphoma through integrative oncology. At the time, he was working at four hospitals under extreme stress. His cancer stemmed from toxins, inflammation, infections, sleep deprivation, and poor diet. This led him to study integrative medicine worldwide.

In his book *How AI Can Kill Cancer*, Dr. Silver shares how to prevent, treat, and stay in remission. He explains the metabolic approach to cancer, why it recurs, and new tests to detect cancer in the blood before scans show it. The book also explores personalized treatments beyond high-dose chemotherapy, which can have severe side effects.

For 25 years, Dr. Silver has stayed in remission using repurposed drugs, vitamins, and plant therapies. Now, he helps others through health coaching, no matter where they are.

For more information, contact Dr. Silver at <https://cangpt.ai>



**Andreas Kazmierczak, MS, is a German AI engineer with a distinguished career as an AI scientist at a renowned technical university in Aachen. His interest in cancer treatment was sparked by a personal case connected to Dr. Silver's work.**

He has authored books on computer-aided design, AI, and data transfer. In his first medical book on AI in integrative cancer treatment, he explores how AI can support therapy, using the **CANCERASE AI** to analyze the book's data.

Kazmierczak trained **CANCERASE AI** on over 300,000 pages of integrative and conventional cancer treatment data collected by Dr. Silver in the **CANCERASE AI** project. In the coming years, this AI could revolutionize cancer treatment.

Together with Dr. Dean Silver, Kazmierczak and his team continue to refine this AI, shaping the future of cancer care. With rapid advancements in AI and billions of dollars in investment, there is growing hope that a breakthrough in cancer treatment will come soon.

For more information, contact Andreas Kazmierczak at <https://cangpt.ai>

ISBN 979-8-9916163-0-0



9 798991 616300